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Abstract 
Optical Contrast Agents to Visualize Molecular Expression in Breast 
Cancer 
by 
Robert James Langsner 
Breast cancer is the second leading cause of death of women in the United States.  
Improvements in screening technology have increased the breast cancer incidence rate, as 
smaller lesions are being detected.  Due to the small size of lesions, patients can choose 
to receive breast conservation therapy (BCT) rather than a modified radical mastectomy.  
Even though the breast retains cosmesis after BCT, there is an increased risk of the 
patient having residual microscopic disease, known as positive margins.  Patients with 
positive margins receive increased radiation and have an increased chance of second 
surgery.  Pathology with hematoxylin and eosin (H&E) remains the gold standard for 
diagnosing margin status in patients.  Intraoperative pathology has been shown to reduce 
the rate of positive margins in BCT. However, a minority of surgery centers have 
intraoperative pathology centers, limiting the number of patients that receive this standard 
of care. 
The expression profiles of surface receptors such as ErbB2 (HER2-positive) and 
epidermal growth factor receptor (EGFR) provide information about the aggressiveness 
of a particular tumor.  Recent research has shown that there was elevated EGFR 
expression in patients with a local recurrence even though the biopsies were assessed to 
be disease free using standard H&E.  If the physicians had known the molecular 
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expression of these biopsies, a different treatment regimen or excision of more tissue 
might have prevented the recurrence.  
This thesis investigates targeted molecular contrast agents that enhance the 
visualization of molecular markers such as glucose transporters (GLUTs) and growth 
factor receptors in tissue specimens.  First, application of 2-NBDG, a fluorescent deoxy-
glucose, enhances signal in cancerous tissue with a 20-minute incubation.  Then, 
antibody functionalized silica-gold nanoshells enhance the visualization of ErbB2 
overexpression in specimens with a 5-minute incubation. 
To image these contrast agents in cancerous tissue, a portable, inexpensive device 
was developed as a tool to help physicians visualize expression of surface markers.  The 
system visualizes absorbance from nanoshell aggregates and fluorescence in the visible 
and near-infrared light spectrum.  This study represents the first step in the development 
of an intraoperative optical imaging device to enhance the visualization of molecular 
markers overexpressed in cancerous cells.  
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Chapter 1 
Introduction 
Breast cancer accounted for approximately twenty-nine percent of all female 
cancers diagnosed in 2012 [1].  It is treated with a combination of chemotherapy, 
radiotherapy, and surgery.  Recent advances in screening and diagnosis techniques have 
led to the discovery of smaller lesions [2]. One effect of this has been an increase in the 
number of breast conservation therapy (BCT) surgeries in place of modified radical 
mastectomies (MRM) [2].  Women who receive BCT have a better cosmetic outcome, 
which can remove some of the psychological burden that results from traumatic surgery.  
BCT also lowers infection risk at the wound site [3] and has similar survival rates to 
patients who receive MRM [4–6].  However, there are risks associated with BCT.  About 
forty percent of breast cancers present as multi-focal disease [7], which adds 
complications to the surgery [8].  It is also more difficult for surgeons to detect in situ 
disease intraoperatively, leading to inadequate removal of cancerous cells, known as 
positive margins.  A patient with positive margins receives increased radiation dosage 
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and will often undergo a second surgery a short time period after the first surgery [8].  A 
2012 retrospective study by Jeevan et al. showed that twenty percent of women receiving 
BCT had a re-excision to remove residual disease with in situ disease accounting for 
nearly twice as many re-excisions as isolated cancers [8].  A second surgery involves 
poorer cosmesis [9] and higher psychological trauma for the patient [8,10].  Reducing the 
rate of positive margins will dramatically decrease the rate of second surgeries in BCT; 
however, it is difficult to visualize microscopic disease intraoperatively.  Currently, 
intraoperative pathology has demonstrated lower recurrence of re-excision in patients 
[11,12].  However, intraoperative pathology is only available in approximately five 
percent of hospitals, limiting its widespread use. 
Intraoperative pathology has other limitations as well.  Studies by Camp and 
Riedl demonstrated lower rates of re-excision but not lower rates of positive margins 
[11,12].  A study by Vosoughhosseini et al. showed pathology using standard 
hematoxylin and eosin (H&E) had false negatives that would have been diagnosed if 
pathologists had analyzed surface expression of epidermal growth factor receptor 
(EGFR), a protein associated with aggressive cancers [13].  One growth factor receptor, 
ErbB2, is of particular importance to breast cancer, as it is over-expressed in up to 
twenty-five percent of breast cancers (known as HER2-positive) and is associated with 
particular aggressive subtypes of breast cancer [14–17].  HER2-positive tumors are a 
majority of high grade ductal carcinoma in situ (DCIS) [14], and a 2004 study by Miller 
et al. showed that surgeons operating on patients with HER2-positive DCIS had a more 
difficult time obtaining negative margins [18].  These facts demonstrate that there is a 
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clinical need for a method to visualize the overexpression of this surface receptor during 
BCT.   
As HER2 is only overexpressed in twenty-five percent of breast cancers, there is a 
need to develop methods to visualize breast cancer subtypes with different surface 
receptors whose overexpression have been linked to breast cancer [19].  A 2012 study by 
Vermeulen et al. showed that eighty percent of invasive breast cancers express at least 
one of these proteins: CD44v6, GLUT1, EGFR, HER2, and IGF1-R) [19].  GLUT1 
(glucose transporter 1) has demonstrated utility as a marker for cells with high metabolic 
activity (such as cancer).  Clinically, its overexpression has been visualized through the 
use radio-labeled deoxy-glucose (18FDG) that is visualized using positron emission 
tomography (PET) [20,21].  However, as this imaging modality can not be used 
intraoperatively, recent research has focused on the development of a fluorescent deoxy-
glucose analog, 2-NBDG, [22–25].  2-NBDG signal can be monitored through optical 
imaging techniques and enhances the fluorescent signal from cancerous cells to provide 
contrast between malignant and normal tissue.  Additionally, contrast agents targeted to 
EGFR enhance tumor signal via fluorescence [26,27] or reflectance [28].  These are 
examples of methods to visualize surface receptor overexpression in breast cancer that 
have potential to assist surgeons identify microscopic disease intraoperatively. 
This thesis discusses the use of targeted contrast agents to visualize molecular 
expression.  First, three introduction chapters review breast cancer, the use of 
nanotechnology in breast cancer treatment and diagnosis, and optical imaging with breast 
cancer.  Then, the utility of 2-NBDG as a contrast agent in cells and freshly excised 
cancerous tissue is explored using microscopy and a wide-field multispectral imaging 
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system.  Next, glucose is conjugated to the surface of small diameter (~2 nm) gold 
nanoparticles (AuNPs) to investigate a new targeting moiety for nanoparticles.  Also, 
anti-HER2 antibodies are functionalized to the surface of large diameter (~314 nm) 
silica-gold nanoshells (NS) for use as rapid diagnostic probes to visualize HER2 
expression in ex vivo tissue specimens.  Finally, an inexpensive, portable device is 
developed to image the enhanced contrast provided by 2-NBDG, anti-HER2 NS, and 
anti-EGFR fluorescent dye.  The device is constructed as an instrument that surgeons can 
use in the surgical suite to visualize signal provided from the contrast agents in order to 
determine if there is presence of microscopic disease. 
This thesis represents the first step in the development of an inexpensive, portable 
device that can be used with commercially available contrast agents to provide optical 
images of molecular expression of cancerous tissue.  The research demonstrates that 
rapid incubation with targeted contrast agents can differentiate non-cancerous tissue from 
cancerous tissue, and the enhanced signal from the contrast agent can be visualized. 
 
  
 
Chapter 2 
Breast Cancer: Statistics, Imaging, and 
Treatment 
2.1. Introduction 
In the United States (U.S.) in 2011, there were approximately 230,480 new cases 
of breast cancer and nearly 39,250 deaths from breast cancer [29]. Nationally, breast 
cancer mortality rates have been in decline from the 1990s (2.2% per year), whereas 
incidence rates have been increasing (Fig. 2.1).  This increase is thought to be a result of 
the increase in screening mammograms in the U.S [29]. In this chapter, we will discuss 
the types of breast cancer, the methods of treatment of breast cancer, current techniques 
to improve intra-operative visualization of breast cancer, and how the research in this 
dissertation can be applied to improve treatment of breast cancer.  
  
 
6
2.2. Breast Cancer Characterization 
Ninety-five percent of breast cancers are classified as adenocarcinomas; the other 
classifications include: squamous cell carcinomas, phyllodes tumors, sarcomas, and 
lymphomas [30]. There are two divisions of carcinomas: in situ and invasive. In situ 
indicates that the cancerous cells have not broken through the ducts or lobules in which 
the cancer has originated, and the cells are still limited by the basement membrane. 
Invasive carcinomas are classified as having penetrated the basement membrane of the 
duct or lobule of origin.  Ductal carcinoma in situ (DCIS) is seen approximately four 
times more frequently (80% vs. 20%) than lobular carcinoma in situ.  In situ incidences 
have increased recently due to improved diagnostic technology, and the increased number 
of screening mammograms resulting from more breast cancer awareness [29–32]. Even 
though in situ carcinomas have not spread beyond the duct or lobule of origin, they can 
 
Figure 2.1. In situ and invasive breast cancer incidence rates and mortality rates from 1975-2008 for breast cancer 
in the United States.  In situ incidence has increased as the number of screenings has increased and screening 
technology has improved to detect smaller lesions. Reproduced from [29]. 
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be very dangerous because the malignant cells can spread throughout the entire duct or 
lobule and take up a very large volume in the breast [30].   
2.2.1. Types of breast cancer 
There are six types of invasive carcinoma, about eighty percent of all invasive 
carcinomas are deemed no special type (NST), also known as invasive ductal carcinoma 
(IDC), which can not be classified as a specific subtype [30].  IDC have a wide variety of 
protein and gene expression, and there have been recent studies that have looked to 
classify these cancers more specifically by their expression profiles so that more specific 
prognoses and treatments can be accomplished. These will be explored later in the 
manuscript. Invasive lobular carcinoma (ILC) is the second most common breast 
adenocarcinoma, occurring at a rate of ten percent of all invasive carcinomas.  ILC 
requires a different type of treatment and monitoring regiment.  First ILC metastasizes to 
different organs than other breast cancers [30], such as the GI tract, ovaries, and uterus.  
Additionally, chemotherapeutic treatment of ILC is difficult to monitor using Positron 
Emission Tomography and Computed Tomography scans (PET/CT) because detectors 
have more difficult time detecting the radioactive isotopes that target the malignant tissue 
[33–36].  One explanation for this is the difference in cell density between cancer cell 
types and their respective infiltration into surrounding tissues [37,38]. Figure 2.2 
demonstrates the inability of PET/CT to differentiate an ILC tumor that is easily visible 
with MRI, while also demonstrating the ability of PET/CT to localize IDC in a patient. 
Other breast adenocarcinomas include tubular carcinoma, which accounts for six 
percent of invasive carcinomas and ten percent of cancers less than one cm.  Ninety-five 
percent of these cancers will express hormone receptors and they are well-differentiated 
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[30].  Medullary carcinoma occurs in approximately two percent of invasive carcinomas. 
It is characterized by high nuclear grade and proliferation rates, yet despite these factors, 
it still has a better prognosis than IDC.  Invasive mucinous carcinoma also occurs in 
about two percent of invasive carcinoma and grows slowly over the course of years.  It is 
very soft and looks like gray-blue gelatin.  Two other invasive carcinomas include 
invasive papillary carcinoma and metaplastic carcinoma.  Both of these cases are rare, 
totalling less than one percent of all invasive breast cancer. Disease heterogeneity and 
rarity make it difficult for physicians to institute patients’ prognoses for these types of 
cancers.  
There are also rare cases of stromal tumors in the breast that include benign 
fibroadenomas, sarcomas, and phyllodes tumors.  Fibroadenoma is the most common of 
 
Figure 2.2. Magnetic Resonance Imaging (MRI) and PET/CT images of IDC (A&B) and ILC (C&D).  Arrows 
delineate the respective locations of the tumor in the breast.  It is very difficult to differentiate ILC in the PET/CT 
image, but IDC presents a very nice negative contrast.  Reproduced from [34]. 
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benign tumors and is often presented as a palpable mass, which allows for patients to 
discover them with self-examination.  Phyllodes tumors originate in intra-lobular stroma 
that are palpable, but are rarely detected in mammography [30].  Most phyllodes tumors 
are benign, but those that are more aggressive have been shown to over-express 
epidermal growth factor receptor (EGFR), a receptor whose over-expression correlates 
with cell proliferation [39].  Sarcomas of the breast, that present as large masses, are very 
rare.  A final area of concern for physicians is that there is a slight risk of angiosarcoma 
formation (0.3-4%) in the breast after a patient receives radiation therapy to treat the 
primary breast cancer [30].  
2.2.2. Molecular phenotypes of breast cancer 
As mentioned previously, there have been studies to classify all breast carcinomas 
by receptor phenotype; these studies were aimed towards helping physicians determine 
treatment options and prognosis for patients [40,41] with a specific phenotype.  Cell 
types have been broken into three main subtypes based on protein expression: luminal, 
HER2 over-expressing (HER2-positive), and basal-like.  Luminal tumors are 
characterized by the expression of hormone receptors progesterone and estrogen 
(ER+/PR+) [40,41].  Tamimi further differentiates the luminal subtype into luminal 
A&B, where luminal A is characterized as ER+/PR+/HER2-negative and luminal B is 
ER+/PR+/HER2-positive [41].  HER2-positive tumors are classified as hormone receptor 
negative with HER2 over-expression (ER-/PR-/HER2-positive).  Finally, basal-like cells 
are negative for all three receptors and are also known as triple-negative cancers (TN). 
Luminal tumors have been targeted with an anti-estrogen drug, Tamoxifen, that has 
demonstrated success in lowering recurrence and increasing long-term survival of 
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patients that are ER+ [42] by binding to the estrogen receptor and disallowing oestradiol 
from binding to the receptor (Fig. 2.3) [43]. However, tamoxifen treatment can cause 
endometrial cancer and cells will develop tamoxifen resistance [42]. Additionally, ER+ 
patients can receive oophorectomy (removal of the ovaries), to remove sources of 
estrogen from the body. These two treatments have been recommended as a 
combinatorial use to treat malignant tissue in the breast and lower the chance of 
recurrence by removing a source of estrogen in the body [44].  HER2+ cancers over-
express the growth factor receptor ErbB2 [45]. Breast cancers of this molecular 
phenotype and their treatment will be discussed in greater detail in section 2.4.4.  TN 
cancers are of major concern for physicians and patients due to the lack of receptors on 
the surface which does not allow for targeted therapy that is used with the other two 
 
Figure 2.3. Mechanism of action of Tamoxifen, which blocks oestradiol from binding to the estrogen receptor 
(ER), which prevents dimerization of the receptor (ER).  This stops the ER from binding to the Estrogen Receptor 
Elements (EREs) which then stops genes that are responsible for proliferation from being translated and 
transcribed. Reproduced from [43]. 
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subtypes of cancer [46].  Lowery et al. showed that TN patients were more than likely to 
have a recurrence of cancer when compared to the luminal type cancers [40]. This is a 
result of a lack of a properly targeted therapeutic that physicians can use to treat the 
tumors.  
2.3. Treatment of Breast Cancer 
There are three major treatment methods for breast cancer patients: 
chemotherapy, radiation therapy, and surgery.  Chemotherapy involves the administration 
of agents to the body that will cause damage to the malignant cells. However, these 
compounds are also toxic to healthy cells in the body, so physicians must balance the 
drugs’ potential health benefits with the overall health of the patient. Chemotherapeutics 
can be administered pre-surgery (neoadjuvant) to reduce tumor volume before patients 
undergo surgery [47,48].  They can also be administered after surgery to control tumor 
recurrence and metastasis.  The two main types of chemotherapeutic agents are small 
molecule therapeutic agents and biologically specific targets [49].   
Small molecule agents include anthracyclines and taxanes. Anthracyclines’ 
mechanisms of therapy include inhibiting DNA synthesis and creating free radicals in the 
cells that attack DNA [49].  Studies have shown that using multiple anthracyclines in 
combination raises the efficacy of the drugs [50], but there is cardio-toxicity associated 
with anthracyclines that limits the amount that can be administered to the patient [51]. 
Taxanes, which include the drug paclitaxel, disrupt microtubule formation and function 
to disrupt mitosis. Because taxanes and anthracyclines have different mechanisms (and 
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therefore different mechanisms of toxicity to healthy cells), combination of these 
therapies has proven an effective method of prolonging survival of patients [52].   
Biologically specific agents are targeted at specific receptors on the surface of 
cancers such as ER, PR, and HER2.  VEGFR (vascular endothelial growth factor 
receptor) is another important surface receptor in tumor health, as it stimulates 
angiogenesis and vasculogenesis that build blood vessels specifically for the tumor when 
bound with VEGF [49]. Bevacizumab is an anti-VEGFR antibody that competitively 
inhibits VEGF binding and prohibits vessel formation for the tumor area. As a single 
therapeutic, there is a very low response (9.6%) [53], but when boosted with an 
anthracycline, the time to disease progression in head and neck cancers more than 
doubles [54]. The combination of these drugs can also be used to lower toxic effect of the 
small molecule drug.  Cameron et al. showed that lapatinib (an anti-HER2 antibody) in 
combination with the anthracycline capecitabine increased survival time by 11 weeks in 
comparison to patients treated with capecitabine alone [55].  Chemotherapeutics play an 
important role in patients’ treatment plan and have great uses both pre and post surgery. 
However, cytotoxicity issues will always arise with these drugs, as they inhibit both 
healthy and diseased tissue.  
Whole breast radiation therapy has been used for decades as a conjunction to 
breast conservation therapy and has reduced the rate of recurrence and increased long-
term survival of patients [56,57]. However, it delivers a large amount of ionizing 
radiation to the breast that is dangerous and has potential long-term harmful effects.  A 
newer technology is accelerated partial breast irradiation (APBI) that treats a smaller 
volume of breast, just around the area of excision and does not expose the whole breast to 
  
 
13
ionizing radiation.  However, one concern is that areas of the breast with a multi-focal 
tumor will not receive enough radiation and could lead to an increase in tumor recurrence 
[48].  There have been recent advancements to improve APBI. The first is interstitial 
multi-catheter brachytherapy that places multiple catheters around the lumpectomy cavity 
and then delivers radiation through these catheters to localize radiation delivery.  The 
patients can be given high or low radiation dosages, and 5-year recurrence rates ranged 
from 0-6% [58].  Mammosite is very similar to interstitial multi-catheter brachytherapy, 
but in place of multiple catheters, a single balloon catheter (Figure 2.4) that is loaded 
with saline and fills the entire tumor cavity. Radiation is delivered through this balloon 
twice a day. A 2008 study by Stewart et al. showed a local recurrence rate of 3.8% and 
good cosmetic results (>90%) after a 60-month follow up.  One potential downside of 
Mammosite is that tumors that are in the deep breast might be too close to the heart and 
 
Figure 2.4. Radiograph of Mammosite balloon catheter for delivery of radiation therapy to a localized area of the 
breast.  This catheter is located in the right breast of a patient. A radio-opaque ruler is placed over the breast with 1 
cm intervals marked for sizing of the catheter. Reproduced from [59]. 
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deliver too high of a dose to the organ [59]. The final option for APBI delivery is using a 
3-dimensional external beam to treat the tumor cavity.  This requires extensive planning 
and modeling to ensure maximized dosage delivery to the tumor cavity because there is 
no catheter to deliver the radiation.  Multiple studies showed no local recurrence three 
years after treatment [60,61]. Even though whole breast therapy is still the standard 
therapy for breast conservation therapy (BCT), APBI offers a new method of maintaining 
cosmesis and minimizing local recurrence.  
Surgery remains the primary method of removing the bulk of breast cancers.  
There are two main surgical methods, modified radical mastectomy (MRM) and BCT. 
MRM involves total removal of the breast tissue [62] that lowers the chance of disease 
recurrence and removes the need for post-operative radiation therapy [62]. However, one 
major downside of MRM is the removal of the full breast, and its resulting trauma for the 
patient. BCT involves the surgeon removing the part of the breast with the malignant 
tissue and attempting to preserve as much of the breast as possible to maintain cosmesis 
for the patient. There is a higher chance of recurrence [4,63] with this procedure whose 
factors will be explored in further detail later in this section. Because of the amount of 
local recurrences during BCT, surgeons may remove larger volumes of breast tissue, and 
that has adverse effects on patient cosmesis. A new surgical specialty has developed in 
response to this problem, termed “onco-plastics,” which involves the use of volume 
replacement or reconstruction of the breast during the BCT after all malignant tissue has 
been removed [48]. These are very difficult surgical procedures and are the source of 
some controversy because it is thought that surgeons who are skilled enough to perform 
the plastics aspect of the surgery do not have enough knowledge of cancer as breast 
  
 
15
cancer surgeons and vice versa [64].  Due to these complications Clough et al. developed 
a two-tier classification system (Clough I&II) based on the percentage of tissue being 
removed from the breast (Clough I <20%) that aids the surgical teams to determine the 
specialty of the surgical procedure [48,65]. Margenthaler defines Clough II surgeries as a 
surgery where two surgical specialists are present (breast and plastic) that work in tandem 
to complete the complicated procedure; these surgeries include radial excision 
lumpectomy, batwing mastopexy lumpectomy, and lumpectomy with concurrent 
reduction mammoplasty [48].  
Technical advancements in breast cancer screening technologies have led to the 
detection of smaller cancerous lesions within the breast [31,66].  Due to the decreased 
size of the lesions, a higher number of patients are opting to undergo BCT followed by 
radiotherapy than the more traditional MRM [2].  Recent studies have shown that there is 
no difference in long-term survival rates for patients that undergo the respective 
treatments for early stage breast cancers [4,67–69]. While BCT is optimal for cosmesis 
because it preserves the original breast, many studies have shown that local recurrence 
occurs at a higher rate for patients receiving BCT, especially with younger patients [70–
72].  Even though the rate of recurrence does not effect overall survival rate [69], patients 
must undergo re-excision and increased radiation dosage [2,73]. Additionally, these 
patients undergo stress and psychological trauma that has an additive effect on the stress 
already seen with initial treatment [74,75].  Most importantly, local recurrences have 
been associated with increased rates of metastases in patients [76,77], and these 
metastases due to recurrence lead to a higher mortality rate.  
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Many retrospective studies have been conducted to determine the factors that lead to 
a local recurrence after therapy [2].  These studies include patient age [78–82], tumor 
size[78,81,83], radiation treatment [79,80,83], and lymph node status [78,83,84]. Even 
though these studies found that these factors can be used as independent predictors of a 
local recurrence of breast cancer, tumor margin status is still thought of as the strongest 
predictor for recurrence [85–88]. 
 
2.4. Tumor Margins 
The tumor margin is the area around the edge of the resected tissue specimen of 
the patient (Fig. 2.5).  Tumor margin status refers to the question of whether or not there 
are microscopic cancer cells located at the edge of the excised tissue specimen; a positive 
status indicates microscopic disease, whereas negative indicates disease free tissue. It is 
generally thought that if there are cancerous cells on the edge of the tissue, then the 
patient has an increased chance of a local recurrence due to the increased chance of 
cancerous cells not being removed from the body [87].  However, this is where the 
consensus on margin status ends, and argument begins [87].  Many studies have argued 
 
Figure 2.5 Cartoon rendering of margin status interpretation. Negative margins indicates that there are no 
cancerous cells in the predetermined margin width. Close margins indicated that there are cells within the margin 
width, but not at the edge of the resected specimen.  Positive margins indicate that malignant cells are on the edge 
of the resected specimen. Reproduced from [95] 
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and presented evidence as to what constitutes a proper negative margin for patients [89–
93].  In particular, the argument over what is the proper distance from the edge of the 
tissue that must be disease free in order for the patient to have negative margins.  For 
example, Zavagno used a distance of 3 mm whereas a panel led by Kauffman 
recommends that as long as there are no cells “touching ink” then the patient should be 
declared to have free margins, effectively a margin distance of 0 mm [91,94].  
Additionally, some studies use a third diagnosis: a close margin. Close margins are 
defined as tissues that contain microscopic disease within the pre-determined margin 
width, but not at the edge of the tissue [95].  This leads to the conclusion that it is very 
difficult to compare studies that use different indications of negative margins; however, it 
is accepted that the margin status (regardless of the definition of distance) is an important 
predictor of local recurrence.    
The distance in margin status is important in BCT because surgeons are trying to 
strike a balance between treating the disease while also maintaining cosmesis for the 
patient.  Studies have shown that having a more normal breast appearance has positive 
psychological effects for patients who have undergone breast cancer treatment [96–98].  
Increasing margin width will add to the amount of excised tissue during surgery leading 
to a higher difficulty of maintaining cosmesis [99] and perhaps leading to future 
psychological problems for a patient.  In 2010, Houssami et al. performed a meta-analysis 
of 21 margin status studies to determine how well margin status and width correlated 
with local recurrence rates.  The authors found that positive (or close) margins correlated 
positively with local recurrence and patients with a negative margin status had a lower 
rate of recurrence.  However, the study also concluded that the increasing the tumor 
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margin width (ranges of different studies were 1-5 mm) did not significantly lower the 
rate of recurrence, especially when they considered if the patient received a radiation 
therapy boost [87].  However, Houssami et al. did recommend that surgeons use at least a 
1 mm margin width when determining margin status in contrast to the “touching the ink” 
method recommended by Kaufman [87,94].   
Proper margin width is debatable throughout the medical community; however, 
the principle of removing as much diseased tissue as possible during surgery still holds 
paramount to reducing local recurrence.  There are numerous ways that physicians can 
increase the amount of diseased tissue removed by obtaining information about the tumor 
preoperatively [2].   
2.4.1. Pre-operative imaging to improve margin status 
Pre-operative imaging includes mammography, which allows the surgeon to assess 
the borders of a palpable tumor before the procedure begins.  Additionally, physicians 
can determine if there are micro calcifications in the breast, an indicator of possible DCIS 
presence [100].  A recent study by Rauscher et al. discovered that mammography has a 
high sensitivity in cancerous detection (94%), however it is lacking in specificity (61%) 
due to the presence of islands of fibroglandular or fibrocystic tissue in the breast that are 
indistinguishable from malignant tissue [101,102]. In some patients, ultrasound is used to 
supplement mammography findings as it provides better information on size and growth 
patterns of tumors [2].  MRI is a newer technology that provides significant improvement 
in pre-operative imaging of cancerous tissue when compared to mammography and 
ultrasound [103], especially with DCIS (Fig. 2.6) [104]. MRI provides patients and 
physicians with extensive information, such as multifocality of the disease, that can help 
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determine if a patient should even undergo BCT [3].  A study by Houssami et al. 
demonstrated that MRI helped detect additional cancer in 16% of patients, leading 1.1% 
of patients to select a mastectomy over BCT [105].  Even though MRI can help direct 
patients away from a surgery in order to decrease the chance of local recurrence, its 
preoperative use does not have a significant impact on margin status or local recurrence 
[106,107].  This is likely due to intra-operative MRI not being available [108].  
 
2.4.2. Current intra-operative visualization of breast cancer 
Due to limitations of implementing pre-operative techniques intra-operatively and 
their minimal effect on overall margin status and local recurrence, methods of peri-
operative tumor localization have been developed to improve resection of tissue. For 
twenty years the standard for intra-operative localization was wire-guided localization 
(WGL). WGL involves a pre-operative procedure in which a wire is placed in the tumor 
 
Figure 2.6. Pre-operative MRI image (A) of Ductal Carcinoma In Situ that was not detected with mammographical 
screening. B&C demonstrate zoomed in pre-operative mammographical views of the same breast with clips 
localizing the tumor.  Notice the lack of contrast in the mammography, demonstrating the efficacy of MRI in 
delineating DCIS.  Clips were placed with MRI. Reproduced from [104].  
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under the guidance of ultrasound, X-ray, or mammography.  The surgeon would then use 
the wire’s location during surgery to help extract diseased tissue. There were many 
problems with this procedure;the wire tended to move between procedure and surgery, 
the wire did not provide 3-dimensional information for the tumor (making edges of the 
tumor difficult to locate), and it was very uncomfortable for the patient [2,109].  Recent 
studies also demonstrate that WGL was ineffective, with 21-43% of patients diagnosed 
with positive margins [110–112] after surgeries implementing WGL.  A newer technique 
is intra-operative ultrasound (IOUS) guided excision that uses ultrasound in the surgical 
suite to guide resection of both palpable and non-palpable tumors. Several studies have 
shown that positive margin rates for this technology range from 3 to 11% [113–116], 
with Rahusen’s study directly comparing IOUS to WGL and showing a much better 
sensitivity (11% positive margins for IOUS compared to 45% for WGL) [115]. However, 
IOUS cannot detect the micro-calcifications that are associated with ductal carcinoma in 
situ (DCIS), which limits the usefulness of the technique.  X-ray radiography of the 
excised tissue is another intra-operative technique to improve patients’ margin status.  
However, this technique has very low sensitivity and is limited to detection of tumors 
without calcification [117]. Cryoprobe-assisted localization (CAL) is another 
methodology that is helpful in resection of non-palpable tumors.  An ultrasound helps 
guide a cryoprobe into the tumor, which then freezes the tumor into a detectable sphere 
that is easier to find and remove.  Tafra et al. found that there was no significant 
difference between CAL and WGL in reducing the amount of positive margins or rates of 
re-excision; however, there was a significant reduction in excised tissue volume which 
improved cosmesis [118].  Even though these techniques have shown promise as an intra-
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operative technique for margin detection, each has its limitations and each is a 
supplement to surgery. They have also yet to replace the gold standard for peri-operative 
margin detection: intra-operative pathology. 
Intra-operative pathology involves the use of an on-site pathological team that 
slices, stains, and analyzes the resected specimen while the patient is still under 
anesthesia.  The pathological team stains the various edges of the tissue to give spatial 
orientation of the tissue (Fig. 2.7) in order that the physician can tell the physical location 
of malignant tissue with regards to the edge of the resected specimen.  Next, the tissue or 
cells are stained for hematoxylin and eosin (H&E) [119].  A pathologist then reads and 
analyzes the samples and informs the surgeon where there is still microscopic disease 
present.  The surgical team will then decide whether to proceed with a re-excision.  
Hematoxylin is a blue stain that stains DNA in the nucleus, and eosin is a pink dye that 
stains other cellular structures. There are two different methods of intra-operative 
pathology, frozen section analysis (FSA) and intra-operative touch prep cytology 
(IOPTC). 
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FSA involves freezing, slicing, staining, and a pathologist analyzing samples to 
determine the presence of malignant cells.  The pathologist will work with the surgeon 
while the patient is under anesthesia, and the team of physicians will determine whether 
or not the surgeon needs to remove more tissue from the patient.  This process adds an 
average of 30 minutes to each surgery [12]. While there is risk with holding the patient 
under anesthesia for an extended amount of time, the benefits outweigh the risks because 
this procedure decreases the chance that patients will have to undergo a second surgery 
(and subsequently go under more anesthesia) and increased radiation dosage. Since 1994, 
M.D. Anderson Cancer Center (MDACC), a leading cancer research institution, has been 
performing FSA during BCT.  In a 2007 article published by Cabioglu et al., the authors 
evaluated the effectiveness of the FSA procedure at the institution and found that the 
overall accuracy of the procedure was 87.4% [71].  Studies by Camp, Riedl, and Olson 
showed that 24-27% of patients undergoing lumpectomy had additional tissue resected 
after FSA [11,12,120] during the same surgery, however Camp and Riedl’s studies did 
 
Figure 2.7.  Inked breast specimen indicating spatial orientation of the resected specimen.  Green area is thought to 
be area of tumor.  Tissue will be frozen, sliced, and stained for H&E. An on-site pathologist will then indicate 
where cancerous cells are present.  Reproduced from [85].  
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not show an overall improvement in local recurrence [11,12].  Additionally, studies have 
shown that FSA has high specificity but a lower and more inconsistent sensitivity rate 
[71,120,121].  Pleijhuis et al. concludes that while FSA lowers the need for a second 
excision, it does not reliably improve negative margin rates [2].  
IOPTC has been promoted as an alternative to FSA because of its speed, 
simplicity, and relative low cost [122,123].  Its process involves placing a glass slide at 
the edge of the tissue.  Surface characteristics of the cancerous cells will allow them to 
stick to the slide, whereas the benign mammary cells do not.  The cancerous cells are then 
stained with using H&E, or other cellular stains [124,125], and margin status is 
determined. A study by Weinberg et al. showed that IOPTC significantly lowered 
recurrence rates (2.8% vs. 8.8%) when compared to all other margin assessment 
procedures [126]; however this study did not differentiate between patients who received 
intra-operative pathology or had permanent analysis performed post-operatively.  
Additionally, IOPTC is adequate for determining if there are malignant cells on the edge 
of the tissue, but does not give any indication if there are cells within the margin width, 
and pathologists will not be able to determine margins [2,71].  Additionally, there may be 
scarring, cell damage, and artifacts on the edge of the resected tissue as a result of the 
cauterization that the surgeon has to perform when the specimen is removed [89].  
While both FSA and IOPTC are promising techniques, they have limitations.  
Firstly, they require an on-site pathological team consisting of technicians and a 
pathologist.  This is not feasible in many community hospitals due to costs and number of 
physicians (currently, <5% of hospitals offer this service) [127–129].  There is a vast 
unmet need for surgeons to be able to visualize tissue peri-operatively without the use of 
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a full pathological team. Techniques continue to evolve to aid surgeons in determining 
margin status.  We are now going to discuss some future techniques that range in stages 
of development, from taking part in clinical trials to still being developed on the bench-
top.  
2.4.3. Future intra-operative imaging devices 
One device that has been developed for use in a clinical setting is the 
MarginProbe™ from Dune Medical Devices.  The device is a spectroscope that measures 
the response of cells when interacting with broad range of radiofrequencies [85].  The 
device has a detection volume of about 38.5 mm3 that uses an algorithm to compare 
signal reflected from tissue to previously recorded signal from tissue (Fig. 2.8).  It gives 
the surgeon a simple readout of negative or positive using this algorithm. Recently it 
received a pre-market approval from the food and drug administration for clinical use in 
the United States.  The sensitivity of the device over a range of margin widths averaged 
67% sensitivity and a specificity of 68% [85]. Another study by Allweis et al. 
demonstrated that the MarginProbe™ was effective at lowering rates of a second surgery 
(12.6% to 18.6%) that was not statistically significant. Additionally, the volume of 
excised tissue for the device was higher than that of the control group, which may have 
skewed the results in the device’s favor [130].  Even though the device is not as effective 
as other options, it does show that there is potential for development of an intra-operative 
tool for surgeons to use as a supplement to already existing technologies.  
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PET has been used for imaging malignant breast tissue for many years 
[20,33,131], especially as a noninvasive method of monitoring chemotherapeutic 
response [132]. PET uses a radio-labeled glucose analog, 18F-FDG, that accumulates in 
areas of high metabolism, such as malignancies [21].  PET has a high sensitivity value in 
detection of large lesions (>1 cm) [33,133,134] but its specificity is low due to 
accumulation in non-malignant cells that are associated with infection and inflammation 
[135].   In addition to the sensitivity and specificity concerns of PET, it originally was not 
a good candidate for intra-operative imaging because the device was large and not 
practical for a surgical suite.  However, recent technological developments have enabled 
hand-held PET probes in colorectal [136], renal [136], ovarian [137], and breast cancer 
[138].  The handheld probes are a very nice proof of concept; however, for BCT 
 
Figure 2.8.  Examination of gross tumor specimen (A) of the MarginProbe™ intra-operative margin assessment 
device. (B) shows the effective volume of examination of the assessment device on the resected specimen.  
Reproduced from [85]. 
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implementation, there is still the issue that PET cannot detect lesions under 1 cm, and 
with recent screening technologies being able to detect lesions even smaller than that, the 
handheld probe would not be useful during BCT because as it could not detect something 
below its resolution limit.  Additionally, the use of a radio labeled tracer in the surgical 
suite not only has safety implications for the patient but for the entire surgical staff [139], 
and repeated exposures may have long-term carcinogenic effects on medical personnel. 
Another radio labeled visualization technology is radio guided occult lesion 
localization (ROLL).  This technology is described as a theranostic device that can both 
visualize and resect the desired tissue from the patient.  ROLL is similar to WGL in that 
it uses a pre-operative procedure to inject a non-targeted radioisotope into the tumor. 
During the surgery, a handheld gamma probe locates the isotope in the tumor and guides 
excision.  As with WGL, the placement of the isotope is paramount to maintain 
specificity and sensitivity.  Studies have shown correct placement of the radiotracer in 
95-100% of cases [110,112,140–142]. This technique shows approximately the same 
clinical success as WGL. 20% of patients in the study by Sarlos et al. had positive 
margins post-operatively [140], and surgeons were able to detect the lesions at a rate of 
98%.   Even though, ROLL achieved the same clinical results as WGL, it was found to be 
more comforting for the patients and an easier technique for surgeons to perform [142]. 
Even though ROLL seems to be an alternative to WGL; however, surgeons have yet to 
see an improvement in re-excision rates for this technique, which likely means that the 
limitations seen with both technologies are probably from the pre-operative placement 
and the imaging device used to implant the radiotracer or wire.  
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The next evolution of imaging breast cancer is the use of optical imaging with 
targeted contrast agents and autofluorescent signal of tissue.  Currently, near-infrared 
fluorescence (NIRF) has shown strong development and progress as a clinically relevant 
breast cancer imaging modality [2]; however, most clinically relevant trials have been 
limited to mapping sentinel lymph nodes with indocyanine green (ICG) [143–146] and 
not breast malignancies [147].  NIRF is considered a candidate for optical imaging of 
breast cancer as it has resolution down to 10 µm, higher penetration depth than light in 
the visual range, and autofluorescence of molecules in this wavelength is reduced [146–
148]. Even though NIRF has shown great potential in cancer studies, it is limited to the 
use of contrast agents that must be injected into the patient, and there are cytotoxicity 
issues involved with the agents inside the patient, particularly at the levels needed to 
differentiate tissue [148]. However, NIRF contrast agents can still be used on excised 
tissue, which would allow physicians to use the contrast agents’ positive aspects while 
minimizing their negative impact. This possibility will be discussed in chapter 4.  
 
Other imaging modalities use the endogenous signal differences between 
cancerous and non-cancerous tissue to attempt to differentiate tissues without contrast 
 
Figure 2.9.  Future intra-operative in vivo methods to visualize cancerous tissue during BCT. (A) Radio-guided 
occult lesions localization (ROLL). (B) Handheld positron emission tomography (PET), (C) Near-infrared 
fluorescence (NIRF) Reproduced from [2]. 
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agents.  These signal differences arise from a difference in oxygenation of blood, 
hemoglobin content, and cell density [149–151].  One of the most successful of these 
technologies is Diffuse Optical Imaging (DOI).  DOI has been used to measure the 
absorption of a broad spectrum of NIR light that is directed into specimen.  Due to the 
presence of absorbers such as deoxy-hemoglobin, hemoglobin, lipid, and water, light will 
propagate through a tissue in different time lengths.  These lengths can be measured, and 
correlated to the presence of specific absorbing molecules that characterize malignant or 
benign tissue [152].  Figure 2.10 shows a DOI image corresponding to the amount of 
oxygenated hemoglobin that is present in IDC in a patient.  The data corresponds well to 
the MRI image delineating the tumor.  This data can be combined with other imaging 
modalities such as mammography, and a quantitative 3-dimensional map of the breast 
can be created.  Additionally, a study by Kurkredi et al. demonstrated tumor only spectra  
(650-1000 nm range) in 22 cancerous patients versus 43 normal patients [153]. However, 
those studies were not used to study margin status, and reconstructing an image intra-
operatively would be very difficult. Wilke et al. developed a spectroscopic imaging 
 
Figure 2.10. DOI (A) and corresponding MRI (B) images of a breast with invasive ductal carcinoma with a volume 
of 5.5 X 6.5 X 7.5 cm.  Color map of DOI image shows areas of high oxygenated Hemoglobin that correspond very 
well to area of tumor. Reproduced from [151]. 
  
 
29
device that measured β-carotene scattering coefficient in negative, close, and positive 
margins.  The increased coefficient is due to decreased adipose tissue and higher cell 
density [149].  Though this study showed success, (identified 79% of positive tissues 
correctly), there was decreased accuracy with patients who received neoadjuvant therapy 
which affected physiologic and metabolic parameters that were used in their algorithm 
[149]; this device shows great potential for intra-operative margin assessment. 
Many technologies have been developed to help physicians visualize diseased 
tissue intra-operatively.  Whether it is pre-operative procedures, radiolabeled tracers, or 
using endogenous tissue differences, there are a number of methods to delineate 
malignant tissue.  As previously stated, less than 5% of BCT are completed with the use 
of intra-operative pathology assessment [127]. The overall goal of this project has been to 
develop a method of differentiating malignant breast tissue that has the potential to be 
used in a portable, inexpensive, and rapid manner, with minimal processing performed on 
the tissue to maximize speed and minimize time that a patient is under anesthesia. Our 
aim is the construction of a system that can be used intra-operatively without the added 
cost and time of extra technicians or pathological staff.  This system would enable the 
surgical team to take whole tissue at the margin area, add a targeted contrast agent, and 
visualize malignant tissue during surgery.  Previous work has demonstrated the efficacy 
of using antibody targeted silica-gold nanoshells (NS) as a visual contrast agent in cells 
[154,155], tissue slices [129], and even as a theranostic [156]. These studies have 
demonstrated that NS can be used in an efficient and rapid (<5 minutes) manner to 
differentiate cells that can be visualized using a variety of optical imaging techniques. 
However, these studies were performed on cell lines or tissues that needed to be sliced to 
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obtain images. Tissue slicing requires an element of time, equipment, and personnel that 
would add to the cost and complications of the surgical procedure.   
Additionally, these studies used expensive imaging equipment, and with 
exception of the Bickford et al. study from 2010 that utilized a Lucid VivaScope 2500 
(Fig. 2.11) [129], images were acquired with modalities that do not readily translate to 
the clinic. There remains a vast unmet need to further research into developing methods 
of imaging whole tissue rapidly with a portable and inexpensive system used in 
conjunction with targeted contrast agents. 
2.4.4. Importance of visualization of the over-expression of HER2 receptor 
Our previous research has used silica-gold NS linked to the anti-HER2 antibody that 
attaches to HER2 on the surface of cells, and we can use this targeting mechanism to 
visualize over-expression of HER2 in malignant cells.  HER2 is an EGFR that is part of 
the ErbB family [39], a group of four tyrosine kinase receptors expressed on the surfaces 
of cells in various levels.  When expressed in proper levels, the receptors have a role in 
cell growth, proliferation, and differentiation; however, abnormal expression levels are 
 
Figure 2.11. Reflectance Confocal Microscopy (RCM) images of tissue slices incubated with anti-HER2 silica 
gold Nanoshells.  Images show that HER2+ tissue had much higher signal due to the presence of the antibody 
targeted nanoshells. Reproduced from [ref 129]. 
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apparent in malignancies of a variety of organs, not only breast, and lead to uncontrolled 
cell growth [14].  The other three receptors include HER3 and HER4, and the commonly 
known EGFR.  The HER2 receptor is most commonly associated with breast cancer 
because it is found in 25% of all breast cancers and is thought to be a more aggressive 
subtype of cancer [14–17] that is associated with less favorable clinical outcomes. Even 
though tumors that are HER2-positive are considered to be a more dangerous subtype, the 
over-expression of the receptor has made it easier for targeted therapy using a 
monoclonal antibody against the receptor, either trastuzumab [157,158] or lapatinib 
[159,160]. This has also led to research in targeting the HER2 receptor for contrast 
agents, such as silica-gold NS [154–156] that can help physicians visualize HER2 status 
in tissues and cells. 
Visualization of growth factor receptors at the margin status could be more 
important for pathologists than previously thought.  As mentioned previously, cells at the 
tumor margin are stained for H&E, and pathologists use these slides to determine disease 
extent and margin status. This helps the team of physicians determine the course of action 
for post-operative treatment of the patient.  However, a recent study of oral squamous cell 
carcinoma by Vosoughhosseini et al. demonstrated that there were cells that over-
expressed EGFR in the samples that were deemed to be negative margins by normal 
H&E [13].  This is significant because patients who are declared cancer free, are, in fact, 
not, which is a possible explanation for local recurrence when patients are declared to 
have negative margins.  Additionally, a false-negative leads to a different post-operative 
treatment regimen that could possibly allow the cancer to proliferate at a higher rate than 
if the proper diagnosis was made.  Another growth factor, VEGF, has been studied as a 
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possible marker of local recurrence. With only three published studies, no conclusive 
evidence has yet to be established. Moran et al. found that in only a specific sub-group of 
patients with local relapse, was VEGF an independent indicator; however when 
performing multi-variate analysis with that same group, they were not able to reach 
statistical significance [161]. Linderholm et al. found that VEGF status contributed to 
overall survival but did not mention VEGF as a predictor of local recurrence [162].  A 
study by Manders et al. concluded that VEGF contributed to reducing the effectiveness of 
radiotherapy in patients with negative lymph node status [163].  These studies indicate 
that physicians are delving deeper into receptor phenotype as indicators for all aspects of 
the treatment of breast cancer and that there is much to be gained from knowing these 
phenotypes.  
Lowery et al. states that knowledge of the molecular phenotypes in breast cancer 
will not only help drive treatment decisions that will optimize patient care, but will offer 
valuable insight into prognosis [40]. Recent reviews that have studied the relationship of 
tumor expression and results such as margin status and local recurrence [18,39,45]. Tse et 
al. found that high EGFR expression was implicated in the pathogensis of phyllodes 
tumors [39].  Wang et al. concluded that DCIS patients that were HER2-positive had a 
higher rate of recurrence than patients that were hormone receptor positive [45]. 
Additionally, in a retrospective study of 143 patients by Miller et al., 27% of patients 
with a positive margin were HER2-positive versus 15% of patients with a negative 
margin (p-value 0.04) [18].  DCIS was of particular importance to these studies due to the 
increased incidence and smaller lesions that are a result of the improved screening 
technologies.  Over-expression of HER2 occurs in up to 50% of lower grade DCIS; 
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however, 50-100% of higher grade DCIS over-express the receptor [14]. Wang et al. 
found that patients that were ER-/PR- but HER2-positive had a higher rate of recurrence 
than patients that were ER+/PR+ and HER2-negative [45]. A 2004 study by Miller et al. 
states that in DCIS patients with HER2-positive status it is more difficult for surgeons to 
reach negative margins on patients with these characteristics than other types, including 
invasive carcinomas that were HER2-positive [18]. In 2011, Munirah et al. found that a 
higher percentage of HER2-positive patients had positive lymph nodes (regardless of 
estrogen receptor status), indicating the aggressiveness of the subtype [164]; a 2006 study 
by Kim et al. showed that HER2-positive cancers were the most frequent subtype found 
in distant metastases [165].  
Due to the increasing incidence of DCIS [166,167], the increased number of 
DCIS patients choosing BCT over mastectomy for DCIS [14], the increased prevalence 
of HER2-positive tissue in DCIS [41], and increased chances of local recurrence with 
HER2-positive DCIS [168,169] there is a need for a method not to identify cancerous 
tissue at the margins, but HER2-positive cells at the margin during BCT for DCIS. As 
stated previously, Vosoughhosseini et al. demonstrated that normal H&E might not be 
good enough to identify all cancerous cells at the margin [13], and a method to identify 
HER2-positive cells rapidly and intra-operatively gives physicians another tool to ensure 
negative margins are achieved during excision. 
Our aim is to use these targeted contrast agents to differentiate tissue that over-
expresses HER2-positive tissue from HER2-negative tissue optically.  An imaging 
system that combines proper optical set-up to visualize an agent with high luminescence, 
such as silica-gold NS, could be an invaluable tool for surgeons intra-operatively as they 
  
 
34
attempt to achieve negative margins that have been difficult to achieve in HER2-positive 
cancers [18]. As demonstrated with earlier research, our targeted nanoshells have shown 
measurable results in differentiating individual HER2-positive cells from noncancerous 
cells because an average of 1500 nanoshells were bound to each HER2-positive cell 
[155].  This is important because studies deem patients to be HER2-positive when there 
is strong immunohistochemical staining in greater than 10 [41,165] – 20% [170] of the 
cells being examined.  During an intra-operative procedure where cells will be visually 
detected, such a small percentage of cells might be difficult to detect optically.  The 
optical properties of silica-gold NS offer vast potential for use as an intra-operative 
contrast agent.  Additionally, the use of a NIR fluorescent dye (IRDye) that targets EGFR 
has potential for use.  Using NIR LEDs and white light imaging, we hypothesize that we 
can visualize both the IRDye fluorescence and the scattering and absorbance of anti-
HER2 to detect HER2-positive cells and tissues. 
In the proceeding chapters, we will discuss the increased use of nanotechnology 
as a theranostic, the utility of optical imaging for cancer diagnostics, and how our 
research will combine the use of optical imaging and nanotechnology to provide a new 
method to visualize cancerous tissue intraoperatively.  
  
 
Chapter 3  
Nanoparticle Use in Cancer Treatment 
and Diagnosis 
3.1. Introduction 
The previous chapter presented a review of breast cancer from the different 
subtypes to intra-operative imaging options.  In this chapter, we will explore 
nanotechnology and overview the current use of nanoparticles (NPs) in treating cancer 
through improved diagnostic and therapeutic applications.  Nanotechnology in medicine 
has been in use for approximately thirty years [171,172], with different NP materials 
offering various clinical uses.  For example, iron oxide NPs are used as contrast agents in 
MRI because of their magnetic properties [173,174]. Dendrimers are branched polymers 
whose size can be controlled by the number of polymer generations [171]. The 
physicochemical properties of dendrimers have been utilized for photodynamic therapy 
[175] and gene delivery [176].  Liposomes are nanostructures with a core of water (and 
  
 
36
drug) surrounded by a lipid bilayer [177]. The first NP approved for human use by the 
FDA is a liposome that encapsulates the anti-cancer drug doxorubicin.  Studies 
demonstrated that encapsulating doxorubicin in these liposomes not only decreased 
cardiotoxicity of the drug, but also improved the accumulation efficiency of the drug in 
breast cancer [178,179].  In addition to particle type, other factors such as size, surface 
charge, and targeting mechanisms also have an effect on particle efficiency and uptake in 
both in vitro and in vivo studies.  This chapter will explore the classes of NPs and the 
evolution of NPs that has resulted from increased study and understanding of the 
interactions between NPs and the biological environment into which they are introduced. 
3.2. Classification of Nanoparticles in Cancer Treatment 
In the introduction, we introduced three different NPs that are used in breast 
cancer treatment.  This section will explore those NPs and other formulations in depth.  
From a materials standpoint, NPs can be classified into two categories: “flexible” 
particles that are made of polymers or liposomes and particles that are composed of 
inorganic material [177]. 
3.2.1. Flexible nanoparticles 
Most flexible NPs are in the size range of 30 to 100 nm and have an advantage 
over inorganic particles, as they are composed of materials that have natural interactions 
with the cell membrane.  These characteristics help inorganic NPs penetrate the cell 
membrane more easily than inorganic NPs.  Correspondingly, this can increase the 
amount of drug delivered to the inside of a target cell. 
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The second NP to be approved by the FDA for use in cancer therapy was 
Abraxane®, a 130 nm diameter conjugate of Taxol® to albumin [171,177].  Albumin can 
solubilize Taxol® as efficiently as Cremophor EL®; however albumin does not have the 
same toxic side effects that are a result of using Cremophor EL® [171,177].  In addition 
to increased solubility, there was an increase in intratumoral accumulation with these 
particles. Desai et al. hypothesizes this is due to the caveolin-1 transport mechanism that 
naturally occurs in cells that express the gp60 receptor, and this system actively 
transports the bioconjugate into the cells after albumin binding [180].  Miele et al. and 
Hawkins et al. both suggest that the overexpression of osteonectin, a matrix glycoprotein 
that shares the same binding sequence as gp60, in breast and prostate cancers leads to 
high accumulation of Abraxane® in these tumors [181,182].   
Solid lipid nanoparticles (SLN) were introduced in 1995 by Müller et al. [183]; 
they can be optimized to carry either lipophilic or hydrophilic drugs depending on the 
method of NP production [177]. Additionally, SLN have controlled release mechanisms 
that allow the NPs to exhibit versatility in drug administration (oral or otherwise) [177].  
SLN can protect their encapsulated drugs from degradation [184] with low systemic 
toxicity [185], but they handle a low volume of drugs [184].  While SLN have 
dramatically decreased toxicity of standard chemotherapeutic drugs, there is a lack of 
targeted SLN mechanisms that can increase targeting in vivo. 
Dendrimers are promising agents for breast cancer treatment as researchers can 
easily control the particles’ molecular weight and structure [186].  Their unique chemical 
and physical makeup allows for binding and packaging of an array of chemicals: from 
contrast agents, to targeting ligands, to therapeutic compounds [177].  They can either 
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physically encapsulate drugs inside their spherical structure or act as drug-dendrimer 
complexes [171,177].  This diversity in application is evidenced by two studies released 
by the Baker group.  In the first study, researchers conjugated both fluorescein 
isothiocyanate (FITC) and fibroblast growth factor-1 (FGF-1) to the same dendrimer, 
poly amidoamine (PAMAM), to visualize the cellular trafficking of FGF-1 time (Fig. 3.1) 
[187].  In the second study, Choi et al. demonstrated that the same generation PAMAM 
dendrimer could be conjugated to doxorubicin and folic acid to function as a targeted 
drug delivery agent.  This compound was then excited with ultra-violet (UV) light and 
the drug was released in a controlled manner [188].  Even though dendrimers have shown 
great pre-clinical promise as agents in the treatment of cancer, only one has entered 
clinical trials, the VivaGel™ microbicide [171], a treatment for HIV.  The lack of clinical 
progress may be because the dendrimer itself can be cytotoxic to the host or because the 
drugs encapsulated within the NP are released very rapidly upon entry into the host 
[171,177].  
3.2.2. Inorganic nanoparticles 
The other main class of NPs is the inorganic NP that is composed of one or more 
inorganic compounds such as gold, iron, or silica.  Super-paramagnetic iron oxide 
nanoparticles (SPIONPs) are currently the most popular type of NP as they offer a multi-
modal particle whose iron core can be imaged via T2 weighted MRI [171,177,189].  
Researchers have also been able to conjugate contrast agents, drugs, or siRNA to its 
surface [190,191].  A study by Yu et al. demonstrated that SPIONPS labeled with both 
doxorubicin and Cy5.5 could be used as a multi-modal contrast agent that also delivered 
a therapeutic drug to the target [192]. 
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Treatment of cancer using gold-based NPs (AuNPs) has increased in the past 
decade.  AuNPs are popular because they are non-toxic, a variety of molecules can be 
functionalized to their surface, and they exhibit strong plasmon resonance (PR) properties 
[193–195].  PR is the oscillation of electrons along the surface of the particle upon 
interaction with an electric field [196], and the PR of AuNPs is manifested in their strong 
absorption or scattering capabilities [195].   The PR wavelength of a particle is dependent 
upon the physical characteristic of the AuNP such as size [197,198], shape [199], and 
surface chemistry.  The PR wavelength can be tuned to achieve scattering of the incident 
light at wavelengths from the visible to NIR [200].  Both Sokolov and El-Sayed et al. 
have demonstrated enhanced molecular targeting of AuNPs by conjugating an anti-EGFR 
antibody to the surface of AuNPs and visualizing the particles via reflectance [201] or 
transmission [200] (Fig. 3.2). 
 
Figure 3.1 G5-FTIC-FGF complexes incubated with MCF7 cancer cells at 1 and 24 hr timepoints.  Controls of 
cells without NP incubation and cells incubated with non-targeted NPs demonstrate specificity of complex.  
Different time points show that complexes can be tracked as NPs enter cell via cell internalization mechanisms due 
to FGF interaction with the cell line. Reproduced from [187]. 
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Due to their electron dense structure and non-toxic effects, AuNPs have also 
demonstrated utility as contrast agents and therapeutics in CT and X-ray systems.  
Hainfeld et al. demonstrated increased CT contrast in a mouse breast cancer model by 
injecting 1.9 nm diameter AuNPs intravenously. The small size of the NPs allowed for 
clearance of the particles in 24 hours, demonstrating the safety of the particles [202].  
Kim et al. injected 30 nm AuNPs conjugated to polyethylene glycol (PEG) and 
 
Figure 3.2 Representative scattering images and absorption spectra of anti-EGFR AuNPs incubated with 
noncancerous and two malignant oral cell lines.  Representative spectra from 23 cells in each condition is shown.  
Peaks for cancerous cells are shown to be at 543 and 545 nm respectively, where as non-cancerous HaCaT have a 
peak at 552 nm. Reproduced from [200]. 
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demonstrated increased contrast with no increased cytotoxicity in a rat hepatoma model 
[203].  A study by Geng et al. showed decreased proliferation in ovarian cancer cells due 
to the increased presence of glucose-capped AuNPs inside the cells interacting with X-
rays [204].  Another study by Zhang et al. demonstrated increased cytotoxicity in prostate 
cancer cells due to the combination of glucose-covered AuNPs and X-ray radiation (Fig. 
3.3) [205].  AuNPs have also been used as delivery agents for gene transfection as 
ammonium groups functionalized to the particles’ surface can bind plasmid DNA and 
protect the DNA from digestive enzymes such as DNAse I [206].  
 
The studies mentioned previously were examples of NPs composed solely of one 
material. Another class of NP is termed a nanoshell (NS), which consists of a core of one 
 
Figure 3.3 Thioglucose capped AuNPs localized to the interior of Du-145 prostate carcinoma cell. High-resolution 
TEM images show aggregates of AuNPs in vesicles in the cytoplasm near the cell membrane. Reproduced from 
[205]. 
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type of material (usually silica) with metal functionalized to the surface of the core.  
Silica-gold NS are generally the most common form of NS whose size can be designed 
for diagnostic, therapeutic, or theranostic approaches.  Oldenburg et aldemonstrated that 
the thickness of the gold shell on the same size core can shift the plasmon resonance of 
the structure so that a particle can be tuned to scatter or absorb a specific light wavelength 
(Fig. 3.4) [207].  These particles have demonstrated efficiency as photothermal agents 
that accumulate in tumors via the enhanced permeability and retention effect (EPR) [208–
210].  Once in the tumors, an NIR laser illuminates the tumor (and subsequently, the NS).  
Depending on the size of the NS, it will either scatter the incident light for imaging 
purposes or absorb the energy of the laser and convert that laser to heat to cause tumor 
death via hyperthermia [211].  NS can also be functionalized with a targeting antibody 
such as HER2 for both visualization [128,129,154] and therapy [156,212,213] to improve 
the specificity of the particles. There are a variety of types of nanotechnology available 
for the treatment of breast cancer, from use as a delivery vesicle for highly toxic 
chemotherapy drugs to contrast agents for MRI.  However, recent research has been 
 
Figure 3.4 Extinction spectra of silica-gold NS changes as the thickness of gold shell is varied.  Reproduced from 
[207]. 
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trending towards making an “all-in-one” particle that will act as both the contrast agent 
and as a therapeutic.  These particles are called theranostics and have shown high 
potential for future clinical use.   
3.2.3. Theranostic nanoparticles 
Earlier in this chapter, we alluded to the use of multi-use NPs such as multi-modal 
contrast agents and theranostic NPs.  This section will review the increase of 
theranostics-based research in the past decade and catalog the most recent developments 
published.  The multi-modal NP is still in its infancy, as the term theranostics was first 
used in literature in 2002 [214].  However, a SCOPUS search reveals that the number of 
published articles has risen steadily over the past decade to 191 in 2012 (480 total).   A 
comprehensive review by Jokerst and Gambhir separates theranostics into five classes 
[215].  Types I and II are NPs used in conjunction with surgery; surgeons use the contrast 
provided by the diagnostic aspect of the theranostic to delineate the cancerous tissue.  
Type I has intrinsic contrast (like an SPIONP) whereas type II is functionalized with an 
imaging agent such as a fluorophore [215].  Types III and IV are liposomes [216] or 
quantum dots [217] that act as drug carriers.  These classes of NPs can accumulate in 
tumors in a variety of manners such as EPR or via more specific receptors such as EGFR 
[218]; once again, the difference between the classes of particles is that they can be 
imaged via endogenous contrast or a secondary agent attached to the particle.  Class V 
theranostics are particles that respond to stimuli such as magnetic field [219] or NIR light 
[211] to cause hyperthermia in targeted cells or release of therapeutics.  These particles 
can also respond to external stimuli such as a magnetic field or ultrasound waves to 
facilitate more active targeting of the NPs to the tumor site.  A study by Chertok et al. 
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demonstrated the use of an applied external magnetic field to polyethyleneimine (PEI) 
coated iron oxide NPs to improve delivery of the particles to an intra-cranial brain tumor 
[220].  Watson et al. demonstrated that ultrasound could be used to enhance the delivery 
of therapeutic NPs to tumor phenotypes with limited vascularization and loose cell-cell 
adhesion sites by lowering pressure inside the tumor [221].   
Significant hurdles such as cytotoxicity and biodistribtion still remain before 
theranostics enter widespread clinical use.  Theranostics also require different dosages of 
therapeutic and diagnostic agent to be effective; this affects the dose and, subsequently, 
systemic toxicity of the NP.  Cole et al. also reports that embolisms in blood vessels can 
occur with iron oxide NPs as a result of an incorrect angle of applied magnetic field 
[222]. 
Despite challenges and limited knowledge of the nano-bio interactions of the 
particles, clinical translation of theranostic research has risen at a dramatic rate, resulting 
in five different particle formulations undergoing human clinical trials [215].  As 
scientists become more familiar with how the properties of theranostic NPs (and all NPs) 
affect their biodistribution and circulation time, these particles will likely become more 
effective in the treatment of cancer.  In the next section, we will discuss the different 
characteristics of NPs and how these properties affect NP circulation time and interaction 
with a host’s defense system.  Additionally, we will discuss modifications to NP surfaces, 
such as addition of a targeting ligand, to improve targeting efficacy.   
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3.3. Effect of Different Nanoparticle Characteristics on Biological 
Interactions 
As mentioned above, when NPs are introduced into a host’s system the shape, 
size, and surface charge of the particle affect the interaction of the particle with 
components such as serum proteins in the blood [223].  When designing NPs for cancer 
treatment, researchers must optimize their agent’s characteristics to insure it remains in 
the body long enough for its intended use and maintains low toxicity for the host.  This 
section will review how NP characteristics affect particle behavior when introduced into 
a biological environment. 
3.3.1. Effect of surface charge 
NPs with a neutral surface charge have a much longer circulation half-life than 
charged particles [172,223].  Serum proteins like immunoglobulin and metal-binding 
proteins interact with a charged particle instantaneously form a layer of proteins coating 
the surface called the hard corona [224,225].  The addition of the proteins to the surface 
can affect the properties of the NPs and cause them to aggregate, which will affect the 
distribution of the particles [223].  Additionally, the type of proteins that adsorb will 
affect particle distribution. For example, if opsonins adsorb onto the surface, NPs are 
tagged for immediate consumption by macrophages [226]. If antibodies adsorb onto the 
surface, the complement system is activated, and the particles will be consumed by 
receptor mediated phagocytosis [227].  In in vitro studies, positively charged NPs have a 
higher uptake, which could be a result of the slightly negative charge of the cell 
membrane [228,229].  Additionally, a negatively charged bound NP can cause gelation in 
the fluid membrane of the lipid bilayer [172].  The medium in which the NPs are being 
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introduced to the cells must be considered, as the protein composition will affect the 
protein corona.  This is seen in vivo, so any reaction by the cells to the NPs could be due 
to the particular proteins that are adsorbed onto the particle surface and not necessarily 
the charge of the particle that was introduced to the cell.  
To combat rapid adsorption, a strategy of stabilizing the particles with a layer of 
PEG (also known as PEGylation) has been adopted for all types of particles.  PEG 
prevents rapid protein adsorption and has been shown to increase the blood half-life of 
particles [172,230,231]; however, a majority of the particles are still found in RES organs 
after an extended period of time [230].  The thickness of the PEG layer can be controlled 
by the molecular weight of the PEG [232] with increasing layer thickness increasing the 
blood half life of the same size AuNP [232]. However, the PEG layer will affect overall 
diameter, which has a very significant effect on biodistribution, including tumor 
accumulation [232,233].  Additionally, even though a longer PEG chain length adds 
further stability for the particle, it limits the ability to functionalize targeted ligands to the 
particle (Fig 3.5) [234]. 
 Even though PEG is the most common mechanism for prolonging blood half-life, 
other compounds have been used.  Almeida et al. offer a very thorough review of the 
biodistribution of SPIONPs with different coatings [223].  A brief summary will 
beprovided here.  Dextran (an anti-thrombotic) and its variants have been researched with 
various degrees of success.  For example, Bourinett et al. reported on SPIONPs coated 
with a low molecular weight dextran and injected three separate times to have a blood 
half-life of 97, 208, and 222 minutes respectively [235], with approximately 11% of the 
injected dose being found in the liver.  Whereas Lawaczeck et al. coated SPIONPs with 
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low molecular weight carobxydextran in two phases with a clearance time of 2.2 and 41 
minutes respectively [236] with approximately 80% of the injected dose found in the 
liver.  In contrast, Chen et al. reported on the coating of SPIONPs with a copolymer of 
anti-thrombotic polysiloxane and amphiphilic polyethylene oxide that was able to lower 
the amount of iron in spleen and liver significantly when compared to dextran coated NPs 
[237].  In addition to the surface charge having an effect on the fate of NPs, ligands and 
molecules bound to the surface also can affect systemic distribution and intracellular 
localization of NPs. In the next section, we will explore how ligands bound to the surface 
can affect NP fate.  
3.3.2. Surface-bound ligands’ effect on nanoparticle fate 
Targeting ligands such as antibodies against cell surface receptors have been 
functionalized to NP surfaces to improve the targeting ability above the EPR effect.  A 
study by Choi et al. showed that active targeting of AuNPs with transferrin did not 
 
Figure 3.5 Illustration displaying the “PEG dilemma,” where increasing PEG thickness increases blood 
biocompatibility of a particle but also limits the number of biomolecules that can be attached to the surface of the 
PEGylated particle.  Reproduced from [234]. 
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improve the amount of particles that accumulated in the tumor. However, it did improve 
the intra-cellular localization of the AuNPs, as the particles were identified inside 
endosomes of cells that overexpressed the transferrin receptor [238].  A 2012 study by 
Kievit et al. demonstrated the efficacy of HER2 targeted SPIONPs versus NPs 
functionalized with a non-specific IgG antibody in a breast cancer murine model (Fig. 
3.6) [239].  In addition to providing enhanced specificity, surface ligands can also 
improve circulation time of AuNPs. Goel et al. demonstrated that AuNPs with PEG and 
tumor necrosis factor (TNF-α) had a longer circulation and slower uptake by the RES 
organs; however this was only a temporary effect as gold levels in the liver were similar 
at 24 hours [240].  Currently, there is one targeted theranostic in clinical trial, a 
melanoma treatment that targets the transferrin receptor and delivers RNAi [215]. 
Several studies have demonstrated the binding efficacy of anti-HER2 targeted 
nanoshells for diagnostic [128,129,155,241] and therapeutic [156] uses.  Carpin et al. 
demonstrated the utility of anti-HER2 funcionalized therapeutic NS in photothermal 
ablation of a Herceptin resistant HER2-positive cell [156].  NPs are good carriers for 
ligands because the curvature of the surface can increase the overall density of the 
antibodies on the surface, leading to increased affinity.  Jiang et al. demonstrated that 10 
nm particles with anti-HER2 had two orders of magnitude better binding affinity then 
Herceptin in solution with even higher affinity on larger particles [242].  However, Jiang 
et al. also showed that even though larger particles had a higher binding affinity than 
smaller particles they did not necessarily have a stronger impact on the activation of 
downstream enzymes, as particles with 40-50 nm diameter had the greatest effect when 
compared to sizes in the 2-100 nm range [242].   
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NPs with targeting ligands are likely internalized by receptor mediated 
endocytosis, but the intracellular fate of these particles is still relatively unknown [172]  
See et al. suggest that Cathepsin L in the endosomes cleaves the ligands from the 
nanostructure [243], which could lead to removal of the particle from the cell [172].  
They can also remain in the cell and be passed to daughter cells through mitosis [244]. 
The only direct conclusion about intracellular particle fate is that it is size and cell 
dependent [245].  Additionally, some NPs are engineered to leave the endosomal system 
so they can interact with subcellular organelles. For exampled, once inside cells, silver 
NPs can disrupt mitochondrial function leading to reactive oxygen species (ROS) that 
induce cytotoxic effects [246].  As well, Kang et al. attached nuclear targeting sequences 
to the surface of AuNPs to direct the particles into the nucleus to cause apoptosis in a 
cancer cell line [247].   
Targeted surface ligands can play an important role in the distribution, 
accumulation, and intracellular fate of NPs.  Researchers have been able to tune a particle 
behave in a specific manner when encountering a specific environment.  As this field 
 
Figure 3.6  (A) MRI images of a HER2-positive tumor implanted in a mouse. Images display T2 color maps of 
tumors pre and post injection.  (B) Graph representing the decrease in relaxation signal from the tumors after 
injection of non-targeted and targeted SPIONPs.  Reproduced from [239]. 
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grows, researchers will be able to optimize particle design to achieve even higher target 
specificity and desired therapeutic effect.  In the next section, we will discuss how 
particle size and shape affect the interaction between a NP and its environment. 
3.3.3. Effect of size and shape on nanoparticle fate 
The cellular uptake of NPs when introduced to cells has a strong dependence on 
overall diameter of the particle.  This is likely due to the thermodynamics of the 
membrane wrapping process [172] and the number of surface ligands bound by the 
particle.  For example, small (2 nm) NPs have high curvature, which requires more 
energy for membrane wrapping.  This indicates that multiple particles need to bind in the 
same area to cause a large enough free energy change to induce endocytosis.  
Additionally, the small amount of ligands attached to a NP surface lower the ability of 
that particle to interact with its targeted surface receptor.  In contrast, a large 100 nm 
particle holds a greater number of surface ligands, decreasing overall uptake because one 
particle can bind too many receptors and limit binding of other particles [172].  NPs with 
a range of 30-50 nm are able to bind enough receptors to induce endocytosis individually 
while not exhausting the receptors on the surface.  However, for each cell and receptor 
type, the optimal diameter is different due to different protein expression levels for each 
cell line. 
Size also has a significant effect on cytotoxicity and intracellular fate of particular 
particles.  For example, Pan et al. demonstrated that small (<2 nm) AuNPs were more 
cytotoxic than 15 nm particles [248]  with different size small AuNPs (1.2 & 1.4 nm) 
inducing cell death via different mechanisms.  The 1.2 nm clusters had slower 
cytotoxicity with an equal number of cells being apoptotic or necrotic; whereas the 1.4 
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nm NPs caused necrotic death very rapidly [248].   A second study by Pan et al. found 
that these 1.4 nm particles cause intracellular creation of ROS and damage to the 
mitochondrial membrane leading to rapid necrosis [249].  Additionally, surface charge of 
these small particles needs to be factored as studies by Goodman and Arvizo et al. 
showed that positively charged AuNPs were more cytotoxic than neutral or negatively 
charged particles, which is likely due to the positively charged AuNPs depolarizing the 
cell membrane and causing a calcium influx into the cell [250,251]. 
In vivo distribution of NPs is also very size dependent. For example, Choi et al. 
found that QDs ≤ 5.5 nm in diameter were cleared through the urine because they were 
able to pass through pores in the kidney [252].  The researchers were able to show that 
after 4 hours, half of the injected dose of particles had been excreted from rats [252].  
However, the majority of particles developed for clinical applications are larger than 5.5 
nm and a high percentage of the injected dose resides in the liver and spleen and can 
remain there for up to 8 months [253]. 
For larger particles, biodistribution is still important as researchers aim to design 
particles that are non-toxic to the spleen and liver and also accumulate in tumors.  Two 
studies by De Jong and Sonavane et al. showed that smaller AuNPs (10 and 15 nm 
diameter, respectively) had a much wider distribution than larger particles used in the 
studies, with both groups observing particle presence in the brain [254,255].  A study by 
Hirn et al. found this same size dependent distribution of particles found in the liver (less 
of the smaller particles detected in liver) but not in the spleen after 24 hours [256].  The 
researchers posit that smaller particles have higher “diffusional displacement” that limits 
the binding ability of receptors in the liver; this could help explain why smaller particles 
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are more widespread in the body.  Furthering this research, a 2011 study by Zhang et al. 
studied the systemic cytotoxicity and distribution of 5, 10, 30, and 60 nm PEGylated 
AuNPs and found widespread distribution in the smaller particles (Fig. 3.7) [257].  
However, the researchers found that toxicity of the particles did not follow a trend as the 
10 and 60 nm particles were found to be toxic to the liver and kidney, but the 5 and 30 
nm AuNPs were not, warranting further investigation [257].  Size is significant in both in 
vitro and in vivo distribution and intracellular fate of NPs.  It is an important factor in the 
design and optimization of a particle for treatment of cancer.   
The final parameter that ties directly to size is the shape of the NP.  Throughout 
this chapter, we have been only discussing NPs that are spherical in shape.  However, 
there are nanostructures other than spheres that have been fabricated and the work using 
these particles warrants mention in this section.  The most common non-spherical shape 
is a nanorod, which is cylindrical in shape with two different axes.  A study by Gratton et 
al. showed that nanorods had higher cellular uptake than spheres at sizes greater than 100 
nm [258]; however at sizes below 100 nm there is higher uptake of spherical particles 
[259].  Another study by Chithrani et al. speculates it is more difficult for cells to 
endocytose nanorods because the membrane must wrap around the entire length of the 
nanorod as the surface receptors are only located along the ends of the particle [260].  For 
in vivo biodistribution assays, reports conflict whether spherical AuNPs or nanorods have 
wider distribution [223].  A study by Arnida et al. showed that PEGylated 10 X 45 nm 
nanorods had a longer blood half-life compared to 50 nm PEGylated AuNPs [261];  
however, Sun et al. demonstrated that bare 30 X 80 nm nanorods had a higher 
accumulation in the liver than 40 nm AuNPs [262]. These studies are too different to 
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draw any significant conclusions, and much more research needs to be completed before 
a meaningful conclusion can be reached on biodistribution differences between the 
different nanostructures.   
The nanourchin, whose structure resembles a sea urchin, has been synthesized by 
Yu and Bakr [263,264]; the spikes of the “urchin” increase the electromagnetic field of a 
particle, which is helpful for imaging [265].  In a study by Hutter et al. nanourchins that 
were capped with cetyl trimethylammonium bromide (CTAB) were non-toxic to a 
microglial cell line in vitro. In vivo studies revealed that the structures were preferentially 
taken up by glial cells and not neurons [265].  This study did not investigate 
biodistribution or intracellular fate, and there is still further research to be completed on 
this shape.  
 
Figure 3.7 Tissue distributions for various sizes of PEGylated AuNPs.  Smaller NPs (5 nm) show widespread 
distribution to organs whereas larger particles are not as widely distributed.  Graph displays the role that size plays 
in particle distribution.  Reproduced from [257]. 
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Differing sizes and shapes can change the properties of a nanomaterial such as 
increased local plasmon resonance and enhanced raman scattering [266].  However, for 
these specialized structures to be translated to clinical relevance, more characterization of 
these particles needs to be done.  Assays from simple in vitro cytotoxicity to in vivo 
distribution assays will need to be performed for each new structure.  As researchers 
improve the ability to control size and shape at the nanoscale, new particles will continue 
to be synthesized and will contribute to our knowledge of how size and shape effect the 
fate of particles. 
3.4. Conclusion 
There are a large number of NPs being designed, optimized, synthesized, and 
characterized for use in biomedical applications.  Each type of particle has its own unique 
use and characteristics that can be used in the treatment of cancer.  Depending on the 
final goal of treatment, researchers can choose from any number of parameters to 
optimize the use of a particle.  In this chapter, we explored some of the more common 
NPs and the factors that affect their behavior in cells and animals. We explored the 
different core materials, how their surfaces interact with biological systems, how 
targeting ligands affect their ability to differentiate cancer, and how their size has an 
effect on distribution in animals and cells.  
In this thesis, we discuss the development of biodmedical applications of two 
types of particles.  In chapter 5, we will discuss the use of 2 nm gold colloid capped with 
glucose for use as a targeting agent in cancer cells with high metabolism.  We will 
explore the ability of this particle to penetrate the cell membrane in different cell lines, 
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compare the targeting ligand to other ligands, and examine its mechanism of entry.  We 
also demonstrate the use of large (314 nm diameter) silica-gold NS with targeted ligands 
to differentiate HER2-positive cancerous tissue from HER2-negative tissue.  We will 
optimize these structures for use in tissue as diagnostic agents and then explore the 
methods with which NS can be visualized in tissue.  
  
 
Chapter 4  
Background on Optical Imaging and 
Contrast Agents 
4.1. Introduction 
In the previous chapter, we discussed the use of nanoparticles in both the 
treatment and diagnosis of cancer.  This chapter continues with the use of other types of 
targeted contrast agents such as fluorophores and quantum dots.  This chapter will also 
relate the use of these agents in optical imaging and catalog the recent refinements in 
optical imaging technology that have improved visualization of malignant tissue.  
As cancer treatment has progressed over the past century, therapeutics have 
evolved from broad chemotherapeutic agents that kill both healthy and diseased cells to 
agents that are more specific for molecules that correlate with malignant tissue 
development [267], thus halting cancer spread and sparing healthy tissues from 
cytotoxicity.  Therapeutic compounds such as lapatinib and bevacizumab, which target 
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growth factor receptors that are overexpressed, are prime examples of molecularly 
targeted therapeutics that have proven effective [49,53].  Unfortunately, these successes 
in molecularly-targeted therapeutics have not transitioned to vast improvements in 
molecularly targeted diagnostics [267].  However, molecular imaging allows clinicians to 
visualize an almost infinite array of information by choosing the proper target, targeting 
agent and imaging technique [268].  Molecular imaging can be used to feature each 
molecular step that neoplastic tissue undergoes until it becomes malignant tissue 
[267,269].  Depending on cancer type and stage, molecular imaging can be used to 
visualize gene expression [270,271], angiogenesis markers (i.e. integrin αvβ3) [272,273], 
and metabolic activity [274,275]. Molecular imaging can also offer the ability to detect 
cancerous tissue earlier in its development by increasing contrast in tissues to help 
increase sensitivity and specificity.  This early detection is paramount as it has been 
shown that early detection in breast cancer correlates with a higher survival rate for 
patients [276].  Molecular imaging also locates multiple biomarkers on a single sample, 
allowing physicians to use the molecular profile of the tissue to tailor specific molecular 
therapeutics [267].  
One goal of this project is to take advantage of the variety of biomarkers that can 
be screened using molecular imaging by combining the specificity of molecular targeting 
with the ease and low cost of optical imaging to create an optical molecular imaging 
platform.  Our aim is that this system will be fast, inexpensive, and highly specific for 
malignant tissue.  We hope to accomplish this by finding specific optical contrast agents 
that target neoplastic tissue and using known optical imaging techniques.  The purpose of 
this chapter is to explore optical imaging technologies and contrast agents that have vast 
  
 
58
potential to be used to target malignant tissue in a clinical setting, with a focus on breast 
cancer.  
4.2. Optical Imaging Background 
Optical imaging has taken great strides in providing new methods of molecular 
imaging.  It has the ability to provide a variety of data from sub-cellular to macroscopic 
images [267,277]. It offers fast, high lateral resolution, and inexpensive options for 
imaging a range of disease states, such as hypoxia, hemoglobin levels, and metabolic 
state [277–279]. Optical imaging is generally thought to involve the analysis of visual or 
NIR light (i.e. scattering, absorption, or fluorescence) and its interactions with normal 
and malignant tissue. [277].   
Optical imaging has shown limitations in clinical practice, however, because of 
the lack of penetration depth of the wavelength used to interrogate target tissues.  The 
lack of penetration depth is due to the presence of water, collagen, and other extracellular 
components that all have different indices of refraction [280,281].  This heterogeneity in 
tissue and indices causes light to scatter randomly as it travels through the tissue [281], 
lowering the utility of optical imaging.  Additionally, light in the visual range (400-650 
nm) is absorbed by the skin at almost two orders of magnitude greater than NIR light (see 
Fig. 4.1) [282,283].  The NIR range (700-1000 nm) has become known as the “optical 
window” due to the penetration depth of the illumination light into the tissue of interest. 
This has been exploited for techniques such as diffuse optical imaging and optical 
coherence tomography [284,285].  We will now review some of the current optical 
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imaging technologies that have been used to visualize molecular profiles and expression 
of neoplastic tissue. 
 
4.3. Optical Imaging Using Endogenous Tissue Signal 
As discussed briefly in Chapter 2, imaging systems, such as MRI, use energy to 
interrogate tissue and detect lesions based off of the tissue’s interactions with the 
excitation energy. Optical imaging systems are mainly focused on the use of visual/NIR 
light and its interactions with the breast to detect changes in absorption and scattering of 
this illumination signal [286].  Increased absorption in the NIR corresponds to an 
 
Figure 4.1 Absoprtion values for deoxygenated and oxygenated hemoglobin and water showing the NIR window 
that is optimal for optical imaging because of the minimal interaction of light with these chromophores. Reproducd 
from [283]. 
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increased level of oxy- and deoxy-hemoglobin that is indicative of angiogenesis [287], a 
hallmark of cancer [288].  In three separate 2005 studies by Floery et al., Tromberg et al., 
and Zhu et al., malignant lesions are detected using optical imaging of the breast [289–
291]. Example absorption spectrum from one of these studies is presented in Figure 4.2. 
However, even though these papers showed the promise of optical imaging, it has been 
suggested that these technologies are not sensitive enough to be used as method of 
detection like mammography [286,292]. This is due to oxygen levels in the breast being 
affected by factors such as a patient’s age [293], menstrual cycle phase [294,295], or 
even type of cancer [296]. It has been suggested that the optimal use of this technology is 
to monitor tumor response for chemotherapy because it can use the patient’s baseline 
lipid and hemoglobin levels to specifically follow tumor size as shown by Enfield et al. 
[297]. This could serve as safer alternative than PET/CT, which uses ionizing radiation 
that might have long-term adverse effects on the patient [132,298,299]. 
Optical imaging has also been used to measure autofluorescent signal changes of 
neoplastic tissue in organ sites that can be accessed without invasive surgery.  These 
areas include the oral cavity [300–302], the cervix [303], and the lung [304], where the 
illumination and detection is accomplished with the use of an endoscope.  These devices 
operate under the principle that malignant tissue loses autofluorescent signal under white-
light imaging [267] and appear dark where normal tissue is white.  Even though there has 
been recent FDA approval of autofluorescent imaging devices in oral, gastrointestinal 
(GI), and pulmonary systems to visualize neoplastic areas, these devices have a low 
specificity because inflammatory response has the same effect on the autofluorescent 
signal that is seen with malignancies. This causes many benign areas that 
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are areas of inflammation to be mistaken for cancerous areas [305–308].  To improve 
specificity of optical imaging, there has been a large portion of research dedicated 
towards using contrast agents that can identify neoplastic cells by targeting specific 
biomarkers.   
In the previous chapter, we discussed nanoparticles that behaved as contrast 
agents because they were conjugated to antibodies that targeted specific biomarkers such 
as HER2.  In the next section, we will explore other targeted contrast agents that have 
been used in optical imaging to improve disease visualization.  
4.4. Targeted Contrast Agents for Optical Imaging 
Molecular imaging with contrast agents can be thought of as a three-piece system 
that needs all pieces present to work.  The first piece is the biomarker (molecular target) 
 
Figure 4.2 Average absorption spectra of 13 tumors (red) and normal (tissue). Increased absorption in the 650-850 
nm indicates higher hemoglobin concnentration and increased signal in the 950-1000 nm range indicates increased 
water content in the tissue.  Reproduced from [290].  
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that is characteristic of malignant cells and located on the cell membrane or inside the 
targeted cell.  The biomarker that researchers choose to target is site, organ, and cancer 
type specific. The second piece is the optical agent that will be visualized and provide the 
contrast that is necessary to differentiate the malignant and benign tissue.  Optical agents 
include fluorophores, quantum dots, and nanoparticles.  Each agent has advantages and 
disadvantages and will be explored later in this chapter.  The third and most important 
piece is the targeting molecule that is the linker between the optical agent and the 
biomarker so that the specific marker can be visualized.  In most cases the linker is 
chemically attached to the optical agent on one end and the targeting moiety for the 
specific biomarker on the other end.  An example of a targeting moiety attached to an 
optical agent is seen in the paper by Loo et al., in which the authors described attaching 
an anti-HER2 antibody to the surface of the same theranostic gold nanoshell (AuNS) as 
described by Carpin et al. [156,309].  Using an OPSS-PEG-NHS linker, the Fc region of 
the antibody was conjugated to the PEG with the NHS functional and then self-assembled 
onto the surface of the NP through the Au-S dative bonds.  These targeting moieties will 
be explored in further detail in this chapter.  
4.4.1. Biomarkers 
It would be ideal if the biomarkers were only present in the neoplastic cells; 
however, most biomarkers are present on each membrane, so most molecular contrast 
agents are targeted against the overexpression of a specific biomarker, such as HER2.  
For example, Carpin et al. demonstrate that there is still expression of HER2 on the 
surface of a HER2-negative epithelial breast line. The MCF10A (HER2-negative) cell 
lines expresses an average 2.43 X 104 HER2 binding sites per cell, but the HER2-positive 
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SkBr3 cancer cell line expresses 2.19 X 106 sites per cell.  This large expression 
difference led to an increased targeting efficiency of a theranostic particle in SkBr3 cells 
that led to enhanced contrast and therapeutic effect from the nanoparticles [156].   
In addition to surface markers, the overexpression of different glucose 
transporters (GLUTs) in the cell membrane has been used to differentiate breast cancer in 
both cell lines and ex vivo tissue [22–24].  Due to the increased metabolic rate of the 
disease, a high number of cancers overexpress GLUTs to increase the amount of 
available energy for the cancer to grow.  Different cancers overexpress different GLUTs 
and these GLUTs are specific for the different types of glucose they transport. For 
example, GLUT1 transporter allows for the common D-glucose to pass though the 
membrane where as GLUT5 is a commonly known as the fructose transporter [310,311].  
A final biomarker that has been targeted for use with molecular contrast agents is the 
expression of specific mRNA molecules that are translated into proteins such as survivin 
that help cancer cells overcome apoptosis [312].  
4.4.2. Optical agents 
In the previous chapter we discussed the use of nanoparticles as optical agents for 
disease visualization; however, there are two other agents that are much smaller in size 
that are frequently used in optical imaging: fluorophores and QDs.  Fluorophores are 
organic dyes that, when interacting with a photon, promote an electron from a lower 
energy orbital to a higher energy orbital (called absorption), when the electron returns to 
the ground state, a photon is emitted. Generally, this photon has less energy than the 
excitation photon so the wavelength of light emitted will be longer [313].  Specific 
fluorophores have different absorption and fluorescence maximums and researchers need 
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to ensure that their optical imaging set-up is optimized to excite and visualize the 
fluorophore of interest. Some specific examples of fluorophores used in optical imaging 
of cancer include Alexa Fluor® and cyanine dyes that were used to visualize the 
overexpression of EGFR [314,315] in oral and breast cancers.  Fluorophores have many 
advantages in that they are low-cost and can easily be conjugated to targeting molecules 
[267].  These properties allow fluorophore based contrast agents to be manufactured with 
high fidelity. The small diameter of most of these molecules (<1 nm) also improves the 
ability of the contrast agent to penetrate the cell membrane or pass through transporters, 
as is seen with 2-NBDG.  However, there are challenges with fluorophores: they 
photobleach over time when excited, and there are limited agents with approval for use in 
humans.  A very significant problem with fluorophores is that the majority of dyes emit 
in the visual wavelength range, limiting enhanced contrast to epithelial layer of the tissue 
of interest.  There are studies that have focused on the use NIR fluorophores because of 
minimized light absorption in this range using both targeted [316] and non-specific 
agents [317].  We point to a comprehensive review by Luo et al. that thoroughly 
examines NIR dyes that are being used for cancer visualization [279]. The largest hurdle 
to overcome with the use of fluorophores is that the fluorophores emit the same signal no 
matter if they are attached to the desired biomarker or not, so if there is not a proper 
method of removing unbound contrast agent, then there will be a high signal from areas 
where the specific biomarker is not present, leading to a much lower specificity for the 
contrast agent. 
QDs are semiconductor crystals whose diameter varies in size from 2-10 nm, 
whose optical properties vary with size and core composition (see Fig. 4.3) [318].  QDs 
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are very useful optical agents because their semiconductor material ensures minimal 
photobleaching, their optical properties can be tuned to have a very broad absorption 
spectrum but very narrow emission peak, and they have a higher quantum yield than 
fluorophores.  This allows for different QDs to be targeted against various biomarkers 
used in one sample because of the minimal spectral overlap between different QDs’ 
emission profiles [319].  Even though QDs have superior optical properties, their use is 
very limited because the cadmium that makes up the majority of QD cores is toxic to 
humans and animals at very low concentrations [320].  Due to the high toxicity concerns, 
the only in vivo studies performed with QDs has been limited to mice [253,321] and rats 
[322].  There have been recent studies that have used rare earth based nanocrystals as a 
more biocompatible alternative to cadmium based QDs.  Kumar and Setua et al. 
synthesized Ytterbium based nanocrystals that were combined with fluorescent and 
magnetic elements (Eu3+ and GD3+) to create multimodal imaging agents that have been 
used to image cancer cells in vitro with no toxicity [323,324].  However, there have yet to 
be further studies published on the use of these QDs in in vivo studies.  
The use of nanoparticles as targeting agents was discussed in the previous chapter 
and will not be discussed here.  However another contrast agent warrants further 
discourse is proflavine.  Proflavine is a DNA intercalator that binds reversibly to DNA 
with a strong absorption peak at 445 nm [325].  Muldoon et al. showed that, when used in 
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Figure 4.3 (A) Chemical makeup of different core-shell combinations of cadmium QDs and corresponding 
fluorescence emission spectra each combination. Results show the spectral shifts that are a result of core and shell 
composition. (B) Fluorescence emission spectra of different combination of QDs with different particle diameters 
showing both spectral changes due to chemical composition and overall diameter.  Reproduced from [318]. 
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combination with a high-resolution micro-endoscope, proflavine could be used to 
visualize the spatial distribution and density of nuclei in highly suspicious areas in the 
oral mucosa [326].  The researchers were able to visualize the nucleus and use an 
algorithm to calculate the ratio of nucleus to cytoplasm to differentiate patients with 
moderate dysplasia to cancer [326].  Proflavine has seen use in clinics as a form of 
protection from infection for newborns’ umbilici [327] and has seen use in exploratory 
GI surgeries [328,329].  However, very few groups outside of Dr. Richards-Kortum’s 
research group have explored its use as contrast agent for the diagnosis of dysplasia. 
 
The final optical agent that is important in optical imaging is the use of a 
fluorescence quencher with a fluorophore that helps indicate the presence of a specific 
mRNA molecule or a specific peptide sequence from a target protein.  These are known 
as smart probes or molecular beacons.  These probes are conformed so that when they are 
unfolded there is an absorbing (or quenching) molecule on one end and a fluorescent 
molecule on the other end.  The two molecules are linked linearly via a specific mRNA 
sequence that is designed so that the molecule will naturally conform to bring the donor 
and quenching molecule in close proximity to each other.  If the targeted sequence is not 
 
Figure 4.4 High resolution microendoscope images of proflavine accumulation in (A) normal squamous mucosa 
(B) moderate dysplasia, and (C) invasive squamous cell carcinoma.  The higher signal from B&C indicates an 
increased amount of DNA present.  These images were then used to calculate DNA to cytoplasm ratios and 
compared to histopathological results.  Reproduced from [326]. 
  
 
68
present and the fluorophore is undergoing fluorescence it will transfer its energy to the 
quenching molecule and no signal will be seen.  However, in the presence of the mRNA 
sequence, the molecule will unfold which moves the quenching molecule away from the 
fluorophore whose signal can now be visualized.  Another example of these moieties are 
fluorescent smart probes in which the quencher and donor are linked by a specific peptide 
sequence that is cleaved in the presence of specific proteases like caspase-1. These 
optical agents are much more specific than normal fluorophores because their signal is 
only seen when the quencher is no longer near the fluorophore, allowing for specific 
sequences to be delineated and raising the target to background ratio to a much higher 
level than with normal fluorophores.  
4.4.3. Targeting moiety 
As discussed before, targeting moieties are the molecules that are used to link the 
optical agent to the biomarker of interest.  These molecules can range in size from sub 
nanometer to 10s of nm [267].  There are a wide variety of agents that are used as 
targeting moieties for cancer visualization.  Choosing the proper moiety is dependent 
upon desired biomarker and ease of functionalization to optical agent.  Small moieties 
such as glucose and fructose are chosen because they can target the overexpression of 
GLUTs that is frequently seen in cancer cells.  Generally, small moieties such as glucose 
are paired with a fluorophore as a contrast agent because the small size of the 
fluorophores does not interfere with the ability of glucose to pass through the GLUTs.  
Additionally, the functionalized fluorophore attached to the glucose prevents the glucose 
from undergoing glycolysis past the first glycolytic step [25].  Other targeting moieties 
that are used to visualize overexpression are growth factors such as EGF and VEGF.  The 
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overexpression of the surface receptors for these growth factors is seen in malignant cells 
and the binding of growth factors leads to downstream signaling in cells that promote 
certain hallmarks of cancer such as uncontrolled growth, cell survival, and increased 
vascularization [330–333].  As the location of these receptors is on the surface of cells, 
growth factors can be paired with a variety of optical agents because researchers do not 
have to worry about transporting the optical agent across the cell membrane.  For 
example, EGF has been functionalized with fluorophores [314], QDs [334], and AuNPs 
[201] for visualization of EGFR on the surfaces of cancer cells. 
Another targeting strategy is the use of antibodies against surface receptors like 
VEGFR and EGFR to visualize their overexpression [128,335].  Antibodies paired with 
fluorescent optical agents have demonstrated very high specificity in both in vitro and in 
vivo studies [336,337] with a very high signal to background ratio.  One major 
disadvantage of antibodies is that their size prevents from penetrating tissues and that has 
a potential to limit their use both in vivo and ex vivo [338].  Additionally, antibodies 
might induce an immune response in the host’s body, which is thought to be due to the 
presence of murine antibody regions in the antibodies [339].  To combat these, 
researchers have engineered antibody fragments [340], chimeric antibodies [341], and 
humanized antibodies [342,343] to improve specificity and reduce immune response.  
Using antibodies as a targeting moiety has high potential for clinical use because of the 
ability to engineer very specific antibodies and the theranostic potential of using a 
therapeutic antibody conjugated to an optical agent.   
The final two moieties are specific for use with smart probes (molecular beacons).  
As discussed earlier, these moieties are constructed so that they are turned off when the 
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specific molecular target or enzyme is not present and there is fluorescent signal when it 
is.  The molecular beacon moiety is known as a nucleic acid aptamer with a specific 
complementary RNA (or DNA) sequence that is modified to a variety of targets including 
nucleic acids and proteins [344–346].  The aptamers are generally 25 nucleotides long 
with the middle 15 nucleotides acting as the complementary probe for the sequence 
[347].  The 5 nucleotides on each side of the target sequence are complementary to each 
other and attached to the two fluorescent molecules (donor and quencher).  When in the 
presence of the target sequence, the unbound complementary sequence will bind to its 
target which forces the aptamer to unfold and fluoresce, signaling the presence of the 
target nucleotide sequence.  One restraint of using molecular beacons is that they must be 
able to enter the cell to detect the sequence of interest.  Therefore, ensuring delivery of 
the probe is of utmost importance.  The other moiety that is used with fluorescent donor 
and quencher molecules is an enzyme cleavable peptide sequence with two fluorescent 
probes attached to each end of the sequence.  These specific sequences are cleaved by 
specific proteases, such as caspase-1, an indicator of apoptosis [348].  These probes can 
be used to interrogate the protein expression of neoplastic areas and probe for 
upregulation (or down-regulation) of proteins that are characteristic of malignant cells, 
such as cathepsin protease [349].  While there are some very promising results, using 
cleavable peptides has two downsides: uptake of the peptides into cells is slow and there 
are also specificity issues due to the presence of other cleaving enzymes that can cleave 
the target sequence [267].   
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4.4.4. Delivery of contrast agents 
The final hurdle researchers must overcome when considering the use of a 
contrast agent is the delivery of that contrast agent to the specific site.  For some 
epithelial contrast agents, delivery is done topically and can be easily accomplished by 
exposure of the agent to the surface of interest.  However, there are two factors that limit 
topical agent delivery. First, the surface must be easily accessible, so only areas such as 
the oral cavity, skin, or resected specimens can be targeted with topical agents.  Second, 
the agent needs to be able to penetrate the epithelial surface, or else only a small layer of 
cells will interact with the agent.  This limits the use of the agent to specific cell types 
and locations.  Research by Van de ven et al. described the application of an anti-EGFR 
fluorophore diluted in Triton-X100 that allowed for penetration of the contrast agent to 
approximately 400 µm from the surface of malignant tissue, whereas agent diluted in 
PBS or DMSO did not penetrate the surface (Fig. 4.5) [350].  However, even using a 
permeation agent such as Triton-X 100 has limited penetration depth, which restricts the 
use of topical contrast agents to very specialized instances.   
Systemic injection of contrast agents intravenously is the other method for 
delivery of contrast agents.  Systemic injection can increase the likelihood of agent 
penetration and accumulation in desired tumor tissue through the enhanced permeation 
and retention effect.  However, larger doses of injected agent are used for systemic 
injection, which can involve toxicity issues.  Nanoparticle based contrast agents tend to 
have much higher accumulation in the spleen and liver [233] because their presence can 
induce an immune response in the host [223,226].  Nanoparticle fate is due to many 
different factors: size, shape, surface charge, and nanoparticle material are just a few of 
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the considerations researchers must consider when picking a nanomaterial, and we point 
to a review by Almeida et al. as a more thorough exploration of these factors and how 
they affect the biodistribution of nanoparticles [223].  However, one can apply the same 
reasoning to the factors that affect systemic delivery of nanoparticles to contrasts agent 
that are delivered systemically.   
In addition to avoiding an immune response, agents must also be able to 
accumulate in tissue of interest while minimizing non-specific binding in other areas of 
the body.  Once an agent reaches the targeted cell (via topical or injection) it must also 
penetrate the cell membrane and perhaps the nuclear membrane if the agent is targeting 
DNA expression.  There is not one correct method for agent delivery; determining the 
delivery method is based on biomarker, target, and optical agent, amplifying the factors 
that must be considered.   
 
Figure 4.5 Fluorescent images of tumor tissues sliced so that the top of the image is the surface of the tissue that 
interacted with the contrast agents.  Images display an anti-EGFR fluorophore  (red) that has been diluted with 
Triton-X100, DMSO, and PBS. Acriflavine is counter stained in green to give tissue morphology.  Images show the 
penetration of the anti-EGFR molecule to areas below the surface. In contrast to the other two images that had 
different dilution compositions so little to no penetration. Scale bar = 100 µm.  Reproduced from [350].  
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4.5. Conclusion 
Optical imaging is a new field that has great potential in helping researchers and 
clinicians visualize and delineate cancerous cells from non-cancerous cells.  There are 
different approaches to optical imaging, from using endogenous signal of patients’ tissues 
to using a systematically injected contrast agent that can penetrate the cell membrane and 
interact with a specific nucleic acid.  Optical imaging is a promising tool that can help in 
both clinical and basic research.  Choosing the proper target organ, proper target cancer 
type, and type of optical imaging will have a tremendous impact on a researcher’s 
success.  
The goal of this thesis is to use two contrast agents in conjunction with an 
inexpensive imaging camera to provide surgeons with a tool to visualize microscopic 
disease presence, macroscopically.  We aim to use a fluorescent-based contrast agent, 2-
NBDG, that targets the overexpression of GLUT1 seen in breast cancers, and an anti-
HER2 targeted silica-gold NS that targets the overexpression of HER2 that is seen in 25-
30% of breast cancers.  The goal of this work is to combine two agents that have shown 
the ability to differentiate cancer cells in less than 10 minutes as an optical imaging tool 
for breast cancer surgeons intraoperatively.  Using two contrast agents will help increase 
the specificity of the agents as there will be two different enhanced signals that need to be 
present in order to confirm the presence of HER2-positive cancer cells.  In the next two 
chapters, we will discuss how we have used these contrast agents separately to 
differentiate and visualize tissue in resected cancerous specimens. Then, in the final 
chapter we will discuss the visualization of these agents (and IRDye) with a portable, 
inexpensive camera. 
  
*Partially adapted from: Langsner, R J, L P Middleton, J Sun, F Meric-Bernstam, K K Hunt, R A Drezek, and T K Yu. 
2011. “Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue.” Biomed Opt 
Express 2 (6): 1514-1523.  
 
Chapter 5  
Glucose to Enhance Targeting of 
Fluorescence and Scatter Based 
Contrast Agents 
5.1. Introduction 
As discussed previously, there is an unmet need for physicians to visualize 
malignant tissue intraoperatively.  The combined use of optical imaging and contrast 
agents has the potential to allow surgeons to visualize microscopic disease during 
surgery.  In this chapter, we demonstrate the use of the fluorescent contrast agent 2-
NBDG to differentiate cancerous cell lines from non-cancerous cell lines.  We then 
expand upon this research by demonstrating that there is increased signal from 2-NBDG 
in freshly excised cancerous tissue when compared to benign tissue.  Finally, we translate 
the use of glucose with a fluorescent contrast agent to its use as a targeting moiety for 
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small diameter (~2 nm) gold nanoparticles (AuNPs).  We demonstrate the mechanism of 
entry of glucose-capped AuNPs and demonstrate the specificity of glucose to enhance 
contrast in in vitro experiments.   
5.2. Background 
In many tertiary care centers, appropriate facilities and staff exist to allow 
assessment of margin status intraoperatively. Surgeons in these centers have the 
opportunity to remove more tissue during the same procedure to achieve negative 
margins if the initial resection margin is positive. However, many hospitals and smaller 
surgery suites in the general community (>95%) [127] do not have pathology support 
services to allow for intraoperative margin assessment, and thus the margin status is not 
known until several days after the surgery [129].  
Positron Emission Tomography (PET) is currently being used in clinics to stage 
breast cancer and monitor response to therapy [20,33,351]. PET utilizes a positron 
emitter analogue of glucose, 2-(fluorine-18)-(fluoro-2-deoxyglucose) (18FDG) to monitor 
in vivo glucose uptake. PET leverages the higher metabolic state, higher expression of 
glucose transporters (GLUTs), and lower expression of glucose-6-phosphatase of 
malignant cells to image the high level of 18FDG uptake in cancerous cells, distinguishing 
them from non-cancerous cells [352–357].  2-[N-(7-nitrobenz-2-oxa-1, 3-diazol-4-
yl)amino]-2-deoxy-d-glucose (2-NBDG) is a fluorescent glucose analogue that undergoes 
a similar pathway of uptake and metabolism to 18FDG and accumulates preferentially in 
malignant cells [25,358]. In preclinical imaging studies, 2-NBDG accumulation was 
shown to be higher in cancerous cells than in normal cells [25,359]. Nitin et al. have 
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demonstrated the use of 2-NBDG to enhance fluorescent molecular imaging of oral 
neoplasia [359].  
In this study, we perform an important proof of principle study that demonstrates 
that topical application of 2-NBDG can be used as an optical contrast agent to help 
differentiate cancerous tissue using a wide-field imaging system. First, we demonstrate 
the cellular localization of the contrast agent in the cytoplasm of cancerous cells in vitro.  
Then, we imaged fresh human breast tissue acquired from surgical specimens and stained 
them with 2-NBDG. We establish that the 2-NBDG signal in tissue can be visualized 
using a wide-field camera and filters to create multispectral images of tissue.  These 
multispectral images can then be analyzed both qualitatively and semi-quantitatively by 
using the area under the curve metric of the spectral profile of the tissues. Our analysis 
demonstrates that 2-NBDG preferentially enhances the fluorescent signal of malignant 
tissue. Future steps will be to develop a simpler and more portable wide-field optical 
system that uses 2-NBDG and can be applied to assist in the detection of cancerous tissue 
at the time of surgery.  
Additionally, we follow the same principle of using glucose to target cells with 
increased metabolism by conjugating thioglucose to the surface of small diameter (~2 
nm) gold colloid that is made in the lab or purchased commercially.  As discussed in 
chapter 3, AuNPs have excellent plasmon resonance properties that allow for increased 
scattering of incident light.  Successful conjugation of thioglucose to the surface of the 
particles (glu-AuNPs) was confirmed using Energy Dispersive Spectroscopy (EDS).  
Next, different surface coatings (citrate, glucose, or bare) of AuNPs show different 
effects on the targeting of the particles.  Cells treated with glu-AuNPs have an increased 
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scattering signal from inside the cells, indicating preferential cellular uptake.  We also 
demonstrate the difference between cancerous and non-cancerous cell lines by observing 
changes in the cellular uptake of the NPs.  To accomplish this, the AuNPs were localized 
in the cytoplasm and the nucleus using Transmission Electron Microscopy (TEM) and 
EDS.  Finally, we attempt to elucidate the mechanism of entry of these particles in the 
cells by using competitive inhibition and endocytosis inhibition studies. 
5.3. Materials and Methods 
5.3.1. Cell lines 
The SK-BR-3 and MCF10A cell lines were obtained from the American Type 
Culture Collection (Manassas, VA).  The SK-BR-3 cells were maintained in McCoys 
Modified Solution 5A supplemented with 10% fetal bovine serum (FBS) and 3% 
penicillin/streptomycin. The MCF10A cell line was maintained using a Mammary 
Epithelial Basal Medium Kit (Lonza) supplemented with standard growth factors. Both 
cell lines were grown at 37°C and 5% CO2. 
5.3.2. 2-NBDG characterization 
2-NBDG was acquired from Invitrogen in powdered form and was re-suspended 
in 1X DPBS (Gibco) to a final concentration of 194 µM. The pH of the solution was 7.4.  
Aliquots of the fluorophore were kept frozen at -20°C in black centrifuge tubes until 
needed.  Before receipt of the tissue, the aliquots were thawed in a 37°C water bath and 
kept at that temperature until being added to the specimens.  To evaluate variability in the 
imaging system between testing days, 1 ml of 194 µM 2-NBDG was pipetted into a 
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quartz cuvette and placed in the same position in the imaging system and imaged under 
the same conditions for four consecutive days. The spectra of each day was acquired and 
compared to determine the system’s stability between testing days.  
5.3.3. Cellular staining with 2-NBDG 
1 X 105 cells in fresh medium were plated onto glass chamber slides with 
removable plastic wells.  After 48 hr, when the cells were in their log growth phase, the 
medium was removed and PBS with 1% bovine serum albumin (BSA) was added to the 
wells for 20 minutes at 37°C to starve the cells (cell medium alone was used as a 
control). The PBS-BSA was then aspirated and 2-NBDG was added to the wells for 20 
minutes at 37°C in darkness. The 2-NBDG was then aspirated; the cells were placed on 
ice, and rinsed twice with cold PBS to remove any non-metabolized 2-NBDG.   
5.3.4. Cellular imaging 
Immediately after the cells were washed, the slides were placed on a CytoViva 
150 microscope (Auburn, AL) for fluorescence and darkfield imaging.  For fluorescence 
images, the cells were excited with light at 474-510 nm and emission from 515-555 nm 
was captured using a DAGE-MTI (XLMX, 152) charge-coupled device camera with 500 
milliseconds (ms) integration time. For darkfield images, integration time was 1 ms. 
5.3.5. Ex vivo tissue acquisition   
Freshly excised human breast tissue samples were acquired from 14 patients 
undergoing surgical resection of suspected breast cancer at The University of Texas MD 
Anderson Cancer Center (MDACC) with the approval of the institutional review boards 
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at Rice University and MDACC. All patients gave written informed consent to 
participate. Each specimen was received from surgery and inked so that the pathologist 
could identify the in situ location of the specimen. The specimen was then bread loafed in 
2-5 mm increments and visually inspected and palpated to determine the area of residual 
tumor. Leftover specimen that was not necessary for diagnosis by the surgical pathologist 
was used for the imaging process. A separate specimen of normal tissue away from the 
gross tumor was also acquired as an internal control for each patient. For one patient (#2), 
a single specimen was obtained with gross palpable tumor at one end and normal 
appearing tissue at the other end.  Typically, the tissues were processed for imaging 
within 60 minutes of resection.  
5.3.6. Ex vivo tissue sampling   
Upon receipt of the tissue, autofluorescent images of both normal and malignant 
tissue were acquired using a Maestro wide-field multispectral fluorescent camera (CRi, 
Woburn, MA).  The imaging system has a spatial resolution of 25 µm/pixel and the field 
of view for each image acquired was 4.9 X 3.7 cm. The tissue samples were excited with 
filtered light (445-490 nm) and the emitted light was filtered (515 nm LP) before entering 
the camera.  The exposure time for the camera was 18.56 ms. A multispectral image cube 
comprised of the different images at different wavelengths (520-720 nm, every 10 nm) 
was created using these settings.  This process created a prestain image that would be 
used for comparison after the tissue had been stained with 2-NBDG.   
After the prestain image cube was created, both normal and malignant tissue 
specimens were incubated topically with 2-NBDG at 37°C for 20 minutes in the dark.  
The remaining 2-NBDG was aspirated and the tissue samples were rinsed twice in cold 
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PBS on ice in the dark for 10 minutes.  The samples were placed under the wide-field 
camera in approximately the same positions as the prestain images.  The tissues were 
subsequently imaged under the same conditions described above, and a poststain 
multispectral cube was created.  
After imaging, the tissue samples were fixed in formalin for 24 hr, placed into 
70% ethanol, and sent to the research pathology core laboratory at MDACC for 
hematoxylin-and-eosin (H&E) staining.  Both the control and sample tissue slides were 
then reviewed by a breast pathologist  (L.M.), who provided a histological diagnosis of 
the tissue.  Pictures of the slides were taken at a 40X magnification using an Olympus 
DP70 camera (Center Valley, PA). 
5.3.7. Fluorescence spectrum acquisition and quantitative analysis 
For semi-quantitative analysis of the images, a region of interest (ROI) was 
custom-fit along the edges of the tissues on the before and after-staining images.  The 
fluorescence spectrum from 520-720 nm of this ROI was plotted based on the fluorescent 
signal calculated at every 10 nm. The intensity for each wavelength was the average 
intensity for each pixel in the ROI. This allowed the creation of two sets of data for each 
of the tissues that could be used to compare the effect of adding 2-NBDG to both of the 
tissues.  Tissue samples from one patient (#10) had only a data set for the post stain 
image due to a machine malfunction that was not detected until after the tissue had been 
stained; however, samples from this patient were included because poststain comparisons 
between the cancerous and noncancerous tissues could be made.  
Analyses of each tissue spectrum revealed a slight peak in the 560-600 nm range 
for the prestain images and a larger, more prominent peak in the same range for the 
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poststain images.  To quantify the 2-NBDG signal from each tissue and compare the 
different samples, an area under the peak of each curve (AUC) was calculated by 
multiplying the height (fluorescent signal) of each curve at 580 nm by the width of the 
peak (40 nm).  The area under the prestain curves was subtracted from that of the 
poststain curves to normalize the autofluorescence (NAUC).  The average NAUC of the 
cancerous and normal tissue was calculated, as well, the mean of all samples was 
calculated. This mean was then drawn as a horizontal threshold line to help discriminate 
between the two groups.  Statistical significance between the groups of NAUCs was 
determined using a two-tailed Student’s t-test.  
The signal differences between the pre and poststain images at each wavelength 
from 520-720 nm were also calculated for each set of cancerous and normal tissues for 
the patients. For example, the differences at 580 nm for the cancerous tissue from each 
patient (excluding patient #10) were placed into one group and the differences at 580 nm 
for the normal control tissues were also placed into a group.  The two groups were then 
compared by using a two-tailed student’s t-test; this was done for each wavelength from 
520-720 nm.  
5.3.8. Fluorescent imaging of tissue slices 
For further confirmation of the localization of 2-NBDG in the tissues.  H&E 
slides of invasive ductal carcinoma were viewed under darkfield fluorescence using a 
Qimaging Exi blue CCD. Tissue slices were excited with 474-510 nm excitation light and 
signal from 515-555 nm was collected. Additionally, a darkfield image of the tissue was 
acquired for comparison. 
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5.3.9. Gold colloid synthesis and thioglucose conjugation 
Gold colloid synthesis began with 45 mLs of distilled H2O rotating in a glass 
beaker at 800 RPM.  1 mL of 1 N KOH was then added; 1 minute later, 12 uL of THPC 
(Tetrakis(hydroxymethyl)phosphonium chloride) was added for 1.5 mins followed by 2 
mLs of 1% HAuCl4 for 2 minutes to form the colloid solution.  10 mLs of colloid 
solution was then combined with 10 mLs of 10 mM thioglucose or sodium citrate and 
spun at 800 RPM for 15 minutes.  The solution was then rinsed three times using a 
centrifugal dialysis filter (10,000 Dalton cutoff) for 20 minutes at 2500 g. The final 
solution was then re-suspended to a total of 10 ml and kept at 4°C. TEM images of the 
particles were acquired using a JEOL 2010 TEM and carbon-copper TEM grids acquired 
from electron microscopy sciences (FCF-200-Cu).  
5.3.10. Thioglucose binding characterization 
2 nm gold colloid from Ted Pella Inc. (1.25X 1014 particles/mL) were conjugated 
and filtered in the same method as the synthesized colloid above.  However, TEM images 
were acquired with a JEMF-2100 Field Emission Gun Transmission Electron Microscope 
that is equipped with EDS to confirm the presence of gold and sulfur.  Energy spectra 
were collected at different areas in the field of view (FOV).  Electron counts at peaks 
corresponding to gold and sulfur were used to calculate the percentage of atoms present 
at each area.  The percentages of each element present were then calculated using energy 
detected by the scanner.   
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5.3.11. Different surface coatings’ effect on uptake 
175,000 Sk-Br-3 cells were plated onto glass chamber slides and allowed to grow 
as previously indicated.   Media was removed and 1 mL of fresh media was then added to 
each chamber.  500 µL of AuNPs (thioglucose, sodium citrate, or no coating) or 500 µL 
of media (negative control) were added to the cells for an incubation period of 20 minutes 
at 37°C.  The cells were then rinsed in PBS and imaged on the Cytoviva™ darkfield 
microscope.  Images were acquired with a Qimaging Exi Blue CCD.  Images were 
acquired at different exposure times so that cellular features could be visualized. 
5.3.12. Cell line specificity of glu-AuNPs 
175,000 Sk-Br-3 and Mcf10A cells were plated onto separate chamber slides and 
allowed to grow as previously discussed. 250 µL of 0.312 µM particles conjugated with 
either thioglucose or sodium citrate were added to the cells for 20 minutes. After 20 
minutes, the media was aspirated, the cells were rinsed quickly with PBS and then fixed  
with glutaraldehyde fixation buffer for 30 minutes.  Buffer was then removed and the 
chamber slides were imaged under darkfield microscopy. 
5.3.13. Localization of glu-AuNPs inside cells using TEM-EDS 
75,000 Sk-Br-3 cells were plated on a 24 well plate (Corning 3527) and allowed 
to grow to ~75% confluency after 48 hrs.  The cells were then treated with gold colloid 
coated with thioglucose as mentioned in previous studies.  After treatment, the cells were 
fixed in sodium cacodylate buffer with glutaraldehyde and formaldehyde (Electron 
Microscopy Sciences 15949) and placed in the refrigerator for further processing.  After 
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fixation, the samples were washed, postfixed with 1% buffered osmium tetroxide for 30 
min, and stained en bloc with 1% Millipore-filtered uranyl acetate. The samples were 
dehydrated in increasing concentrations of ethanol, infiltrated, and embedded in LX-112 
medium. The samples were polymerized in a 60° C oven for 2 days. Ultrathin sections 
were cut in a Leica Ultracut microtome (Leica, Deerfield, IL), stained with uranyl acetate 
and lead citrate in a Leica EM Stainer, and examined in a JEM 1010 transmission 
electron microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating voltage of 80 
kV.  Digital images were obtained using AMT Imaging System (Advanced Microscopy  
Techniques Corp, Danvers, MA). 
After visualizing the AuNPs in the cells, EDS was used to confirm the presence of 
gold inside the cell.  A single cell was visualized on a JEOL TEM microscope (Jeol JEM 
2100F), then, using a Scanning Transmission Electron Microscopy (STEM) EDS 
technique, we were able to pinpoint specific points around the cell to excite with an 
electron beam. The characteristic energy emitted by the sample corresponds to unique 
atomic structures, allowing us to detect presence of specific atoms.  The amount of gold 
in specific areas was tabulated by measuring the height of the gold peak at 2.5 keV and 
comparing its height to the peak of the maximum energy level (measured at 70 counts) to 
calculate the amount of gold in specific intracellular areas. The areas interrogated include 
intranuclear, cytoplasm, and extracellular spaces.  We interrogated three intranuclear, 
three cytoplasmic, and one extracellular area for comparison.  Additionally, spectra of 
untreated cells were acquired.  For each specific area, 5 runs were completed and 
averaged.  For this experiment, a TEM grid from the same set of cells that is displayed in 
Figures 5.13 & 5.14 was analyzed.  However, due to the destructive nature of the EDS 
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imaging process that damages the sample grids, different grids were analyzed.  
Additionally, the specific areas of AuNPs that are highlighted in 5.13-5.14 are not the 
areas analyzed for EDS. However, these cells were from the same experiment and were 
treated with the same glu-AuNPs.   
5.3.14. Inhibition of clathrin mediated endocytosis 
75,000 Sk-Br-3 cells were plated on a 4 well chamber slide (Labtek 154941) at 
37° C and 5% humidity for 48 hours.  After 48 hours, the clathrin mediated endocytosis 
inhibitor chlorpromazine hydrochloride was added to the cells at a concentration of 5 
µg/ml for 2 hours without changing media.  The concentration of chlorpromazine needed 
to inhibit endocytosis is cell-type dependent [360], so optimization studies were 
performed to determine the optimal concentration of chlorpromazine that inhibits 
endocytosis without being cytotoxic. After 2 hours, glu-AuNPs were added to the cells in 
the same fashion as previously described.  Additionally, human transferrin tagged with 
Alexa Fluor 488 (Invitrogen T13342) was added at a concentration of 1 mg/ml as a 
marker for endocytosis. After 20 minutes, the entire media, transferrin, and glu-AuNPs 
mixture was aspirated and cells were fixed in cytofix buffer.  After fixation, the cells 
were imaged on the Cytoviva darkfield microscope where images were acquire in both 
standard darkfield mode (exp. 5 ms) and fluorescence darkfield mode (500 ms) of the 
same field of view.  Both sets were converted to 8-bit and contrast was adjusted to 
remove background signal (fluorescent images were set at a range of 44-255 and the 
darkfield images were set at 0-100).  Next, the fluorescent and darkfield images were 
false colored red and blue respectively, and the images were combined.  
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In addition to darkfield and fluorescence images being acquired, TEM images of 
cells that were treated with both chlorpromazine and AuNPs were also acquired.  TEM 
images of the cells were then acquired at various magnifications to localize the glu-
AuNPs inside the cell.  
5.3.15. Competitive inhibition with D-glucose 
To further elucidate the mechanism of entry of the particles into cells, a 
competitive inhibition assay was performed with D-glucose.  First, cells were plated in 
the same manner as previously stated and allowed to grow for 48 hours.  Then, 500 µL 
each of AuNPs and 40 µM D-glucose were added to 500 µL of media.  Additionally, D-
glucose alone and glu-AuNPs alone were added to cells as controls.  After 20 minutes, 
cells were fixed and imaged as previously described.   
In addition, flow cytometry analysis was conducted to evaluate the impact of glu-
AuNPs and citrate-AuNPs on the 2-NBDG signal in Sk-Br-3 cells. For this experiment, 
75,000 cells were plated in 24 well plates and allowed to grow for 48 hrs. Media was then 
aspirated and 200 µL of 10 µM 2-NBDG was added to each well.  Additionally, 200 µL 
of two different concentrations (20 and 40 µM, respectively) of D-glucose were added to 
different sets of cells as positive controls.  1.67 µM of citrate or glu-AuNPs were added 
to the cells with 2-NBDG for 20 minutes at 37°C. After incubation, the media was 
aspirated and the cells were trypsinized from the wells and fixed in cytofix buffer.  
Samples were analyzed in a flow cytometer (BD FACSCANTO II) and the mean 
fluorescence intensity (MFI) of the FITC channel was calculated for the cells.  Samples 
were run in triplicate and the average FITC intensity for each group was compared using 
an ANOVA and tukey-kramer t-test. 
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5.4. Results 
5.4.1. In vitro 2-NBDG results 
Figure 5.1 demonstrates the cellular specificity of 2-NBDG and its ability to 
differentiate cancerous cells (Fig. 5.1(A)) from non-cancerous (Fig. 5.1(B)) cell lines in 
vitro.  Additionally, normal darkfield images of the same field of view (not shown) were 
used to confirm the presence of cells in the area.  The increased metabolism of cancerous 
cells leads to an increase in expression of GLUTs on the cell membrane.  This leads to an 
increase in 2-NBDG uptake in malignant cells that is visualized with fluorescence 
microscopy.  These results demonstrate an important proof of concept that allowed us to 
move on towards using 2-NBDG in resected tissue specimens and using glucose to target 
other contrast agents such as AuNPs.  
 
5.4.2. 2-NBDG in freshly excised breast specimens 
After establishing that using glucose to target contrast agents in cancerous cell 
lines that over-express GLUTs, our next step was to use the fluorescent contrast agent 2-
 
Figure 5.1 Fluorescent images of cancerous Sk-Br-3 (A) and non-cancerous Mcf10A (B) cell lines demonstrate the 
preferential uptake of 2-NBDG in the cancerous cell lines due to the over-expression of GLUTs in the cell 
membrane of the cancerous cells. 
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NBDG to target and optically differentiate malignant tissue.  Figure 5.2 displays the 
patient characteristics of the tissues that were sampled for imaging.  The pathologic 
diagnosis of each tissue sample was confirmed by a breast pathologist in a blinded 
fashion.  There were five tissues that contained invasive ductal carcinoma (IDC), one that 
contained invasive mammary carcinoma (IMC), three that contained invasive lobular 
carcinoma (ILC), three that contained ductal carcinoma in situ (DCIS), and two that 
contained no cancer cells.  Of the two specimens that did not contain cancer cells, one 
was obtained (patient #13) from the periphery of resected breast tissue that did contain 
metaplastic carcinoma with both spindle cell and IDC components. The other tissue 
sample was from a patient (#14) who had received neoadjuvant chemotherapy and 
achieved a complete pathologic response.  In that specimen, there was evidence of tissue 
repair and fibrosis. 
Patient/Sample Number Diagnosis Nuclear Grade 
1 Ductal Carcinoma in Situ 3 
2 Ductal Carcinoma in Situ 3 
3 Ductal Carcinoma in Situ 3 
4 Invasive Ductal Carcinoma 2 
5 Invasive Ductal Carcinoma 2 
6 Invasive Ductal Carcinoma 2 
7 Invasive Ductal Carcinoma 2 
8 Invasive Ductal Carcinoma 2 
9 Invasive Lobular Carcinoma 3 
10 Invasive Lobular Carcinoma 3 
11 Invasive Lobular Carcinoma 3 
12 Invasive Mucinous Carcinoma 1 
13 No Cancer Cells N/A 
14 No Cancer Cells N/A 
Figure 5.2 Tissue characteristic and grades for 14 tissues that were declared to be malignant tissue by on-site 
pathology. 
 
Figure 5.3 represents the images acquired of both the malignant (IDC) and normal 
non-cancerous tissue before and after incubation with 2-NBDG. These two images are 
representative of the images analyzed from the malignant and normal tissues. The tumor 
specimen clearly showed brighter fluorescent signal after incubation with 2-NBDG (Fig. 
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5.3(B), T) as compared to its prestained image (Fig. 5.3(A), T) and the poststain image of 
the normal tissue (Fig. 5.3(B), N).  Each tissue specimen had similarly low-levels of 
autofluorescence (Fig. 5.3(A)). The non-neoplastic tissue was mildly brighter after 2-
NBDG incubation, which probably reflects the basal level of glucose uptake in normal 
tissue. Figure 5.3(C) illustrates a representative H&E stained tissue slice from the tumor 
specimen imaged in Figure 1B.  It confirmed the presence of carcinoma in the tissue with 
high fluorescent signal. 
Figure 5.3(D) illustrates the post stain image of a single specimen in which it was 
unknown whether there was presence of malignant tissue. This fluorescent image was 
used to slice the tissue into two different specimens, one that was believed to be 
cancerous and one that was non-cancerous.   The presence of DCIS in the left-side aspect 
and normal tissue in the right-side aspect of the specimen was confirmed histologically.  
The fluorescence spectra of the tissues imaged in Figure 5.3 (A&B) was 
calculated and is presented in Figure 5.4.  The spectra are representative of the spectra 
seen with the other tissues.  The fluorescent signal of the malignant tissue after 2-NBDG 
staining was on average 13.1±1.0 (average±standard error of the mean) times greater at 
eachwavelength than the signal calculated from the prestain image.  Conversely, the 
fluorescence of normal breast tissue was only an average of 1.7±0.1 times greater after 
addition of 2-NBDG.  Hence, the fluorescence increase after 2-NBDG staining of the 
malignant tissue was much higher than that of the normal, non-cancerous control tissue, 
indicating that there was increased 2-NBDG consumption in the malignant tissue relative 
to the normal tissue.   
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Additionally, spectral analysis of the two different slices from Figure 5.3(D) 
showed that the intensity at each wavelength was 2.0±0.1 (data not shown) times greater 
in the malignant tissue than the normal tissue for each spectral measurement.  This 
demonstrates that there was clear demarcation of an area of high fluorescence 
corresponding to DCIS and an adjacent low level of fluorescence corresponding to 
normal tissue. 
One issue addressed was 2-NBDG variation on a day-to-day basis. Our tests 
showed that the intensity variability at each wavelength was less than 3.2% of the 
average intensity calculated for each wavelength over the 4-day period; this demonstrated 
the system’s stability and allowed us to perform quantitative analysis of the images. 
 
Figure 5.3 Wide-field multispectral images of invasive ductal carcinoma (T) and normal breast tissue (N) from 
patient #6. (a) Tissues pre 2-NBDG stain; (b) tissues post-2-NBDG stain.  Tissues were excited with 445-490 nm 
light and images were collected after having passed through a 515 nm LP filter. (c) Tissue slice stained with 
hematoxylin and eosin depicts IDC. (d) One tissue slice with ductal carcinoma in situ (DCIS) and normal tissue. 
The left, brighter side was diagnosed as DCIS, whereas the other half was diagnosed as normal tissue. 
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The fluorescent signal difference between the poststain and prestain images from 
all the tumor samples and normal controls were averaged separately at each wavelength 
and are illustrated in Figure 5.5.  The difference in the intensity of fluorescence of the 
tumor samples was significantly higher than that of the normal controls at each 
wavelength from 520 to 720 nm (P<0.0001).  At 580 nm (the center of the fluorescence 
spectrum peak ranging from 560 to 600 nm), the average intensity difference from the 
malignant tissues (1,878.2±169.7) was 2.7 times higher than that from the normal non-
cancerous tissue (704.9±108.2). 
 
Figure 5.4 Emission spectra of multispectral cubes represented in Figure 1.  Regions of interest were hand-drawn 
on each tissue; fluorescent signals every 10 nm from 520 to 660 nm are shown. 
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To quantitatively distinguish the fluorescence of malignant tissue from that of 
normal, non-cancerous tissue, the NAUC values for the 560-600 nm range of the spectra 
were calculated for each sample (Fig. 5.6). The mean NAUC for the tumor samples 
(81,670±7,142) was significantly higher than that for the control (31,170±5,411, 
P<0.00001). The difference between malignant and non-cancerous tissue for some 
samples (#1, #5, and #10) exceeded a factor of 2; however, other tissues (#3, #6, #7, and 
#8) had less than a 2-fold difference between the tissues.  The small differences did not 
seem to be limited to a particular type of breast cancer, as IDC had both some of the 
largest differences and some of the smallest differences.  These differences may be 
 
Figure 5.5 Average signal difference between the poststain and prestain images calculated at each wavelength. A t-
test comparison between the groups at each wavelength revealed that all of the groups were statistically different 
(P<0.0001). Error bars represent standard error of the mean. 
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attributed to each specific tissue and the part of the normal breast tissue that was provided 
by the pathologist.   
Using the average NAUC (56,420) as a discrimination line, the NAUC values for 
nine of the malignant samples were above the line while the NAUC values for three were 
below.  However, the NAUC value of all but one of the normal control samples was 
below the threshold.   
 
Figure 5.7 demonstrates the localization of the fluorophore to the cancerous tissue 
cells on the H&E slide.  There was concern that due to the very different tissue structures 
of cancerous and normal tissue that 2-NBDG accumulation could be occurring in the 
 
Figure 5.6 Areas under each curve for the range of 560-600 nm.  Each point on the graph represents the difference 
in AUC between the prestain and poststain images of the tissues from each patient. Dots represent the differences 
for tissues considered to be cancerous at time of collection. The black line represents the average NAUC of the two 
groups. 
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extracellular matrix of the tissue and not in the cells themselves.  These darkfield 
fluorescent images demonstrate that 2-NBDG is found in the cells of the tissue and not 
just the outside of the cell.  Figure 5.7(A) is the darkfield fluorescence image that was 
acquired with the same settings for the cells from Figure 5.1 and 5.7(B) shows that there 
is increased signal in the tissue when in fluorescence mode due to the presence of the 
fluorescent contrast agent.   
  
5.4.3. Glu-AuNPs in vitro results 
After demonstrating the utility of glucose to target a fluorescent contrast agent, 
we hypothesized that we could use this same principle to target small diameter AuNPs.  
The following sections discuss the surface ligand specificity, cell type specificity, and 
mechanism of entry of glucose functionalized AuNPs.  
Figure 5.8 displays TEM images of synthesized colloid after capping with 
thioglucose.  Both figures display the same sample with a zoomed in view displayed in 
Figure 5.8(B).  Using ImageJ, diameters of 13 AuNPs displayed in 5.8(B) were 
calculated to have an average diameter of 3.12 ± 0.71 nm after conjugation with 
 
Figure 5.7 Fluorescence darkfield (a) and darkfield (b) images of hematoxylin and eosin stained invasive ductal 
carcinoma tissue.  The increased fluorescence in the fluorescent image indicates presence of 2-NBDG in the cells 
and not extracellular stroma. Scale bar = 100 µm.  
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thioglucose.  Additionally, Figure 5.8(A) shows that there is very even distribution of 
sizes of AuNPs in the sample allowing us to conclude that there are no particle 
aggregates.  
 
Figure 5.9(A) displays AuNPs commercially produced from Ted Pella, Inc that 
have been coated with thioglucose.  The average size of these AuNPs was 2.4±0.54 nm.  
Two spots where EDS was used to collect the relative percentage sulfur and gold atoms 
that were present at each point.  Sulfur was calculated to show the thiol binding of 
thioglucose to the surface of the gold particle.  Figure 5.9(B) displays the relative 
percentage of elements present at each spot, showing that the edge of the AuNP is where 
the majority of sulfur is localized, confirming the surface coating of thioglucose. 
 
Figure 5.8 TEM images of glu-AuNPs .  5.8(A) displays the size distribution of the nanoparticles. Figure 5.8 (B) 
demonstrates a zoomed in view of the field of view displayed in 5.8 (A).  ImageJ was used to calculate the average 
size of the AuNPs to be 3.12±0.71 nm. 
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Figure 5.10 displays representative images of Sk-Br-3 cells after incubation with 
AuNPs with no coating, two different coatings, and a negative control.  This experiment 
was conducted three times.  The negative control (Fig. 5.10(A)) displays cells with no 
scattering from inside the cell and slight signal from the cell membrane. Figure 5.10(B) 
displays cells that were incubated with AuNPs that had no coating.  Cells incubated with 
citrate-AuNPs and glu-AuNPs are presented in Figure 5.10(C&D).  Cells that were 
incubated with glu-AuNPs showed increased scattering signal from inside the cell.  
Scattering from the  bare or citrate functionalized AuNPs was localized to the cell 
membrane (Fig. 5.10(B&C), which may be a function of electrostatic interactions 
between the membrane and the particles causing them to stick to the surface.  However, 
we see very little scattering inside these cells.   
We also examined the changes in uptake of the glu-AuNPs in cancerous versus 
non-cancerous breast cell lines as was shown with 2-NBDG in previous experiments.  
The results from Figure 5.11(A) show that Sk-Br-3 cancerous cells once again had the 
 
Figure 5.9 Glu-AuNPs after filtration to remove any impurities.  ImageJ was used to calculate the average size of 
these AuNPs to be 2.4±0.54 nm.  Energy Dispersion Spectroscopy (EDS) was used to calculate the relative 
percentage of elements present at points displayed in (A).  Percentages calculated demonstrate the localization of 
thiol bonds of thioglucose to the surface of the AuNP. Where there was very little sulfur in the central area of the 
AuNP. Scale bar = 2 nm  
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intense intracellular scattering signature that delineated the nucleus.  In contrast, the 
normal mammary cell line (Mcf10A) had minimal scattering inside the cells,.  
Additionally, Figure 5.12 displays the controls of cells without treatment and cells treated 
with citrate AuNPs to demonstrate that the intense scattering from theperiphery of the 
Mcf10A cells is not due to the presence of AuNPs but is an inherent signal of the cell 
line.  This could be due to naturally occurring extracellular structures with mismatching 
indices of refraction causing intense scattering profiles outside of the cells [281].  
Additionally, scattering from cells treated with citrate-AuNPs is localized to the cell 
membrane. 
 
Figure 5.10 Sk-Br-3 cells incubated with (A) media only, (B) AuNPs without a surface coating, (C) citrate-AuNPs, 
and (D) glu-AuNPs.  After a 20 minute incubation there is increased scattering signal from inside the cells of (D) 
that are localized to the cytoplasm of the cell.  The other treatments seem to only have increased signal from the 
outside of the cell. 
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Figure 5.11  Sk-Br-3 (A) cancerous and Mcf10A (B) non-cancerous breast cell lines after treatment with glu- 
AuNPs. Sk-Br-3 shows a distinct scattering pattern from inside the cell membranes that is seen with previous 
experiments, whereas the Mcf10A line does not exhibit these characteristics. 
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To determine the precise intracellular location of the glu-AuNPs, TEM was 
performed on cell samples that had been treated with glu-AuNPs in the previously 
described method. TEM images of Sk-Br-3 cells that were untreated (A-C) and treated 
(D-H) with glu-AuNPs are shown in Figure 5.13. Three different magnifications are 
displayed, with circles outlining the area that is magnified in the subsequent higher 
magnificatiodisplayed in the row below.  In the negative control (Fig. 5.13 (A-C)), there 
is a distinct lack of the black, electron dense areas that can be seen at the higher 
magnifications in the treated cells (Fig. 5.13(D-F).  Upon further magnification (Fig. 
5.14), we can see that these electron dense areas have a black pepper structure, which 
indicates presence of a large number of AuNPs.  Even though the particles have 
accumulated inside one large area, there is very little aggregation, which can occur from 
drastic pH changes and protein aggregation on the surfaces of particles (Fig. 5.14).   
An issue with visualizing small diameter AuNPs is the lack of electron density for 
individual particles to show contrast against the cytoplasm, indicating that there needs to 
be a high concentration of particles either from aggregation or localization inside an 
intracellular structure.  An example of this can be seen in Figure 5.13(D) where the 
AuNPs are found inside an autophagosome, which is formed when a cancer cell is 
undergoing autophagy.  Possible reasons for this phenomenon will be explored further in 
the discussion section.  Due the small diameter of these particles, it is difficult to isolate 
individual particles that we hypothesized might be found in the cytoplasm. However, 
further exploration with EDS might allow us to pinpoint specific areas of the cell without 
aggregates and outside of extracellular structures to demonstrate AuNP presence.  These 
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results confirmed the presence of glu-AuNPs within the cell, showing that the scattering 
profile seen inside the cells was due to the presence of the AuNPs. 
 
The final confirmation of the intracellular localization of glu-AuNPs was 
accomplished with EDS.  The presence of any gold signal would confirm that there were 
glu-AuNPs inside the cell.  A representative spectrum of a cell incubated with glu-AuNPs 
is presented in Figure 5.15(A), and a negative control in Figure 5.15(B). There are 
distinct differences in the energy spectra of each cell, with the peak at 2.5 keV indicating 
a high amount of gold inside the cell, with no visible peak in the same region in Figure 
5.15(B).  We were also able to pinpoint specific regions of interest inside the cell using 
this technique.  Figure 5.16 shows the average signal at 2.5 keV taken at different areas 
inside the cell (intranuclear, cytoplasmic, and extracellular).  There is a 
 
Figure 5.12 Darkfield microscopy images of normal (A-C) Mcf10A and malignant (D-F) Sk-Br-3 cell lines 
displaying the scattering differences that between cell lines when treated with the same targeting moiety. It is 
interesting to note that Mcf10A cells all have the same scattering profile, regardless of treatment, but the Sk-Br-3 
cell lines have differences between treatments. 
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Figure 5.13 TEM images of Sk-Br-3 cells treated with glu-AuNPS (D-F) and their negative control (A-C).  
Various magnifications are presented for each row and black circles represent areas that are magnified for the next 
row of magnification.  Magnifications and scale bars for each respective row: (1) 6000X, 5µm; (2) 25,000, 1 µm; 
(3) 100,000, 100 nm. 
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different amount of gold in various areas of the cell, with a higher amount of gold inside 
the nucleus than from inside the cytoplasm; this observation will be explored further on 
in the chapter. EDS is a powerful tool that has allowed us to confirm the presence of 
AuNPs inside Sk-Br-3 cells that have been treated with targeted AuNPs.  When used in 
combination with TEM, we were able to confirm that there was gold inside the cell and 
verify the conclusions from our darkfield microscopy experiments.  Our next step in 
studying glu-AuNPs interactions’ with cells was to investigate the mechanism of entry of 
these particles.   
 
 
Figure 5.14 200,000X TEM images of the autophagosome in Fig. 5.13.  The appearance of black pepper in the 
middle right and upper left of (A) are areas of the autophagosome where AuNPs have accumulated.  Additionally, 
in (B), the AuNPs are spread out throughout the autophagosome displaying a large amount of AuNPs inside the 
cell. Scale bar = 100 nm.  
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5.4.4. Determining the mechanism of entry of glu-AuNPs 
The purpose of these experiments was to determine if conjugating 2 nm AuNPs 
with glucose could improve targeting of the particles.  Our hypothesis was that by placing 
glucose on the surface of these particles, we could take advantage of the increased 
glucose transporter expression in cancerous cells to develop a new method of targeting 
AuNPs.  Almost all NPs are consumed by the cell via endocytosis whether it is by 
receptor mediated or clathrin independent mechanisms.  Our hypothesis was that these 
particles would enter the cells via the glucose transporters and not undergo the same 
cellular processes that most AuNPs go through upon entering cells through endocytosis.  
A new mechanism of entry for particles has implications for the development of 
newtargeting moieties that could improve both diagnostic and therapeutic applications.  
Additionally, if NPs were able to enter the cell through a non-endocytotic process then 
physiologic phenomena such as the low pH of lysosomes, might be avoided and a fully 
intact particle with a specific therapeutic might be more effective.  
Finally, as Nitin and O’Neil demonstrated, fluorescent glucose accumulates to 
90% of maximum signal within 10 minutes of incubation, and at 20 minutes, there is 
maximum accumulation [25,359]. This phenomenon led us to hypothesize that targeting 
AuNPs with glucose might increase the speed of targeted nanoparticles entering 
cancerous cells. Previous studies by Kong and Feng have shown the ability of glucose-
targeted AuNPs to increase radiation cytotoxicity by increasing the amount of gold inside 
the cell that is available for interaction X-rays. However, both of these studies use 
significantly larger AuNPs (10-14 nm diameter) that would be unable to enter cells via 
GLUTs [204,361].  Additionally, neither of these studies explore the mechanism of entry 
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Figure 5.15 Representative electron energy spectra of Sk-Br-3 cells incubated with AuNPs (A) and cells without 
AuNPs (B).  Peaks at the 2.5 keV confirm the presence of gold inside the cell.  
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of the particles into the cells, so it is unclear if the glucose helped improve intracellular 
localization by improving uptake through endocytosis or another method.  Therefore, we 
aimed to show that glu-AuNPs pass through the GLUTs that are over-expressed by 
performing various inhibition assays.  We also aimed to use smaller AuNPs because the 
size of the GLUT1 transporter is approximately 3.6 X 2.6 nm [362], which we believe is 
much too small for AuNPs as large as Kong and Feng used for their respective studies.   
Our first experiment was to inhibit the clathrin-mediated endocytosis of Sk-Br-3 
cells and visualize the cells under darkfield microscopy to determine if we could detect 
AuNPs after inhibition.  The results are shown in Figure 5.17; red fluorescence is a 
marker for endocytosis from the protein transferrin that was conjugated to an Alexa Fluor 
tag.  Blue fluorescence is scattering from the cells when seen in darkfield mode (same 
imaging setup as in Figs. 5.10-12). In Figure 5.17(A), the negative control shows 
 
Figure 5.16 Average electron counts from specific areas inside the cell demonstrate that Glu-AuNPs are localized 
in different areas of the cell, even after a 20-minute incubation. 
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endocytotic activity and scattering on the cell membrane, as seen previously.  There is 
very high scattering signal from inside the cells in Figure 5.17(B) shows cells that were 
treated with AuNPs but were not treated with chlorpromazine, with positive endocytosis 
signal.  Finally, in Figure 5.17(C), there is no signal from transferrin, indicating that 
endocytosis has been inhibited; however there is still scattering from inside the cell, 
indicating that there is a presence of AuNPs inside the cell.  The signal is much less than 
what is indicated in 5.17(B), but is still higher than the signal in the negative control.  
This indicates that even with endocytosis being inhibited, we were able to show 
intracellular uptake of glu-AuNPs. 
Additionally, TEM images of cells that were treated with AuNPs and 
chlorpromazine are displayed in Figure 5.18.  In the different magnifications, we once 
again see the accumulation of the glu-AuNPs inside an autophagosome, as shown in 
Figures 5.13-14, when endocytosis was not inhibited.  Additionally, images in Figure 
5.19 show the localization of glu-AuNPs to a large vacuole inside the cell.  Similarly, in a 
2011 study by Li et al., large vacuoles were found throughout cells undergoing autophagy 
after treatment with AuNPs [363].  Of interest, individual particles in Figure 5.19 can be 
discerned inside the vacuole.  It is important to note that the reason these individual 
particles can be visualized is that there is no background signal from the cell cytoplasm.  
This may explain our inability to locate single particles in the cytoplasm as the 2 nm 
AuNPs do not have enough electron density to provide contrast with the cytoplasm.  This 
highlights the value of acquiring EDS data to confirm the intracellular presence of 
AuNPs.  
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Another assay to determine the mechanism of entry into the cells was a 
competitive inhibition assay.  Both Nitin and O’Neil [25,359] demonstrated that 2-NBDG 
enters cells via the GLUTs by adding increasing concentrations of D-Glucose in the 
presence of 2-NBDG and quantifying the decreasing fluorescence from 2-NBDG.  This 
illustrated that D-glucose was competing with 2-NBDG to enter the cells via the GLUTs 
 
Figure 5.17  Merged images of Sk-Br-3 cells that have been treated with chlorpromazine hydrochloride (5µg/ml) a 
known inhibitor of clathrin mediated endocytosis.  Red fluorescence is a positive marker for endocytosis whereas 
blue is scattering signal from the cells in darkfield microscopy.  (A) Negative control of cells without AuNPs or 
chlorpromazine displaying positive endocytosis and minimal scattering from around the cell membrane. (B) Cells 
treated with glu-AuNPs but not chlorpromazine indicate strong scattering from inside the cell presumably due to 
glu-AuNPs and there is still positive indication for endocytosis.  (C) Cells treated with both AuNPs and 
chlorpromazine showing scattering from inside the cell without indications of endocytosis. Scale bar = 5 µm.  
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and inhibiting the entry of the 2-NBDG into the cells.  We replicated this assay with glu-
AuNPs instead of D-glucose.  Figure 5.20 shows the results of incubating cells with 
media only (A), D-glucose only (B), D-glucose and AuNPs (C), and AuNPs only (D).  In 
Figure 5.20(C) the addition of D-glucose with glu-AuNPs together limited scattering 
signal to the cell membrane.  Figure. 5.20(D) shows the increased scattering that has been 
previously seen.  These results showed promise that a possible mechanism of entry of the 
glu-AuNPs into Sk-Br-3 cells was through the GLUT1 transporter. 
 
Figure 5.18 TEM images of cells treated with AuNPs and an inhibitor of clathrin mediated endocytosis.  Images 
confirmed the presence of cells inside an autophagosome located inside the cell, indicating that the AuNPs could 
enter cells via another mechanism.  Images were acquired at 6,000 (A), 25,000 (B), 100,000 (C), and 200,000 (D) 
zoom. Scales are indicated in each individual image.  
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After confirming that the addition of D-glucose affected the scattering profile of 
Sk-Br-3 cells incubated with glu-AuNPs, we hypothesized that the glu-AuNPs would also 
inhibit the entry of 2-NBDG into cells, thus lowering the 2-NBDG. This signal can be 
calculated using flow cytometry.  Figure 5.21 displays a bar graph of average 2-NBDG 
 
 
Figure 5.19 Inside a large vacuole in an Sk-Br-3 cell at 25,000X (A), 100,000X (B), and 200,000X (C) 
magnification.  Circles show areas of interest that are magnified in the subsequent magnification. (C) Displays 
individual particles that are found inside the vacuole, showing that AuNPs can be identified inside the cell when the 
signal from the cell is not present. Large vacuoles such as these are found in autophagic cells treated with AuNPs.  
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signal observed in the cells after incubation with two types of AuNPs (glucose and 
citrate) and two concentrations of D-glucose as a positive control.  From the graph, we 
observe that the two negative controls are significantly different than the groups 
incubated with 2-NBDG.  We also see that treatment with either D-glucose or either 
AuNP lower the 2-NBDG signal; however, the only condition to significantly lower the 
2-NBDG signal was the citrate covered AuNPs.   
We believe that the decrease in signal from citrate AuNPs can be partially 
attributed to their toxicity due to their ability to cause oxidative stress and damage 
mitochondria [364,365].  This is further validated in studies by Pan and Turner et al. that 
have reported on the size-dependent cytotoxicity of AuNPs in which small (~1.4 nm 
 
Figure 5.20 Sk-Br-3 cells after treatment with (A) media, (B) D-glucose, (C) D-glucose and AuNPs, and (D) 
AuNPs.  Results show qualitative differences between the cell lines after incubation of only 20 minutes. Cells that 
are treated with AuNPs have the same scattering profile that was seen in previous experiments where as cells that 
were treated with both glucose and AuNPs do not have an increased scattering signal from inside the cell. 
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diameter particles) were much more toxic than 15 nm AuNPs functionalized with the 
same surface ligand [248,366].  Tsoli et al. also reported that 1.4 nm AuNPs were able to 
penetrate the nucleus of cells and condense DNA without a nuclear targeting 
sequence[367]; this may explain why we were able to detect signal from gold inside the 
nucleus (Fig. 5.15(B)). 
Additional studies by Pan and Goodman et al. have also demonstrated that the 
capping agent has a significant impact on degree of cytotoxicity for small particles as 
their mechanism of action upon the cell is ligand dependent [249,250].  This is a possible 
explanation for the difference in 2-NBDG signals between citrate and glu-AuNPs. We 
 
Figure 5.21 2-NBDG signal calculated on the FITC channel of a flow cytometer.  Each bar graph represents MFI 
of 3 samples for each condition.  The columns marked with * show that the negative controls fluoresced 
significantly less than samples stained with 2-NBDG (p-value <0.01). The two columns marked with ** indicate 
the only two samples whose means were statistically different from each other (p-value 0.048)  This indicates that 
the incubation of citrate capped AuNPs had a significant effect on the signal of 2-NBDG from inside the cells 
compared to the other conditions. 
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explored the localization of citrate AuNPs using TEM and the results are presented in 
Figure 5.22.  In Figure 5.22, we observe a very high concentration of AuNPs localized in 
large clumps inside and outside the nucleus.  As we increase the magnification, we begin 
to discern the same NP structure as seen in previous experiments.  However, the lower 
magnifications seem to indicate a number of clusters that were not seen previously.  
Additionally, the cells that were treated with citrate AuNPs were unhealthy and 
approximately half the size of healthy Sk-Br-3 cells.  Cells that were incubated with 
serum free media and glu-AuNPs or citrate-AuNPs were also observed to have large 
clusters of AuNPs inside their nuclei (data not shown).  These images confirm that we see 
localization of small diameter particles inside the nucleus, as was previously reported.  
This is a possible explanation for why we observed such low 2-NBDG signal from cells 
treated with citrate AuNPs: they may have undergone a high amount of oxidative stress 
due to the presence of AuNPs in the cell. The stress would lead to the cell undergoing 
apoptosis and therefore not consuming as much 2-NBDG as seen with the normal healthy 
cells. 
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5.5. Discussion 
The presence of positive surgical margins is associated with a higher risk of local 
disease relapse [129,368–370]. Typically, it is recommended that patients with positive 
margins on final pathology undergo re-excision of the margins or intensification of 
 
Figure 5.22 Sk-Br-3 cells incubated with 2 nm citrate capped AuNPs at 5,000X (A), 25,000X (B), 100,000X (C), 
and 200,000X (D).  Images show large clusters of AuNPs mostly found throughout the nucleus.  Higher resolution 
magnifications show the AuNPs that are found in previous figures (Figs. 5.13. 5.14, 5.18)  Figure 5.21 (B&C) also 
display clusters of AuNPs outside the nuclear membrane. Scale bars: (A) 5 µm, (B) 1µm, (C) 200 nm, and (D) 100 
nm. 
  
 
114
adjuvant radiation therapy [371–373], both of which carry additional risks for the 
patients. Therefore, intraoperative evaluation of the surgical resection margins is an 
important component of the patient care. A rapid method of intraoperative margin 
evaluation could reduce second surgeries for breast cancer patients in the general 
community. 
Our study represents an initial step towards the development of an optical imaging 
strategy that would aid both pathologists and surgeons in expediting the process of 
margin assessment during surgery. Our study demonstrates that 2-NBDG signal in tissue 
specimens can be analyzed both qualitatively and semi-quantitatively and that wide-field 
fluorescence imaging has the ability to discern malignant from normal tissue. 
Our strategy is based on the same principles that make PET scans so effective in 
the detection of breast cancer cells in patients.  Similar to 18FDG used in PET scan, 2-
NBDG is a glucose analogue that is transported into cells via the GLUT1 and GLUT2 
transporters [358].  It undergoes the same metabolic processes as 18FDG [25].  Since 
cancer cells express higher levels of GLUTs and lower levels of glucuose-6-phosphatase 
that metabolizes the glucose than normal cells [353–357], both 18FDG and 2-NBDG 
accumulate in the cancer cells [21]. This process allows PET imaging and fluorescent 
imaging of the cancer cells using nuclear 18FDG and fluorescent 2-NBDG contrast 
agents.  
Nitin et al. demonstrated that following topical placement of 2-NBDG, the 
fluorophore entered the cancerous cells in both tissue phantoms and excised oral 
neoplasia [359]; this demonstrated the ability of 2-NBDG to differentiate cancerous cells 
because of their high metabolic activity not because the different extracellular structures 
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found in cancerous tissue allow for better 2-NBDG diffusion. As well O’Neil et al. 
demonstrated that 2-NBDG does enter breast cancer cells and at a much higher rate than 
for non-cancerous cells [25].   
Using 2-NBDG as a topical contrast agent, we were able to optically discriminate 
freshly excised breast tissue that contained cancer cells from the normal surrounding 
tissue using our ex vivo imaging system.  The single specimen with DCIS and normal 
tissue in Figure 5.7(D) demonstrates how readily the area of tissue with cancer cells can 
be imaged by the fluorescence from 2-NBDG uptake compared to the adjacent normal 
tissue and displays the potential of imaging tissue at the margin.  By quantifying the 
fluorescence signal through spectrum AUC, we were able to set a threshold level that 
identified 9 out of 12 tissues that contained cancerous cells.  Hence, this strategy may be 
developed in the future into an automated staining and quantification system to expedite 
the intraoperative assessment of excised specimen of tumor margins. With further 
studies, this strategy could even potentially be implemented to assess cancer cells at the 
surgical margin in vivo.  
Clinical studies had found ILC was associated with lower standard uptake values 
(SUV) [34] and a higher false-negative rate than IDC in PET imaging [21,353,374–376].  
However, our study suggests that the ILC cells do accumulate glucose preferentially over 
normal surrounding tissue.  We found all three cancerous tissues that contained ILC 
showed high fluorescence intensity after metabolizing 2-NBDG (Fig. 4).   In fact, one 
had the largest NAUC.  Most likely, the diffuse growth pattern of ILC does not 
concentrate the FDG signal high enough beyond the resolution limit of the PET imager to 
  
 
116
generate a high SUV.  However, due to the small number of samples that contained ILC, 
this result should be interpreted with caution. 
Similar to PET imaging, high basal metabolic state of the patient is likely to 
influence fluorescent glucose imaging of breast cancer. This most likely contributed to 
the high level of fluorescence in the normal breast tissue from patient #13 (Fig. 4).  It was 
the only normal control tissue with NAUC above the threshold level.  Likewise, the 
tumor sample obtained from this patient also had high level of fluorescence although 
there were no cancer cells in the specimen.  Therefore, similar to the steps implemented 
prior to the FDG-PET imaging in the clinics, the patients’ metabolic state and glucose 
intake may need to be regulated to optimize the use of this strategy.    
Further investigation of this strategy is required before it can be used in clinical 
settings.  Foremost, this strategy is expected to have a minimal threshold limit of 
detection, and thus the minimum number of cancerous cells that can be detected by using 
the ex vivo imaging system needs to be determined.  For this strategy to be clinically 
useful, it does not necessarily have to detect all margin tissue with cancer cells because 
the tissue would ultimately undergo permanent pathology review after the surgery, which 
would identify all cancer cells close or at the surgical margin.  However, detection of 
cancer cells at the margin intraoperatively for some patients would spare those patients 
another surgical procedure for re-excision or adjuvant radiation treatment intensification. 
In addition, the influence of breast cancer sub-types and treatments the patient 
received on the 2-NBDG uptake and imaging needs to be determined and optimized.  In 
our study, patient #14 had received neoadjuvant chemotherapy with trastuzumab prior to 
her surgery.  The tumor specimen from this patient had high fluorescence intensity but 
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did not contain cancer cells.  This elevated fluorescence level could be a result of the 
increase in immune response and activated natural killer cells that was reported in 
patients with breast cancer that overexpresses the human epidermal growth factor 
receptor 2 (HER2) and were treated with chemotherapeutic drugs [377,378].  This is an 
example of the many factors that need to be considered when considering this 
technology’s clinical use.  
We also aimed to develop a new method to introduce AuNPs to cells via GLUTs.  
We first were able to demonstrate our ability to reliably synthesize AuNPs and 
characterize the binding of thioglucose onto the surface of these particles using EDS.  We 
showed that the surface coating had an effect on the interaction of AuNPs with the 
cancerous Sk-Br-3 cell line, and that there was increased scattering inside the cells 
incubated with glu-AuNPs.  Glu-AuNPs were also cell type specific as there was 
increased scattering inside Sk-Br-3 cells but not Mcf10A cells. This increased signal 
from inside the cell was also seen with 2-NBDG in earlier experiments, which led to the 
hypothesis that these glu-AuNPs were entering the cell through the GLUTs and not 
through endocytosis, as is seen with other AuNPs. 
To validate this hypothesis, cells were incubated with a clathrin mediated 
endocytosis inhibitor and 2 nm glu-AuNPs.  Our results showed that there were AuNPs 
internalized by the cell with and without endocytosis inhibition.  These findings are 
consistent with a 2012 study by Moros et al. that shows 6 nm glu-SPIONPs entered cells 
via caveoloae/lipid raft mediated endocytosis [379].  However, the authors found that the 
SPIONPs were colocalized with lysosomes.  This is not consistent with other literature 
that shows NPs internalized via caveloae/lipid rafts do not undergo lysososmal 
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degradation [380]. One possible explanation is that the glu-SPIONPs are taken up by 
autophagosomes inside the cell, which then fuse with lysosomes, leading to further 
degradation of the particles.  This theory is supported by respective work from Li and Ma 
et al. that demonstrate lysosomal degradation of autophagosomes with AuNPs directly 
correlates with the size of AuNPs incubated within the autophagosomes [363,381]  The 
small diameter glu-SPIONPs synthesized by Moros may enter the cells via caveolae 
mediated endocytosis, become consumed by autophagosomes, and consequently 
consumed by lysosomes, explaining the colocalization of the particles in the lysosomes.  
This theory is also supported by data in Figure 5.14, 5.18, and 5.19 that show glu-AuNPs 
inside autophagosomes and large vacuoles that are a result of the autophagy caused by 
AuNPs. 
Even though our initial results from the endocytosis inhibition studies correlate 
well with the conclusions presented by Moros et al, there are still fundamental differences 
between the studies that do not allow us to conclude the mechanism of entry of the NPs 
into the cell.  The particles were of different size and material property, the glucose was 
functionalized via different chemical linkers, and the cell lines used were different.  As 
discussed in previous chapters, each of these factors has a large impact on intracellular 
fate.  Due to these differences, there are further assays that need to be performed to 
confirm the mechanism of entry of 2 nm glu-AuNPs into Sk-Br-3 cells. 
One assay involved incubating the cells with both D-glucose and glu-AuNPs to 
competitively inhibit the entry of the glu-AuNPs into the cell.  Our initial qualitative 
results showed a limited amount of intracellular scattering in cells incubated with both 
particles and D-glucose, indicating that the glucose was successful in stopping the glu-
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AuNPs from entering the cell. This is a strong indicator of some involvement between the 
glu-AuNPs and GLUTs.  We attempted to quantify this inhibition by incubating 2-NBDG 
with glu-AuNPs and quantifying the reduction in 2-NBDG signal due to the presence of 
glu-AuNPs.  Our hypothesis was that the if the glu-AuNPs were entering the cells via 
GLUT1, then the 2-NBDG signal would be reduced as is seen with the D-glucose 
inhibition performed by Nitin et al. [359].  Even though we were able to see a reduction 
in 2-NBDG signal (Fig. 5.21) that was similar to D-glucose inhibition, it was not 
significant.  A possible reason for this is that the concentration of D-glucose used by 
Nitin et al. was much higher than the concentration of glu-AuNPs that were added to the 
cells.  Additionally, an unexpected result from this experiment was the significant loss in 
2-NBDG signal with cells incubated with citrate-AuNPs. 
TEM images of cells incubated with citrate-AuNPs showed a high number of 
AuNPs clustered inside and outside the nucleus that was not previously seen in other 
experiments.  The cells were also unhealthy and half the size of normal Sk-Br-3 cells, 
indicating cells under high stress, possibly a result of the large clusters of AuNPs in the 
nucleus.  Previous studies have shown that cells undergoing stress down-regulate GLUT1 
expression, thus decreasing glucose consumption [382]. This is a possible explanation for 
the significantly decreased 2-NBDG signal in cells incubated with citrate-AuNPs. 
However, other experiments have not shown cells undergoing high stress and this data is 
too preliminary for any conclusions to be made.  Further experiments need to be 
performed to fully explore the mechanism of entry of glu-AuNPs and the cellular stress 
induced by 2 nm citrate-AuNPs .  
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5.6. Conclusion 
In conclusion, this study represents the initial step towards the development of 
fluorescence imaging system that can improve diagnostic imaging in the clinic. Our goal 
was to develop a method that will optically differentiate malignant from non-cancerous 
tissue. Using this ex vivo wide-field imaging system, we were able to use a fluorescent 
glucose analogue and tunable light filters to create multispectral images that were 
analyzed to discriminate the presence of malignancy in excised tissue.  We also began to 
explore the development of a new method of targeting small diameter AuNPs to be 
uptaken by cells with high metabolism.  Our initial experiments showed promise in the 
use of glucose capped AuNPs to target GLUT1 expression in cancer cells. However, 
more characterization assays need to be performed to fully understand these particles and 
their interactions with cells.  Full characterization assays include inhibition of all types of 
endocytosis and tracking the intracellular fate of AuNPs after entering the cell via high 
resolution imaging techniques.  
 
 *Partially adapted from Lissett R. Bickford, Robert J. Langsner, Joseph Chang, Laura C. Kennedy, Germaine D. 
Agollah, and Rebekah Drezek, “Rapid Stereomicroscopic Imaging of HER2 Overexpression in Ex Vivo Breast Tissue 
Using Topically Applied Silica-Based Gold Nanoshells,” Journal of Oncology, vol. 2012, Article ID 291898, 10 pages, 
2012 
Chapter 6  
Functionalized Silica-Gold Nanoshells 
as a Targeting Agent for HER2-Positive 
Breast Cancer  
6.1. Introduction 
In the previous chapter, we presented the use of fluorescent deoxy-glucose as a 
molecularly targeted contrast agent to differentiate cancerous tissue. In this chapter, we 
present the use of silica-gold nanoshells functionalized with an anti-HER2 antibody to 
visualize the overexpression of HER2 on the surface of HER2-overexpressing cancerous 
tissues.  As in the previous chapter, we are using whole tissue sections to better simulate 
the condition in which a surgical team would use these nanoshells intraoperatively.  In 
this chapter, we will demonstrate the ability of the nanoshells to enhance contrast in 
HER2-positive tissue with a 5-minute incubation.  We show that the nanoshells are 
localized to the surface of these tissues.  
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Currently, breast cancer is the second leading cause of cancer-related deaths in 
women, and it accounts for approximately one-third of all cancers diagnosed in women in 
the United States [383].  To reduce cancer recurrence and progression, cancerous tissue 
must be completely eliminated, regardless of grade [384].  Surgical breast cancer therapy 
focuses on removing the primary tumor and identifying the possibility of metastatic 
disease from the evaluation of sentinel lymph nodes. Although some patients may require 
modified radical mastectomy, many patients with less-advanced breast cancer elect 
breast-conservation therapy (BCT). The presence of a positive surgical margin during 
these surgeries has been associated with lower rates of patient survival [385].  Due to 
residual cancer cells being left in many patients that undergo breast conservation therapy, 
as many as 40% of patients have experienced local breast cancer recurrence near the site 
of the original tumor [4]. Intraoperative treatment decisions are, therefore, absolutely 
critical. 
As discussed in previous chapters, intraoperative tumor margin detection occurs 
primarily in specialized tertiary centers, such as The University of Texas M.D. Anderson 
Cancer Center (MDACC).  In these centers, the resected tissue undergoes a preliminary 
evaluation by a pathologist while the patient remains in the operating room; if necessary, 
additional tissue can be removed until the pathologist determines the tumor margins are 
negative. In community hospitals, where greater than 95% of BCT is performed [127],  
pathologic analysis of excised tissue only occurs postoperatively [2].  Patients who 
consequently have positive tumor margins must return for surgical re-excision and 
receive increased doses of adjuvant radiation therapy [386,387]. Thus, the existence of 
positive tumor margins portends additional risks and costs to the patient. Due to the 
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existing limitations of current intraoperative tumor margin detection, there is an 
opportunity to develop superior diagnostic tools to assist in reducing the recurrence and 
progression of cancer due to inadequate tissue removal during primary surgery.   
While histological analysis remains the gold standard for tumor margin 
assessment, the macroscopic evaluation of whole, non-sectioned tissue specimens may 
also be used to provide an intraoperative estimate of tumor margin status prior to 
subsequent processing.  This would be an invaluable tool in hospitals without onsite 
pathology suites. Macroscopic visualization of questionable tissue is attractive for 
enhancing the sensitivity and specificity of tumor margin delineation: if the number of 
suspicious regions that require further microscopic processing can be reduced, surgeons 
and pathologists can focus their attention and resources on areas that remain 
inconclusive. Currently, macroscopic evaluation only occurs for breast cancer specimens 
that are characterized by micro-calcifications or nonpalpable masses and does not occur 
for palpable breast masses [71].  For nonpalpable masses that have been resected, 
radiographic images are used to determine the extent of the breast disease and the 
proximity to the resected margins. Although specimen radiography appears to increase 
the accuracy of tumor margin detection, limitations have been noted.  For instance, 
micro-calcifications that appear as tumor on radiographic images may actually be areas of 
lymphocytic accumulation [388]. The use of contrast agents targeted to specific 
biomarkers associated with disease may present an opportunity to increase the sensitivity 
and specificity of macroscopic evaluations. 
In preceding studies, we confirmed that silica-based gold nanoshells targeted to 
the Human Epidermal Growth Factor Receptor 2 (HER2) could be used for the rapid 
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contrast enhancement of both cells [155] and tissue sections [129] which overexpress 
HER2 biomarkers. While gold nanoshells can be conjugated to a variety of biomarkers 
[201,389], we have selected HER2 due to its association with increased cancer 
aggression, recurrence, and progression when amplified [390,391]. Amplification of this 
cell-surface bound tyrosine kinase receptor occurs in up to a quarter of all human breast 
cancer cases [392].  Importantly, using biomarkers for tumor margin detection has 
recently been shown to better identify patients at high risk of cancer recurrence over 
standard histological analysis [13]. 
To facilitate prompt tumor margin detection intraoperatively, the ability to assess 
tumor margins without physical sectioning is highly desirable as sectioning may incur 
significant time to the surgical procedure [2].  Thus, in this study, we advance our 
previous findings by examining the ability to rapidly target HER2 receptors in intact ex 
vivo human breast tissue specimens without sectioning.  We first confirm the 
predominance of the surface targeting needed to identify the tumor margins and 
preferential labeling of HER2-positive tissue using two photon and hyperspectral 
imaging.  Then, we demonstrate that anti-HER2 targeted gold nanoshells can be used as 
rapid diagnostic imaging agents for HER2-overexpression in intact breast tissue 
specimens using a standard stereomicroscope and confirm these results through 
reflectance confocal microscopy (RCM) and immunohistochemistry.  
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6.2. Materials and Methods 
6.2.1. Nanoshell fabrication and antibody conjugation  
Nanoshells were fabricated as formerly described [213,309,393].  Briefly, silica 
cores were made using the Stöber method [394], in which tetraethyl orthosilicate was 
reduced in the presence of ammonium hydroxide dissolved in 200 proof ethanol. The 
surfaces of the cores were then modified by reaction with aminopropyltriethoxysilane 
(APTES) to functionalize reactive amine groups on the surface.  The final particles were 
measured by dynamic light scattering (DLS) to have an average diameter of 276 nm.  
Next, gold colloid (~1-3 nm diameter) was fabricated and adsorbed onto the surface of 
the silica cores via the amine groups to form gold nucleation sites [395]. To fully cover 
the surface of the silica cores, additional gold was added to these nucleation sites via a 
reduction reaction in which hydrogen tetrachloroaurate trihydrate (HAuCl43H2O) was 
dissolved in potassium carbonate and then reduced by formaldehyde.  After the gold layer 
over the silica cores was formed, the spectrum of the final nanoshell solution was 
visualized using a UV-VIS spectrophotometer (Varian Cary 300) (Fig. 6.1). 
To determine the concentration of nanoshells in solution, the absorption, 
scattering, and extinction coefficients were determined using Mie theory.  The average 
nanoshell diameter, as validated by scanning electron microscopy (SEM), was 314 nm 
with a peak surface plasmon resonance at 840 nm.  The concentration of the working 
nanoshell solution was approximately 2.0×109 particles/ml. 
Nanoshells were targeted to biological HER2-antigens by linking the surfaces of 
the nanoshells to anti-HER2 antibodies using previously described methods [213]. Prior 
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to beginning experimental studies, nanoshells were incubated with an anti-HER2-linker 
cocktail [213] for 2 hours at 4°C. To ensure nanoparticle stability in biological media, the 
nanoshells were next incubated with a 1 mM polyethylene glycol-thiol solution (PEG-
SH, MW = 5kD, Nektar) for 12-16 hours at 4°C.  Finally, unbound antibodies and excess 
PEG-SH were removed from the nanoshells by centrifugation.  Prior to experimental 
studies, the nanoshells were resuspended in antibody diluent (IHC World, pH 7.4) by 
gentle pipetting to a final volume of 165 µl. 
The proper concentrations of PEG-SH and antibody linker were determined using 
an optimization assay. In these assays, we performed a parameter sweep by incubating 
different volumes of both antibody-linker and PEG-SH with the nanoshells.  After 
incubation with either solution, a 10% (weight/volume) NaCl solution was added to the 
nanoshells to make a final concentration of 1% w/v. Excess salt in the solution can cause 
the nanoshells to aggregate, resulting in the loss of desired optical properties. By adding a 
layer of PEG to the surface, we can protect the nanoshells from the aggregation; however, 
the proper concentration of PEG needs to be added to ensure maximum stability. Figure 
6.2(A) shows UV-VIS spectra of the nanoshells after a 25-minute incubation with 
NaCl.
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The positive control graph represents nanoshells without NaCl that did not aggregate; the 
negative control was nanoshells that were not stabilized with PEG.  Time points were 
taken at 10, 25, 45, and 60 minutes.  Figure 6.2(B) shows the spectra of the nanoshells 
that were acquired after conjugation of different volumes of antibody-linker and 2 µl of 1 
mM PEG-SH that were then incubated with salt solution at 30 minutes. 
6.2.2. Ex vivo human breast tissue specimens  
Normal and cancerous (HER2-negative and HER2-positive) breast tissue 
specimens were supplied by the Cooperative Human Tissue Network (CHTN) through a 
protocol approved by the Institutional Review Board (IRB).  Tissues were designated as 
normal or cancerous by pathologists at the medical centers where the tissue samples were 
 
Figure 6.1 Measured extinction spectra of nanoshells with an average core diameter of 276 nm and average shell 
thickness of 19 nm.  Insert depicts corresponding image from scanning electron microscopy.  Scale bar represents 
500 nm 
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obtained.  Additionally, HER2 status was previously determined by pathologists at the 
respective medical centers prior to the patients undergoing any form of medical 
treatment. 
Before use, samples were thawed briefly in a 37ºC water bath and cut on a 
disposable cutting board using a 5 mm punch biopsy to maintain size consistency.  At 
least two punch biopsies were taken from each specimen for control and experimental 
conditions.  Each cut specimen used was 5 mm in diameter with an average thickness of 
1 mm.  Tissue samples were subsequently incubated in pre-warmed antibody diluent for 1 
minute at room temperature with gentle agitation in a 24-well plate.  After pre-rinsing, 
the samples were incubated in either antibody diluent or the aforementioned targeted-
nanoshell cocktail in polyethylene sample vials (Sigma Aldrich). The vials were placed 
on a nutator in an incubator at 37°C for 5 minutes. After incubation, the tissue samples 
were removed from the vials and rinsed 3 times in 1X PBS briefly in a 24-well plate.  
Samples were moved to a clean well of 1X PBS prior to imaging.  
6.2.3. Two photon imaging of human breast tissue specimens  
Both HER2-positive and HER2-negative cancerous samples were evaluated for 
surface labeling of HER2-targeted nanoshells by employing two-photon imaging of intact 
breast tissue specimens.  Samples were placed directly on a glass coverslip (Fisher 
Scientific), and an additional coverslip was placed on top of the tissue in order to 
facilitate moderate tissue compression.  For image acquisition, a Zeiss multi-photon 
confocal microscope (LSM 510 META NLO) was used in tandem with a Coherent 
Chameleon femtosecond-pulsed, mode-locked Ti:sapphire laser.  This system was set to 
operate as formerly described [154].  Specifically, an excitation wavelength of 780 nm 
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and a power setting of 10% maximum excitation power were used.  The collected 
emission
wavelength range was 451-697 nm.  Images were collected at a magnification of 20X and 
a z-stack (depth) increment of 5 µm.  In order to calculate the percentage of area covered 
by nanoshells, ImageJ image analysis software was implemented after image acquisition. 
Recent research has shown that ImageJ can be used to analyze signal intensity of silica-
 
 
Figure 6.2 Absorbance spectra of silica-gold nanoshells after incubation with different volumes of (A) 1 mM PEG-
SH or (B) PEG-Antibody.  It was concluded that incubating the nanoshells with 2.0 µl of PEG-SH and 0.6 µl of 
antibody gave the most stable nanoshells. These concentrations were used for subsequent tissue incubations. 
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gold nanoshells under different imaging systems [129,212].  Each pixel in the images had 
an intensity value in the range of 0-255.  To determine the nanoshell level in each image, 
an intensity threshold of 30 was used to separate areas that did not have nanoshells (≤ 30) 
from those that did have nanoshells (> 30).  The value of 30 was chosen because images 
of negative controls were found to have a maximum intensity of 30.  The number of 
pixels that were above the threshold value was then used to calculate the area of each 
image that contained nanoshells.   
6.2.4. Darkfield hyperspectral imaging of human breast tissue slices 
 To confirm the presence of nanoshells on the surface of the tissues, HER2-
positive cancerous, HER2-negative cancerous and normal tissue samples were incubated 
with nanoshells as previously described. A thin layer of pathological ink was placed on 
the tissue surface for orientation. The tissues were embedded in OCT media (BBC 
chemical) and frozen rapidly over dry ice. The specimens were cut at a section thickness 
of 8 µm using a Leica CM1850 UV cryostat.  Cancerous specimens were sectioned at 
−20ºC and normal specimens at −30ºC.  The different temperatures were used to maintain 
optimal tissue morphology as recommended by Leica. Additionally, Magalhães et al. 
reported on the use of different temperatures to slice normal and cancerous tissue [396].  
The sections were immediately placed on superfrost slides (Fisher Scientific) and allowed 
to dry overnight. The next day the tissue slices were imaged with a 10X objective on an 
Olympus microscope equipped with a Cytoviva high-resolution darkfield illuminator. 
Hyperspectral images of the tissue slices were taken using a hyperspectral camera that 
provides both spatial and spectral data for each image. 
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 Spectral data of each field of view (FOV) was used to determine if nanoshells 
were present on each slice of tissue. Comparisons were made between tissue surfaces and 
tissue beyond the surfaces to determine the presence of nanoshells. Additionally, spectral 
data from tissues that were not incubated with nanoshells was used as a control. A final 
comparison between HER2-positive and HER2-negative cancerous tissue and normal 
tissue was also performed to confirm the specificity of the nanoshells for HER2-positive 
tissue. Data for each spectral graph was calculated by dividing the raw spectral data by 
the spectral profile of the illumination lamp and then normalizing the resultant spectra to 
its largest value.  
6.2.5. Macroscopic imaging of human breast tissue specimens  
Normal and HER2-positive cancerous breast tissue specimens (from patients who 
had and had not received neoadjuvant chemotherapy) were imaged using a Zeiss 
Discovery.V8 stereomicroscope equipped with a VisiLED MC1000 light source.  For 
macroscopic imaging of breast tissue specimens, a thin plastic black stage was placed 
beneath a glass coverslip to enable ease of tissue placement and to provide a consistent 
black background among all samples. The specimens (controls and respective nanoshell-
labeled counterparts) were placed alongside each other on top of the coverslip.  Images 
were taken at both 1X and 2X magnification under the same lighting conditions.   
6.2.6. Reflectance confocal microscopy imaging of human breast tissue 
specimens  
Following widefield imaging, the aforementioned samples were prepared for 
microscopic analysis under RCM.  For this component of the study, a Lucid VivaScope 
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2500 inverted confocal microscope was used.  Samples were placed directly on glass 
slides that were modified by the addition of an adhesive 1-mm-deep, 20-mm-diameter 
silicon isolator (Invitrogen). To compress the tissue slightly and consistently among 
samples, an adhesive tissue cassette (Lucid, Inc.) was placed directly on top of the 
silicone isolators above the tissue specimens. Multiple images were taken at a power of 
0.4 mW and at the same distance from the glass surface for both samples and controls. 
After reflectance imaging, the samples were prepared for histological processing.  
Additionally, RCM was used to confirm the localization of the nanoshells to the 
surface by utilizing the confocal software to change focal planes and acquire images at 
various depths below the surface.  After incubation with the functionalized nanoshells, 
the HER2-positive tissue was imaged every 3 µm at a power of 1.11 mW for each image.  
Finally, RCM was used to image HER2-positive tissue surfaces before and after 
incubation with the nanoshells.  For each tissue, three images were acquired at different 
spatial locations on the tissue surface and the signal intensity was calculated as 
previously described [129]. Averages for each tissue were then calculated for pre and 
post incubation and then compared using a 2-tailed, paired Student’s t-test.   
6.2.7. Immunohistochemistry and histology 
Once images were collected under both stereomicroscopy and RCM imaging 
systems, normal and HER2-positive cancerous samples (with and without previous 
neoadjuvant chemotherapy) were embedded in OCT media and sectioned to a thickness 
of 5 µm. Multiple sections from each specimen were prepared for either 
immunohistochemistry (IHC) or hematoxylin and eosin (H&E) staining.  IHC for the 
HER2-antigen was executed using the Histostain Plus AEC Broad Spectrum Kit 
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(Invitrogen) per manufacturer’s instructions.  H&E staining was also performed per 
manufacturer’s instructions (Sigma Aldrich) for the alcoholic Eosin Y solution.  For 
image acquisition, a standard brightfield microscope (Zeiss Axioskop 2 equipped with a 
Zeiss Axiocam MRc5 color camera) was used at a magnification of 20X. 
6.3. Results 
6.3.1. Optimization of incubation parameters 
 Figure 6.2 displays representative UV-VIS absorbance spectra of the silica-gold 
nanoshells after conjugation with PEG (Fig. 6.2(A)) and anti-HER2 antibody (Fig. 
6.2(B)).  The pH level, proteins, and specific cell types present in the tissue can interact 
with the surface of the nanoshells to cause aggregation [223] which has significant effect 
on their optical properties.  PEG has been used with many different particles to protect 
these particles to improve long-term circulation in in vivo models [231,397,398], which 
can be translated to this project by using PEG to protect the nanoshells during incubation 
with the tissue.  Additionally, the presence of antibodies can have a significant effect on 
the aggregation of the particles in a biological environment [234].  With this in mind, we 
first optimized the volume of PEG-SH to protect the nanoshells at various incubation 
times with NaCl (10, 25, 45, and 60 minutes).  The graph shown in Figure 6.2(A) is for 
the 25-minute incubation experiment.  We compared the spectra of the nanoshells to two 
controls, nanoshells that were not incubated (negative control) and incubated with salt 
(positive control).  The graph shows that two volumes of PEG-SH (1.7 and 2.0 µl) were 
very similar to the negative control; however, over the different incubation times the 
volume of 2.0 µl held its spectra more consistently (data not shown).  Once the optimal 
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PEG-SH volume was determined, we performed the same experiment with the antibody-
linker. Figure 6.2(B) shows that incubation with 0.6 µl of antibody produced the most 
stable nanoshell-linker. These steps suggested that the nanoshells would stay stable while 
incubating with the resected tissue specimens. 
6.3.2. Distribution and penetration of gold nanoshells in intact human breast 
tissue 
The goal of this study was to evaluate the distribution of anti-HER2-conjugated 
gold nanoshells on resected intact tissue specimens.  For comparison, the nanoshell 
labeling between HER2-positive and HER2-negative tissue samples was evaluated using 
a two photon imaging system.  As previously reported, this imaging system is capable of 
enhancing and capturing the luminescence signature of the gold nanoshells [154] while 
also collecting a stack of images taken through the depth of the tissue of interest.  Figure 
6.3 represents such images of HER2-positive and HER2-negative cancerous tissue 
samples incubated with HER2-targeted nanoshells.  Each sequential increment in the z-
direction represents 5 µm into the tissue.  Qualitatively, the first image (taken at the 
surface, or at 0 µm) in Figure 6.3 demonstrates that the nanoshells preferentially label 
HER2-receptors on the surface of the tissue.  Additionally, Figure 6.3 displays decreased 
signal as the focal spot from the confocal microscope penetrates further into the tissue.  
This is believed to result from a minimal number of nanoshells being able to penetrate the 
tissue in the limited incubation time, thus decreasing signal collected beyond the surface. 
A quantitative difference of the nanoshell signal at the surface of the HER2-positive and 
HER2-negative tissue was calculated.  Using ImageJ imaging software, it was determined 
that approximately 66% of the FOV for HER2-positive tissue was covered in nanoshells 
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compared to 2% of the FOV of the HER2-negative tissue.  This confirms the preferential 
labeling and visualization of HER2-positive tissue using anti-HER2 nanoshells. 
 
 
Figure 6.3 Z-stack two-photon luminescence images of HER2-positive and HER2-negative tissue incubated with 
HER2-targeted nanoshells for 5 minutes at 37°C.  Each progressive image represents an increase in depth 
penetration of 5 µm. Magnification = 20X. Scale bar = 50 µm. 
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To further validate the surface binding of the nanoshells, hyperspectral images of 
different tissue sections were also acquired.  Figure 6.4(A) shows a representative surface 
 
 
Figure 6.4 Darkfield images of HER2-positive tissue sectioned after incubation with anti-HER2 targeted silica-
gold nanoshells. (A) Surface of HER2-positive tissue, (B) 24 µm beyond the surface of the same tissue. (c.) 
Scattering spectra of the fields of view depicted in (A) and (B). Additionally, spectra from the surface of HER2-
positive tissue not incubated with silica-gold nanoshells is shown as a negative control. Scale Bar = 50µm. 
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of a HER2-positive tissue section after incubation with anti-HER2 nanoshells. Figure 
6.4(B) illustrates tissue 24 µm beyond the surface of the same tissue. Figure 6.4(C) 
displays the respective spectral information of each FOV shown in (A) and (B).  
Additionally, the spectrum of HER2-positive tissue without nanoshells has been included 
as a control.  As seen in this graph, the spectrum of the surface of the HER2-positive 
tissue incubated with anti-HER2 nanoshells is distinctive from that of the same tissue 24 
µm beyond the surface. In fact, the spectrum of the tissue beyond the surface of the 
nanoshell-labeled specimen is very similar to the spectra of the surface of the control. 
To ensure that we see this spectral data across multiple specimens, three different 
patients were incubated with anti-HER2 nanoshells and the spectral data of the surfaces 
of these tissues was acquired.  Analysis revealed that these surfaces had similar spectra to 
each other (Fig. 6.5) and dissimilar spectra to the negative control spectra presented in 
Figure 6.4(C), showing that the spectral differences is due to the presence of the 
nanoshells on the surface of the tissues.  
 
 
Figure 6.5 Spectra of the surface of three different HER2-positive tissues after incubation with anti-HER2 silica-
gold nanoshells. All three spectra were very dissimilar to the spectrum of the negative control, demonstrating the 
presence of the nanoshells changes the spectral signal of the tissue.  
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Our final experiment to confirm surface localization of the nanoshells used RCM 
to acquire images of tissue incubated with nanoshells. Figure 6.6(A-C) displays images 
acquired of HER2-positive tissue after incubation with the nanoshells at (A) the surface, 
(B) 24 µm, and (C) 45 µm below the tissue surface. These images display the increased 
scattering signal from the surface when compared to the images from below the tissue 
surface. We hypothesize that this increased signal is due to the localization of silica-gold 
nanoshells at the surface.  These results and this hypothesis are consistent with the results 
we observed using two-photon microscopy and darkfield microscopy (Figs. 6.3 & 6.4).  
Figure 6.6(D) displays the average signal intensity from six different HER2-positive 
tissue surfaces that were taken before and after incubation with the nanoshells.  Each 
tissue was scanned three times and the average intensity was calculated for each tissue 
before and after incubation using ImageJ.  The average intensity is higher for tissues after 
tissue incubation (59 to 45); however, variation in signal between tissues led to a non-
significant difference between the groups (p-value 0.122).  These results support our 
findings that the targeted nanoshells primarily localized to the surface of the tissue. 
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6.3.3. Enhanced optical imaging of intact ex vivo human breast cancer tissue 
using gold nanoshells 
Based on previous results demonstrating the preferential labeling of HER2-
targeted nanoshells on the surface of intact ex vivo HER2-positive tissue specimens, we 
assessed the potential of using a standard stereomicroscope to visualize this enhanced 
contrast.  For this component of the study, human breast tissue specimens that over-
 
Figure 6.6 HER2-positive tissue after incubation with anti-HER targeted silica-gold nanoshells visualized using a 
commercially available reflectance confocal microscope at various depths (A) at the surface, (B) 24 µm below the 
surface, and (C) 45 µm below the surface.  There is a much higher scatter signal seen at the surface when compared 
to both the 24 and 45 µm levels. Scale bar = 100 µm. (D) Average reflectance intensity from six HER2-positive 
tissues at the surface before and after incubation with silica-gold nanoshells.  
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expressed HER2 receptors at the time of patient diagnosis were evaluated and compared 
to normal breast tissue.  Due to the ultimate goal of utilizing gold nanoshells to rapidly 
label tumor margins intraoperatively in diverse patient populations, we examined tissue 
from patients who had and had not undergone neoadjuvant chemotherapy.  All tissue 
samples were incubated with either antibody diluent buffer or the anti-HER2-targeted 
nanoshells for 5 minutes at 37°C.  As shown in Figure 6.7, which represents raw images 
taken with a stereomicroscope, intact tissue specimens incubated with antibody diluent 
alone showed no markings or features characteristic of nanoshells.  However, tissue 
specimens incubated with the anti-HER2-targeted nanoshells demonstrate numerous 
particles on the surfaces of the tissues.  Qualitatively, the HER2-positive tissue from the 
patient who did not undergo previous chemotherapy shows the greatest labeling with the 
targeted nanoshells.  The HER2-positive tissue from the patient who did undergo 
neoadjuvant chemotherapy does demonstrate enriched nanoshell labeling when compared 
to normal tissue, though not to the same extent as the patient without previous 
chemotherapy.  In contrast, the normal tissue shows the least amount of nanoshell 
labeling and only a few areas of nanoshells can be visually perceived. 
While the degree of nanoshell labeling can be visualized without image 
adjustments under a standard stereomicroscope, the superior extent of this labeling can be 
seen more clearly after a simple contrast enhancement using imaging software (Image J).  
As seen in Figure 6.8(A) the nanoshells are even more discernable against the tissue 
background regardless of inherent tissue constituents.   
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To validate the enhanced nanoshell labeling seen by macroscopic imaging, the 
surfaces of the same tissue samples were also imaged using RCM (Fig. 6.8(B)). 
Concurrent with the stereomicroscopic images, we see dramatic nanoshell surface-
labeling when using targeted nanoshells with previously untreated HER2-positive tissue.  
For the HER2-positive sample that had formerly undergone chemotherapy, we also see 
 
Figure 6.7 Raw stereomicroscope images of (a.,b.) HER2-overexpressing cancerous and (c.) normal tissue 
incubated with either buffer or HER2-targeted nanoshells for 5 minutes at 37°C. Cancerous tissue taken from a 
patient (a.) without chemotherapy and (b.) following neoadjuvant chemotherapy. Arrows represent nanoshells.  
Images taken at 2X. Scale bars = 2.5 mm 
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enhanced nanoshell labeling, though to a lesser degree than the untreated sample as 
suggested by the stereomicroscopy results.  The normal breast tissue displays the least 
amount of surface labeling with only minimal nanoshells evident with either imaging 
system.  Reflectance intensity measurements (data not shown) were ~2.5 to 3 times 
greater for both the HER2-positive tissue sample receiving chemotherapy and for the 
HER2-positive tissue not receiving chemotherapy when compared to the normal tissue 
sample.  
Subsequent histological analysis shown in Figure 6.8(C) reveals that the 
distribution of HER2 receptors seen with nanoshell-enabled contrast corresponds to that 
seen with IHC against HER2.  The HER2 expression seen by IHC is greater for the 
previously untreated HER2-positive tissue sample than for the sample that had undergone 
neoadjuvant chemotherapy.  This is believed to be due to the effects of chemotherapy.  
Rasbridge et al. previously demonstrated that patient response to chemotherapy is highly 
variable, with patients previously negative for HER2-overexpression occasionally 
becoming positive after treatment and patients previously positive for HER2-
overexpression subsequently becoming negative [399]. Although patient response to 
chemotherapy varies, tissues previously identified as overexpressing HER2 receptors 
during initial diagnosis, regardless of chemotherapy exposure, demonstrate enhanced 
nanoshell labeling over normal tissue.  Additionally, H&E-stained sections of all tissue 
samples have been included (Fig. 6.8(D)) to illustrate the microscopic characteristics and 
differences associated with cancerous vs. non-cancerous conditions. 
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Figure 6.8 (a.) Stereomicroscopic images of HER2-overexpressing breast tissue (with and without neoadjuvant 
chemotherapy) and normal breast tissue incubated with HER2-targeted nanoshells for 5 minutes at 37°C after 
contrast enhancement. Magnification at 2X; scale bar = 2.5 mm. Arrows represent nanoshells. (b.) Respective 
reflectance confocal microscopy images of tissue samples from (a.). Power = 0.4 mW and scale bar = 75 µm. 
Respective (c.) HER2 immunohistochemistry and (d.) H&E results taken under brightfield microscopy under 20X 
magnification. Scale bar = 0.35 mm.  
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6.4. Discussion 
In this study we demonstrated the ability to use targeted gold nanoshells to rapidly 
improve visualization of a specific biomarker (HER2) associated with disease aggression 
and progression in intact ex vivo human breast tissue and confirmed binding location via 
confocal and darkfield hyperspectral microscopy.  By utilizing silica-gold nanoshells 
designed as rapid diagnostic imaging agents, surgeons and pathologists may be able to 
realize tumor margin status directly in the operating room after both macroscopic and 
microscopic assessment. While multiple methods of intraoperative tumor margin 
detection are currently under investigation [85,118,123,359,400], we are developing an 
inexpensive and portable system for rapidly analyzing ex vivo specimens based on the 
desire to enhance current methodologies without delay in clinical translation due to 
regulatory concerns associated with in vivo systems. 
The ability to enhance contrast of malignancy using topically applied agents has 
previously been demonstrated for oral and breast tissue using fluorescently labeled 
deoxy-glucose and epidermal growth factor (EGF) conjugates [23,136,314] as well as 
cervical tissue using fluorescently labeled gold nanoparticles targeted to EGF receptors 
[401].  However, these studies employed incubation times ranging from 20-45 minutes, 
which exceeds the length of time currently needed to obtain tumor margin status using 
frozen section histology.  Additionally, some of the aforementioned studies utilized 
optical clearing agents, which may be necessary for particles that target intracellular 
biomarkers [350,402].  Nevertheless, gold nanoshells targeted to extracellular biomarkers 
may offer more favorable opportunities for ex vivo intraoperative tumor margin detection 
without the need for lengthy incubation times or the use of optical clearing agents.   
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Recently, we verified that silica-based gold nanoshells could be used to enhance 
contrast of both HER2-overexpressing cells and tissue sections within 5 minutes of 
incubation time [129,155].  However, translating this technology towards clinical 
relevancy requires the ability to assess whole, un-sectioned specimens. Here, we confirm 
that gold nanoshells, when targeted to HER2 receptors, can be used to distinguish intact 
HER2-overexpressing ex vivo tissue from normal tissue within the same incubation time 
and we demonstrate that this difference can be observed macroscopically.  These results 
are supported by microscopic imaging and immunohistochemistry against HER2. 
By employing macroscopic imaging intraoperatively, clinicians may be better 
able to distinguish cancerous and normal breast tissue prior to further microscopic 
analysis and subsequent histological processing.  Ultimately, this system could also be 
used for other diagnostic applications, for other anatomical locations, and for other 
biomarkers associated with disease.  By facilitating fast and accurate tumor margin 
results intraoperatively as a supplement to current diagnostic methods, we expect to 
reduce the amount of time spent in surgery due to inadequate tissue removal.   
In the previous two chapters, we have demonstrated the ability to differentiate 
tissue using two molecular contrast agents.  However, these agents were visualized with 
imaging systems that are not expensive and/or portable.  In the next chapter, we will 
demonstrate the combined use of these two agents (2-NBDG and anti-HER2 silica-gold 
nanoshells) with a low-cost, portable widefield imaging system that can be used to detect 
both increased metabolism and HER2 overexpression.   
 
  
Chapter 7  
Development of a Portable Device to 
Visualize Contrast Agents in Cells and 
Ex Vivo Specimens 
7.1. Introduction 
In the previous two chapters, the use of optical contrast agents to enhance the 
visualization of specific molecular markers in both in vitro and ex vivo studies was 
discussed.  In this chapter we further these studies through the development of a portable 
and cost effective imaging device designed to visualize both 2-NBDG and anti-HER2 NS 
in cells and tissue specimens.  The previous studies described in this dissertation reported 
the use of visualization techniques that required expensive equipment and software that 
could not be easily transported [23,128], or the samples required preparation to localize  
the NS [128].  The RCM described in chapter 6, was the only device designed 
specifically for clinical use; however, this instrument was designed to work in the NIR 
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spectrum and is unable to visualize multiple contrast agents in tissue.  In this chapter, we 
describe the design, development, and characterization of a low cost portable imaging 
system to visualize 2-NBDG and anti-HER2 silica-gold nanoshells in cell lines and 
excised tissue. 
7.2. Background 
As discussed earlier, optical imaging can improve cancer diagnostics via minimal 
acquisition time and high lateral resolution.  The addition of contrast agents can increase 
the specificity of optical imaging by improving contrast between cancerous and normal 
cells due to differences in molecular expression.  We have already demonstrated the 
enhanced specificity of both 2-NBDG and anti-HER2 NS in separate studies, and we aim 
to combine their properties to demonstrate the ability of multi-wavelength imaging to 
visualize cancerous tissue.  Multi-wavelength NIRF imaging has been demonstrated in 
vivo in two studies by Baeten and Montet et al.  [403,404].  In the study by Baerten et al., 
the authors used enzyme-cleavable fluorophores to indicate protease activity and 
vascularization of tumors.  The authors were able to use the intensity values from these 
two measurements to correlate cathepsin expression with tumor size.  Another multi-
wavelength imaging system, the multi-spectral digital microscope (MDM), was 
developed by Roblyer et al. [301,405].  This device uses white light, orthogonal polarized 
reflectance (OPR) imaging, and multiple visible range wavelengths for visualization of 
neoplasia in the oral cavity [301] or molecularly targeted NPs in tissue phantoms [405].  
The multiple wavelength approach provided the researchers with information on the best 
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wavelength for interrogating the autofluorescent changes that are consistent with 
neoplastic tissue [406] 
In addition to multiple wavelength imaging, there has been a shift towards the 
combination of wide-field imaging followed by high resolution probes to interrogate 
areas of interest [406,407].  Another study by Lam et al. demonstrated the utility of using 
an endoscope to obtain wide-field autofluorescent images of the bronchi, followed by 
high resolution optical coherence tomography (OCT) of suspicious lesions to differentiate 
invasive carcinoma from carcinoma in situ based on the thickness of the epithelial layer 
[408].  A recent study by Patel et al. demonstrated the use of wide-field imaging followed 
by confocal fluorescence to visualize specific areas of breast cancer on histopathological 
slides [409].  In this study, slides were incubated with methylene blue (MB) and 
accumulated preferentially in malignant areas after 10 minutes.  Wide-field images of the 
tissue were first acquired followed by fluorescence imaging at high-resolution.  The 
researchers were able to separate the malignant from normal cells on the slices by the 
increased fluorescent signal in the cancerous areas [409]. 
Most multi-modal and multi-wavelength imaging systems still rely on 
endogenous contrast or contrast provided by non-specific contrast agents such as MB.  
Additionally, there is little work reported on the use of multiple specific contrast agents 
in one sample to enhance specificity.  In a study by Xie et al., the authors used two 
IRdyes, 2-DG  (deoxyglucose) and EGF for visualization of tumors in a murine model 
[27].  However, in this study, the authors used contrast agents in separate animals.  As the 
optical agent for the biomarkers was the same (IRDye), they would have been unable to 
resolve the differences between the contrast agents in one animal.  Additionally, the 
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authors used the Maestro© system that is both non-portable and costly.  This study is the 
first to approach using multiple molecularly specific contrast agents, and the authors were 
able to show for their particular model that the EGF dye had higher signal than the DG 
dye.  However, this result will vary due to the varied expression of molecular markers, 
especially across breast cancer subtypes [19].  A recent study by Vermeulen et al. 
demonstrated that increasing the number of interrogated biomarkers improved the 
detection of cancer on immunohistochemical slides [19].  Detection of multiple markers 
in one sample is also important due to the heterogeneity of expression levels in one tumor 
[410–412].  The device presented in this chapter aims to use multiple contrast agents as 
the heterogeneity in expression profiles could lead to the system obtaining a false 
negative if only one contrast agent is used.    
In this chapter, we aim to develop a method to visualize multiple molecular 
contrast agents that are used to visualize HER2-positives cells and tissue.  The ultimate 
goal of this research is to develop a system that can be translated for use in the clinic as 
an ex vivo imaging device that provides surgeons with rapid results regarding the 
molecular expression of GLUT1 and HER2.  Our previous experiments have shown that 
the expression of these proteins can be imaged using 2-NBDG and anti-HER2 NS in a 
rapid manner (20 and 5 minutes, respectively) [23,128].  We further this research by 
designing, fabricating, and characterizing a portable, inexpensive imaging designed to 
visualize 2-NBDG fluorescence and anti-HER2 NS.  We show that the device can 
visualize 2-NBDG and anti-HER2 NS in the cancerous Sk-Br-3 cell line.  Additionally, 
we present data characterizing the performance of the system in visualizing the contrast 
agents in ex vivo tissue. 
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7.3. Materials and Methods 
7.3.1. Design of imaging system 
The system was designed to visualize and illuminate 2-NBDG fluorescence and 
NS scattering without displacing the tissue or camera to capture a composite image of 
both fluorescence and scattering.  Preliminary studies demonstrated that 360° 
illumination of tissues with NS was necessary because the varying height in the tissue 
blocked illumination light when there was a single illumination source.  This led to the 
design of placing three separate illumination sources placed on the diameter of a circle at 
an angle of 120° from each other and all facing the center of the circle (Fig. 7.1(A)).  We 
chose the use of high-power LEDs as our illumination sources as they have low cost and 
specific wavelengths are available for our contrast agents.  LEDs were purchased from 
Marubeni Corporation (FL-470-06, FL760-03-80)).  Additionally, we placed excitation 
filters in front of the LEDs to control the wavelength of light interacting with the tissue 
(Fig. 7.1(B)).  Short-pass (SP) 500 and 800 nm filters were purchased from Thor and 
Chroma (FES0500, E800sp). Once the filters and LED circuits were assembled, the two 
parts were placed together and held together with a set screw to create one modular piece 
in which the holes for the LED attachments are lined up with the excitation filters (Fig. 
7.1(C)). The aperture at the top of the device was designed to match the outer diameter of 
the filters that attach to the lens of the camera (58 mm).   
As we are using our system to visualize two different contrast agents, two 
different circuits were designed and are controlled through an On-Off-On switch.  Each 
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circuit was soldered so that the LEDs were connected in series with a 12V battery (GP 
23-AE 12V) as the voltage source and a resistor so that the LEDs would not burn out.   
 
To capture tissue signal, a camera was attached to the device so that the lens of 
the camera was perpendicular to the tissue in order to capture the side scattering of the 
NS.  Camera selection is an important design parameter as our aim was to visualize signal 
in both the visible and NIR wavelengths, our system required a device to detect both 
signals.  RGB  (red, green blue) sensors in digital cameras have the ability to sense in the 
NIR; as a result, most cameras have an internal IR blocking filter so that the sensors do 
not detect IR light and translate it to a color.  Removal of the IR filter would allow for 
 
Figure 7.1 Schematic drawings of portable inexpensive imaging device used to visualize molecular contrast agents 
in cells and tissue.  (A) Schematic of the outside cover in which the LEDs are attached and pointed towards the 
center of the device.  (B) Base attachment of the device displaying placement of tissue samples and excitation 
filters. (C) Assembled device with holes for LED attachments lined up with large holes for excitation filters. 
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sensing of both NIR and visual light from NS and 2-NBDG given that the proper 
emission filter was placed in front of the camera lens.  In addition to their versatility in 
sensing, digital cameras are also relatively inexpensive, another important design 
parameter for the system.  A digital single-lens reflex camera (DSLR) with the NIR filter 
removed was purchased from LDP LLC for $1,095.00 (Xnite Canon450D Rebel Xsi).  
Additionally, a variable zoom lens from Canon was purchased for $199.00 (EF-S 18-55 
mm, F/3.5-5.6 IS II).  Multiple 58 mm lens filters were purchased to help further 
characterize the ability of the system including a 500-550 nm bandpass (BP) and two LP 
filters (720 and 780 nm).  Additionally, the BP filter transmits light above 800 nm.  The 
cost of the filters ranged between $70-$145. 
The system was fabricated with black delrin using a variety of machinist tools, 
including a mill, lathe, and a CNC (computer numerical control) mill.  Threaded holes 
were tapped so screws could be used to attach the machined pieces.  An optical post was 
attached to the top of the system to anchor the DSLR during image acquisition to 
minimize camera movement.  Finally, a one-inch diameter circle was etched into the 
center of the tissue specimen area as a scaling reference.  With all components attached 
(Fig. 7.2), the system weighs 8.2 lbs and has a foot-space of 55.25 in2. 
7.3.2. Characterization of system 
There are three imaging modes for this system. In white light imaging, the LEDs 
are not turned on and there is no emission filter; the only illumination is from 
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the overhead lights in the room.  When the term “blue light imaging” is used, we refer to 
the setup used to image 2-NBDG: blue LEDs illuminated with a BP 525 emission filter 
for the lens.  For “NIR imaging”, the NIR LEDs were illuminated and a LP720 emission 
filter is used (unless otherwise noted).  The overhead lights were turned off during the 
latter two imaging modes so that no background signal is captured by the camera 
Preliminary experiments demonstrated the importance of camera settings such 
ISO speed, aperture size, and exposure time.  These preliminary studies led us to use the 
same aperture size (f/5.6) and ISO setting (800) for all experiments presented in this 
chapter.  Different exposure times were used for all three imaging modes and for 
different lighting settings.  These different settings will be indicated in the materials and 
methods section.  However, any quantitative analysis performed between images was 
performed with images acquired at the same exposure.  Additionally, an optical power 
 
Figure 7.2  Side view of fully assembled imaging device.  An optical pole was attached to the top of the device for 
camera stabilization and adjustable height.  An on-off-on witch allows for easy control of the two circuits. 
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meter (Newport Optics) was placed in the system during different days to confirm that 
illumination power did not decrease between days.  We did not see any measurable 
change between days.  However, as a precaution, any quantitative analysis was 
performed between samples that were acquired during the same experiment so that any 
difference between experiments did not affect the analysis.  
To demonstrate the ability of the system to visualize NS and quantify signal 
intensity changes with the number of particles, 1 mL of a serial dilution (2 X109 particles 
to 31.25 X 106 particles per mL) of NS was placed in a quartz cuvette in the same 
orientation in the imaging device.  Images were acquired in the NIR imaging mode at an 
exposure time of 10 ms.  After image acquisition, ImageJ was used to draw a ROI around 
the NS area and the average intensity for each concentration was calculated and plotted in 
Figure 7.3(A).  Additionally, a serial dilution of 2-NBDG (156 mM to 15.6 nM) was 
characterized in the blue light imaging settings at an exposure time of 1 s and is displayed 
in Figure 7.3(B).  
7.3.3. Performance of system in vitro 
To demonstrate the ability of the system to visualize both contrast agents, the Sk-
Br-3 cell line was chosen as previous experiments have demonstrated increased contrast 
with both optical agents.  Cells were incubated with 2-NBDG only, anti-HER2 NS only, 
or both contrast agents (along with a negative control).  NS were incubated with 
antibodies and PEG-SH in the same ratios as previously described [128].  Briefly, 2.25 
mLs of NS (at a concentration of 2.0 X 109 particles/mL) were incubated with 3 µL of 
antibody-PEG-linker and 237 µL of deionized (DI) water at 4°C.  After 2 hours, 10 µL of 
1mM PEG-SH was added to stabilize the particles. Particles were then centrifuged at 
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2500 RPM for 5 minutes and resuspended in 500 µL of antibody buffer.  2-NBDG was 
diluted to a concentration of 500 µM in 1X PBS.   
 
Sk-Br-3 cells were grown at 37°C and 5% CO2 until reaching confluency.  
Trypsin was added to the cells to detach from the flask and centrifuged into a pellet at 
120g for 3 minutes. Supernatant was aspirated and cells were resuspended in 1X PBS to a 
 
 
Figure 7.3 Pixel intensity versus number of silica-gold NS (A) and concentration of 2-NBDG (B).   
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concentration of 1.77 X 106 cells/ml.  150,000 cells were added to a flat bottom 
centrifuge tube (Fisher 05-406-16) and 500 µL of contrast agent was added to the cells 
and 1X PBS was added to each centrifuge tube so each tube had a total volume of 1 mL.  
Samples were then placed in a rotating hybridization chamber (VWR 23050 TV) for 20 
minutes.  Samples were then centrifuged to remove any unbound 2-NBDG or NS and 
fixation buffer (Enzo ADI-950-011) was added to the cells for 20 minutes.   
Cells were then transferred to coverslips and placed into the center of the device, 
and white light, blue light, and NIR images were acquired at exposure times of 5 ms, 6 s, 
and 66.6 ms respectively.  Results for each wavelength of imaging are shown in Figure 
7.4. As the signal in the 2-NBDG only (Fig. 7.4(D)) image was faint, the images were 
further processed into respective RGB channels and contrast for the green channel was 
enhanced to demonstrate the higher 2-NBDG signal in cells with 2-NBDG versus cells 
with NS only.  These resulting images are displayed in Figure 7.5. 
7.3.4. 2-NBDG in ex vivo specimens 
All tissue used in this chapter was supplied by the CHTN in an IRB approved 
protocol as described in the previous chapter.  To characterize the ability of the system to 
differentiate 2-NBDG signal from autofluorescent signal in tissue, a HER2-positive IDC 
was incubated with 1.56 mM 2-NBDG for 10 minutes at 37°C.  Pre and post incubation 
images were acquired in both white light and blue light settings at an exposure time of 
100 ms and 1 s respectively.  Resulting images are displayed in Figure 7.6.  To quantify 
the difference between the blue light images, ROIs were drawn around the tissues and 
average intensities were calculated for both the RGB composite and green channel image. 
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7.3.5. Anti-HER2 NS in ex vivo specimens 
The same HER2-positive tissue was also incubated with anti-HER2 NS after the 
2-NBDG.  Pre and post incubation images with NIR LEDs, 780 LP filter and an exposure 
time of 1 ms are shown in Figure 7.6(C&F).  1 ms was chosen as the exposure time as 
this was the lowest exposure setting in which there was no endogenous signal from the 
tissue in the pre incubation image.   
As shown in Figure 7.6, there is very little signal from the tissue in both pre and 
post incubation NIR images, due to the low exposure.  Using a different HER2-positive 
tissue, we varied the exposure time for both pre and post incubation from 10 to 50 ms to 
visualize the NS more effectively (Figure 7.7).  However, increasing exposure also 
increased the signal from the tissue, and it became difficult to differentiate the signal 
from the tissue and the NS.   
To reduce the signal from the tissue and increase contrast between the NS and 
tissue, the tissue was incubated with glycerol for 10 minutes at 37°C.  Glycerol is known 
as an optical clearing agent that reduces scattering of tissue through dehydration 
[281,413–415] or reversible disassociation of collagen fibers in the extracellular matrix 
[280,415,416]. Pre and post incubation images were acquired in the NIR imaging setup 
with a LP 780 filter at an exposure time of 20 ms (Fig. (7.8(A&B)).  To demonstrate 
enhanced signal in tissue with NS after glycerol incubation, a different HER2-positive 
tissue was incubated with glycerol for 10 minutes at 37°C, followed by a 5 minute 
incubation with anti-HER2 NS at 37°C, and results are presented in Figure 7.8(C&D).  
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7.3.6. Application of FITC-functionalized NS to co-localize NS in tissue 
As we were unable to demonstrate enhanced signal in tissue after glycerol and NS 
incubation (Fig. 7.8), we chose to examine if the NS were present in tissue using PEG 
functionalized with FITC so that the NS could be localized using the blue light imaging 
settings.  In this experiment, HER2-negative tissue from the same patient was incubated 
with non-targeted NS functionalized with FITC-PEG or PEG for 10 minutes at 37°C.  
Tissues were not rinsed, as we did not want to remove the NS that were bound by 
electrostatic interactions.  Pre and post incubation images and side-by-side images were 
acquired at an exposure of 1 s and 40 ms (Blue light and NIR).  Representative images 
are displayed in Figure 7.9(A&B); the blue light images were split into RGB components 
and the average intensity of the green channel for each tissue was calculated with a hand-
drawn ROI. 
After establishing that FITC-PEG NS could be visualized in the blue light 
imaging settings of our system, we aimed to use targeted anti-HER2 NS that were 
backfilled with FITC-PEG on HER2-positive tissue.  2.25 mLs of silica-gold NS were 
incubated with 2.4 µL of anti-HER2-PEG linker and 189.6 µL of DI water for 2 hours at 
4°C.  Following incubation 8 µL of 1 mM FITC-PEG-SH were incubated with the NS 
overnight.  NS were then centrifuged at 2500 RPM for 5 minutes and supernatant was 
aspirated.  Finally, the NS were re-suspended in 165 µL of antibody diluent buffer. 
HER2-positive tissue was thawed at 37°C in PBS and pre incubation images were taken 
in white light, blue light, and NIR imaging settings (with a LP 720 filter).  Exposure 
times for imaging were 66.6 ms, 1 s, and 10 ms respectively.  Tissues were then 
incubated for 10 minutes in 99.9% glycerol and images were acquired under the same 
  
 
159
conditions.  Next, 165 µL of NS were incubated with the tissue for 10 minutes at 37°C.  
Post incubation images were acquired.  Blue imaging pictures were processed in ImageJ 
to visualize signal from the FITC particles.  Images were split into RGB components and 
the contrast in the green channel was enhanced by 0.05%. 
7.3.7. Application of NIR fluorescent dye 
Anti-EGFR IRDye 800CW was purchased from LI-COR Biosciences (926-
08446) and resuspended in 1.5 mLs of 1X PBS to a final concentration of 133.3 mM.  
HER2-positive tissue was incubated with 99.9% glycerol for 10 minutes at 37°C and pre 
incubation images were acquired in the NIR setting with a LP500 filter at an exposure 
time of 5 s.  Tissue was then incubated 165 µL NIR dye (or PBS) for 10 minutes at 37°C.  
Post incubation images were acquired at the same imaging settings.   
7.4. Results 
Our results show that we were able to design, build, and characterize a portable 
system to image multiple contrast agents in resected tissue specimens.  Concentration 
versus intensity graphs are shown for silica-gold NS and 2-NBDG in Figure 7.3.  Both 
graphs show that pixel intensity decreases logarithmically with the decreasing 
concentration, demonstrating the concentration dependence of the device.   
7.4.1. Performance of system in vitro 
Figure 7.4 demonstrates the ability of our system to capture both 2-NBDG and NS 
signal in separate imaging settings..  Images of SK-Br-3 cells incubated with contrast 
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agents are presented in Figure 7.4.  Cells with 2-NBDG only (A,D&G), anti-HER2 NS 
only (B,E,&H), and both contrast agents (C,F,&I). are presented.  In the blue light 
imaging mode, there is faint green signal in cells incubated with 2-NBDG only that is not 
seen in the NS only cells. However, this green signal is very strong in cells incubated 
with both NS and 2-NBDG.  Also, the cells with 2-NBDG have no signal in the NIR 
imaging setting, which was expected as there were no NS present.  Cells incubated with 
NS only had no signal in the blue light imaging, which was consistent with the negative 
control. There is signal from the cells in the NIR imaging that is also seen in the cells 
incubated with both 2-NBDG and NS.   
 
 
Figure 7.4 Images acquired with Sk-Br-3 cells incubated with 2-NBDG only (A,D&G), anti-HER2 NS only 
(B,E,&H), and both contrast agents (C,F,&I).  Green signal from 2-NBDG is seen in both D&F but not in cells 
incubated with NS only.  Additionally, for cells in NIR imaging settings (G-I), there is no signal from cells 
incubated with 2-NBDG only, but cells incubated with NS only had similar signal to cells incubated with both 
contrast agents.  Cells with no signal (Fig. 7.3(E&G)) had the same signal as negative control cells. Scale bar = 5 
mm. 
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This is an important proof of concept that shows multiple contrast agents can be 
captured using this system and that these contrast agents can be accurately distinguished.  
As the green signal from the 2-NBDG only cells was very faint, each blue light image 
was split into its respective RGB channels and the green channel was used for 
comparison.  The results after enhancing the contrast in each image to further delineate 
cell signal are shown in Figure 7.5.  These results clearly show the 2-NBDG signal in 
both Figure 7.5(A&C) and no signal from 2-NBDG in cells incubated with NS only.  A 
possible reason for the lower signal from the 2-NBDG only cells is that a limited amount 
of cells were transferred to the coverslip, lowering the overall signal detected.  However, 
Figure 7.5(C) clearly shows high 2-NBDG signal from cells on the coverslip.  
7.4.2. 2-NBDG and anti-HER2 NS in ex vivo specimens 
Figure 7.6 displays the initial attempt to visualize both 2-NBDG and anti-HER2 
NS in ex vivo tissue samples.  As the tissue was frozen, the signal from 2-NBDG seen in 
Figure 7.6(E) is from tissue that was not rinsed after incubation as most of the 2-NBDG 
would have been rinsed away.  However, it is important as it illustrates that 2-NBDG 
 
Figure 7.5 Green channel images from Figure 7.4(D-F) that have had contrast enhanced.  Images show high signal 
in the green channel from both cells incubated with 2-NBDG and no signal from cells incubated with anti-HER2 
NS only. This confirmed that green signal seen in Figure 7.4 is from the 2-NBDG. Scale bar = 5 mm. 
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signal on the tissue is much stronger than the autofluorescent signal seen in Figure 
7.6(B).  These are similar to the images we displayed in chapter 5 which demonstrated 
the enhanced fluorescent signal after incubation with 2-NBDG.  This shows that we are 
able to use our inexpensive, portable system can create images similar to the expensive 
Maestro system.  Figure 7.6(C&F) show no difference between tissues after anti-HER2 
NS incubation NS showing that the system is unable to resolve the NS scattering signal at 
this low camera exposure time. 
 
The inability to visualize NS scattering at low exposure settings created a problem 
as increasing exposure time on the camera not only increased NS scatter but also signal 
from tissue (Fig. 7.7).  At 10 ms exposure with a 720 LP filter, the average signal for 
HER2-positive tissue was calculated to be (48 (a.u), n=3).  Using the graph presented in 
 
Figure 7.6 Pre (A-C) and post (D-F) incubation images of HER2-positive tissue after incubation with 2-NBDG 
(B&E) then anti-HER2 NS (C&F).  Images display the system’s ability to differentiate 2-NBDG signal from 
autofluorescence. However, anti-HER2 NS binding was not visualized through NIR scattering. Scale bar = 5 mm.  
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Figure 7.3(A), we see that to visualize NS due to their high scattering, we would need 
approximately 500 million particles to bind in a concentrated area to have enhanced 
scattering from the tissue.  As this high concentration is not feasible, we hypothesized 
that we could decrease tissue signal through the use of the optical clearing agent, 
glycerol.  Figure 7.8(A&B) demonstrates the reduced signal in tissue after incubation for 
10 minutes in glycerol.  The 10-minute time point was chosen to minimize incubation 
time in the glycerol to maintain our goal of developing a system to rapidly differentiate 
ex vivo tissue.  However, we were still unable to show increased NIR signal after 
incubation with anti-HER2 NS (Fig. 7.8(C&D).   
7.4.3. Application of FITC-functionalized NS to co-localize NS in tissue 
As we were unable to show increased scatter signal after glycerol and NS 
incubation, we wanted to confirm that the NS were on the tissue.  To do this, we back-
filled the NS with a fluorescent PEG (FITC-PEG) that could be visualized using the blue 
imaging settings on the device.  We first incubated non-targeted NS (backfilled with 
either FITC-PEG or non-flourescent PEG) with HER2-negative tissue and imaged the 
tissues without rinsing the NS.  Blue and NIR images comparing the tissues are shown in 
Figure 7.9(A&B).  The FITC labeled NS (F) have a much higher signal in Figure 7.9(A) 
due to the presence of FITC on the NS incubating the tissue. The NIR images in Figure 
7.9(B) show that there is no difference between the tissues’ NIR scattering.  Due to 
autofluorescent differences in the tissues, we also calculated the change in green channel 
intensity for each tissue pre and post NS incubation.  The tissue incubated with FITC-NS 
did have higher autofluorescence; however, the signal difference between the tissues is 
much higher after incubation with the particles (10 vs. 35).  This confirms the NS 
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location on the surface of the tissue but that we were unable to differentiate their 
scattering signal from the endogenous tissue signal. 
 
After confirming NS presence via FITC signal, we attempted to use targeted anti-
HER2 NS with FITC–PEG to visualize the distribution of targeted NS on tissue.  Our 
goal was to show that even if there was minimal NIR scatter from the NS, we would still 
be able to demonstrate binding of the NS to tissue through the FITC signal.  If we were 
able to show this, then it would confirm that our optical configuration was not ideal for 
differentiating the binding of the anti-HER2 NS via their NIR scattering.   
Figure 7.10 displays the results from these incubation experiments.  As can be 
seen in the images, the glycerol lowered the NIR signal from the tissue. And as observed 
in previous experiments, the addition of the anti-HER2 NS failed to increase the NIR 
signal from the tissue.  However, the images that display the green channel of the blue 
 
Figure 7.7 HER2-positive tissue pre (A-D) and post (E-H) incubation with anti-HER2 NS at different exposure 
times for the imaging system.  Increasing exposure time increased signal from the tissue and did not improve the 
scatter signal from the anti-HER2 NS on the tissue.  Scale bar = 5 mm 
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imaging settings (Fig 7.10 (C,F,&I)) show increased intensity that is due to the presence 
of the NS throughout the tissue.  Figure 7.10(J) displays the average signal intensity of 
the tissue in the blue imaging settings during each step of the experiment.  As expected, 
the total signal from the tissue decreases after incubation with glycerol, and there is an 
increase in signal after the addition of NS but the overall signal intensity is still much less 
than the normal autofluorescent signal of the tissue.  However, this graph shows a sharp 
increase in green channel intensity that occurs after incubation with FITC-NS.  This 
indicates a presence of NS throughout the tissue that was not visualized through NIR 
scatter but through FITC signal, confirming our hypothesis that this optical set-up could 
 
Figure 7.8 Images displaying NIR scatter reduction in HER2-positive tissue after incubation with 99.9% glycerol 
for 10 minutes.  C&D demonstrate that anti-HER2 NS scatter signal could still not be separated from tissue that had 
been incubated in glycerol (C) and then incubated with anti-HER2 NS (D).  Scale bar = 5 mm 
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not visualize enhanced scattering from targeted silica-gold NS in HER2-positive breast 
cancer. 
 
 
Figure 7.9 NS backfilled with FITC (F) or unmodified (N) PEG on tissue from the same patient. Figure 7.9(A) 
displays the increased signal from FITC in the blue imaging setup tissue labeled F.  However, NIR imaging of the 
tissues showed minimal difference in scatter from the tissues, demonstrating that increased signal in A is due to 
FITC. Scale bar = 5 mm.  Figure 7.9(C) quantifies the signal difference between the tissues before and after 
incubation with NS.  Increased signal in the FITC NS was due to the presence of FITC on the NS.  
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Figure 7.10 Images of HER2-positive tissue after incubation with glycerol (D-F) and anti-HER2 NS backfilled 
with FITC-PEG.  Images demonstrate increased signal from FITC-NS showing distribution throughout the tissue.  
However, even with widespread tissue distribution, there was little increase in NIR signal from the tissue. Scale bar 
= 5 mm. Figure 7.10(J) displays intensities from FITC image composites and the green channel.  Increased signal is 
due to FITC presence on the NS distributed throughout the tissue.  
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Even though we were unable to localize the anti-HER2 NS through NIR 
scattering, we were able to use white light imaging to visualize small pockets of NS using 
their absorbance (Fig 7.11).  This demonstrates the system’s ability to localize contrast 
agents through white light imaging, as long as the agent can provide ample contrast 
against the tissue without any special excitation and emission filters.  These results are 
similar to data presented in chapter 6 (Figs. 6.7 & 6.8) that showed absorbance of 
targeted NS on the surface of HER2-positive tissue. 
 
To further demonstrate the compatibility of the system with other diagnostic 
agents, we incubated HER2-positive tissue with an NIR fluorescent dye that stains for 
EGFR.  Recent studies by Xie, Ke, and Kovar et al. have demonstrated the intratumoral 
 
Figure 7.11 White light image of tissue presented in presented in 7.10(G) showing pockets of anti-HER2 NS 
binding, demonstrating the ability of our system to visualize the absorbance of targeted silica-gold NS in tissue. 
Scale ber = 5 mm. 
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specificity of this dye in EGFR-overexpressing tumor xenografts [27,417,418].  The dye 
has an excitation maximum of 774 nm and emission maximum of 805 nm [418], allowing 
us to visualize the fluorophore in our NIR setting with an LP800 filter.  In Fgure 7.12, pre 
(A) and post-incubation (B) results show distinct differences between tissues after 
incubation with the contrast agent.  The blue hue seen in the tissue incubated with the dye 
is consistent with the signal observed when the fluorophore was suspended in a quartz 
cuvette (data not shown).  This figure demonstrates the proof-of-concept that the imaging 
system can be used with a contrast agent that is not custom made (as was the case with 
the NS), but rather a commercially available product that has already demonstrated high 
specificity in vivo [27,417,418]. 
 
 
Figure 7.12 HER2-positive tissues before (A) and after (B) incubation with an NIR fluorescent EGFR dye.  The 
tissue on the right of each image was the tissue incubated with the dye and the tissue on the left served as a control.  
There is a large difference in the tissues after incubation that was not seen in the pre-incubation images. Scale bar = 
5 mm. 
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7.5. Discussion 
Our results indicate that we have developed a system that has the ability to image 
multiple wavelengths and contrast agents on the same tissue.  The original design of the 
system was to visualize 2-NBDG fluorescence and NIR scattering from targeted silica-
gold NS.  We were unable to develop a method to differentiate NS scatter from tissue 
scatter; however, we were able to visualize NS absorbance from large aggregates using 
white light.  Even though our system did not differentiate NIR scatter from tissue, we 
were able to show that we could visualize NIR fluorescence from the optical probe 
IRDye 800CW EGF.  As its excitation and emission maxima are located in the middle of 
the water window (700-900 nm) [419] , IRDye 800CW is thought to have optimal 
characteristics for in vivo imaging [418].  In addition to imaging EGF, IRDye 800 CW 
has been conjugated to deoxy-glucose to visualize GLUT1 expression in the same 
manner as 2-NBDG [27,316,420].  As the system can visualize contrast agents in three 
different modes (white light and visible/NIR fluorescence), it is conceivable that this 
system could be used to visualize three separate contrast agents on one tissue.  However, 
this system is designed as a portable device to be used intra-operatively and provide 
surgeons with rapid visualization of cancerous tissue, so appropriate contrast agents 
would need to be selected. 
One design parameter for the device was to develop the system using inexpensive 
components with minimum costs for customized parts and contrast agents.  The total cost 
of the materials was $2,954.00.  Additionally, two of the contrast agents that we used (2-
NBDG and IRDye 800CW EGF) were commercially available products that required 
only re-suspension in PBS upon receipt, and their cost was $171.00 and $325.00, 
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respectively.  Our silica-gold NS were manufactured by Nanospectra and required 
functionalization with both an OPSS-PEG-antibody linker and PEG-SH.  The integration 
of inexpensive imaging components with commercially available contrast agents 
dramatically decreases the overall construction and operation for this system while also 
providing enhanced visualization of contrast agents in cancerous tissue. 
Another positive characteristic of this system is the ability to customize the 
system to contrast agents by replacing LEDs, excitation filters, and emission filters.  As 
the majority of optical contrast agents have been focused in the NIR range due to their 
optimal signal-to-background [418,421], one could design the system so that multiple 
NIR dyes (such as Cy 5.5 and IRDye 800CW) with different molecular targets are 
imaged using different combinations of NIR LEDs and emission filters. 
Finally, the speed with which tissues were incubated and imaged is a promising 
indication for the future use of this system.  The goal of this project was to develop an 
imaging device that would provide surgeons with a rapid detection method of cancerous 
tissue using molecular contrast agents as a tool to lower positive margin rates.  We do not 
envision this technology as a replacement for intraoperative pathology, but rather as a 
tool to help surgeons who do not have any method to visualize microscopic disease.   
This device can also be thought of as a tool to supplement intraoperative 
pathology.  As discussed earlier, a recent study by Vosoughhosseini et al. demonstrated 
that patients diagnosed with negative margins via standard H&E pathology were found to 
have positive margins when EGFR staining was performed on the same specimens [13].  
If the pathologists had a method of visualizing specific receptors in a rapid method, there 
is a greater possibility that these false negatives would have been avoided.  Additionally, 
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the system could also be used to pre-screen resected specimens by helping the surgical 
team visualize the specific areas of the margin that need H&E performed and not spend 
unnecessary resources and time on areas that are benign. 
There are system limitations.  As it is a wide-field imaging system, there are 
limitations to the resolution of the system.  While we were able to visualize the signal 
from cells incubated with molecular contrast agents, individual cells could not be 
resolved.  Additionally, this system can only visualize the surface of the tissues.  
However, this is also a limitation of the anti-HER2 NS, as the contrast agents do not 
penetrate the surface of the tissue in the limited incubation time [128].  Additionally, the 
operation of the system is done by hand.  The system could be improved by integration 
with a data acquisition (DAQ) board so that control of the camera and image processing 
would be performed with a graphical user interface (GUI) that would easily translate 
clinically.  An example of this interface is the MDM created by Roblyer at al [301].  
Futhermore, changing the filters between different wavelengths is also done by hand, and 
the use of a filter wheel to control the filters placement would also improve the 
translational ability of the system.  Finally, we were unable to differentiate the NIR 
scatter of silica-gold NS from tissue, but we were still able to image the NS via their 
absorbance after aggregation on the tissue surface.  In addition, we were still able to use 
the system to visualize the NIR fluorescence of a commercially available and highly 
specific contrast agent that has demonstrated enhanced contrast in vivo. 
This system is an important first step in development of a translatable device that 
can be combined with highly specific contrast agents.  It demonstrates that readily 
available components can be engineered to create a system that has the ability to provide 
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physicians with a tool to visualize molecular expression in resected tissue in a limited 
amount of time.  As it is low-cost and portable, one can imagine this system located in 
the surgical suite with a technician performing the tissue processing while the surgeon 
continues operating on the patient.  The system can also be customized to visualize 
different contrast agents for other molecular markers that are more common in other 
cancers. 
7.6. Conclusion 
The portable imaging device developed in this chapter was designed for 
compatibility with contrast agents that were characterized in previous work in our 
research group [23,128,129,155]. Previously, we had found that optical contrast agents 2-
NBDG and anti-HER2 silica-gold NS could differentiate cancerous tissue due to the 
overexpression of GLUT1 and HER2 proteins.  We had also demonstrated that the 
contrast provided by these agents was done in a rapid manner (≤ 20 minutes), 
demonstrating possible use as an intraoperative agent.  However, previous methods to 
visualize these agents were performed with non-portable and expensive equipment.  Our 
system was designed to overcome these issues by developing a platform in which these 
agents could be visualized in tissue using inexpensive and portable components.  By 
using LEDs, a DSLR, and commercially available optical filters, we were able to 
visualize the enhanced contrast of three different contrast agents, 2-NBDG, anti-HER2 
silica-gold NS, and IRDye 800CW.  
 
 
  
Chapter 8 
Conclusion  
The research presented in this thesis demonstrates the utility of using molecularly 
targeted contrast agents in both cells and tissue specimens to enhance contrast using the 
overexpression of molecular markers.  It also represents the first step in the development 
of an intraoperative imaging device that is capable of visualizing multiple contrast agents 
in a single specimen.  To simulate intraoperative conditions, contrast agents that require 
minimal incubation time were chosen; additionally, targeting multiple molecular targets 
using different agents enhances the specificity of the system as areas without enhanced 
contrast would have to be negative for multiple molecular markers. 
This thesis advances research as it demonstrates the ability of a rapid, portable, 
and inexpensive system designed to enhance and visualize contrast in breast cancer.  We 
first demonstrated that 2-NBDG enhanced contrast in breast cancer tissues that had a 
higher metabolic rate than normal tissues from the same patient.  A search on SCOPUS 
and Pubmed for “2-NBDG breast cancer” revealed only seven publications for each 
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search engine.  One of those publications is the work presented by our group in chapter 5.  
No other research has been published on ex vivo fluorescent signal enhancement from 2-
NBDG in breast cancer.  As well, research presented in chapter 6 presents the novel use 
of targeted silica-gold nanoshells as rapid contrast agents in whole ex vivo tissue 
specimens, as well as multiple methods to determine the intratumor location of the 
nanoshells in the tissue.  Using data from our first two ex vivo experiments, we 
hypothesized that we could design a device to image both contrast agents in the same 
tissue via the fluorescence of 2-NBDG and the NIR scatter of the nanoshells.  The device 
was unable to differentiate tissue scatter from nanoshell scatter. However, nanoshell 
aggregation was still visualized in white light imaging.  Additionally, we were able to 
visualize the NIR fluorescence of IRDye 800CW, demonstrating the ability of the system 
to visualize three different contrast agents in tissue.   
The research presented in this thesis provides the foundation for the development 
of a device that can supplement surgeons performing BCT with optical information on 
the molecular expression of tissue.  The contrast agents used in this thesis are able to 
enhance contrast in a rapid fashion to ensure that surgeons are able to probe margin status 
while the patient is still under anesthesia.  Additionally, the low weight and foot-space of 
the device allows for ease of use during a surgery; a larger piece of equipment does not 
need to be moved in to facilitate the intraoperative imaging.  The system uses contrast 
agents that are non-ionizing (unlike the handheld PET probes or intraoperative X-rays), 
limiting the exposure of harmful material to the surgical team.  If the surgeon knows the 
tumor’s molecular expression profile prior to surgery (by using the pre-operative biopsy 
specimen), the system could be prepared to visualize contrast agents different from those 
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presented in this thesis.  For example, if a patient is HER2-negative but ER+, a different 
cocktail of contrast agents such as a FITC-conjugated antibody to estrogen and IRDye 
conjugated with 2-deoxyglucose, could be used to enhance visualization during surgery.  
This system has the potential to improve margin status in patients who do not receive 
intraoperative pathology by offering physicians an opportunity to visualize molecular 
expression through contrast agents. 
This system is not designed to replace intraoperative pathology at centers like 
MDACC; it can be used as a supplement for the surgeon and pathologist when 
determining margin status intraoperatively.  As mentioned in chapters 2 and 6, standard 
H&E does not provide information on the receptor status of tissue at the margins, which 
could lead to a recurrence in patients.  If pathologists had a tool that allowed them to 
rapidly interrogate receptor status of tissue at the margin, they would be able to make a 
more informed decision on further re-excision.  Providing physicians with additional 
information regarding receptor status could save a patient from undergoing additional 
surgeries and enhanced radiation.  Again, the size and portability of this system becomes 
a factor in how this device would work in a pathology suite.  If it were large, bulky, and 
used ionizing radiation, then it would be impractical inside the suite not be beneficial for 
the pathological team.  There is minimal sample preparation, which could potentially 
interfere with the routine preparation.  Finally, this system could even be used to pre-
screen resected tissue for the pathological team by allowing the pathologist to focus on 
areas of the tissue that have enhanced contrast from a contrast agent, rather than 
processing the entire tissue during the surgery.  
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Optical contrast agents can provide valuable information about the molecular 
expression of tissues in a rapid manner.  They allow for physicians to visualize cancerous 
tissue by providing enhanced contrast in areas of high expression.  As research becomes 
more familiar with the application of these agents the benefit they provide to the 
physicians and patients will only increase. 
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